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CHARACTERISING THE REPROGRAMMING DYNAMICS BETWEEN 
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Amanda Jayne Collier 
Abstract 
 
Human pluripotent stem cells (hPSCs) exist in multiple states of pluripotency, broadly categorised 
as naïve and primed states. These provide an important model to investigate the earliest stages of 
human embryonic development. Naïve cells can be obtained through primed-to-naïve 
reprogramming; however, there are no reliable methods to prospectively isolate unmodified naïve 
cells during this process. Moreover, the current isolation strategies are incompatible for enrichment 
of naïve hPSCs early during reprogramming. Consequently, we know very little about the temporal 
dynamics of transcriptional changes and remodelling of the epigenetic landscape that occurs during 
the reprogramming process.  
To address this knowledge gap, I sought to develop an isolation strategy capable of identifying 
nascent naïve hPSCs early during reprogramming. Comprehensive profiling of cell-surface markers 
by flow cytometry in naïve and primed hPSCs revealed pluripotent state-specific antibodies. By 
compiling the identified state-specific markers into a multiplexed antibody panel, I was able to 
distinguish naïve and primed hPSCs. Moreover, the antibody panel was able to track the dynamics 
of primed-to-naïve reprogramming, as the state-specific surface markers collectively reflect the 
change in pluripotent states.  
Through using the newly identified surface markers, I found that naïve cells are formed at a much 
earlier time point than previously realised, and could be subsequently isolated from a heterogeneous 
cell population early during reprogramming. This allowed me to perform the first molecular 
characterisation of nascent naïve hPSCs, which revealed distinct transcriptional changes associated 
with early and late stage naïve cell formation. Analysis of the DNA methylation landscape showed 
that nascent naïve cells are globally hypomethylated, whilst imprint methylation is largely 
preserved. Moreover, the loss of DNA methylation precedes X-chromosome reactivation, which 
occurs primarily during the late-stage of primed-to-naïve reprogramming, and is therefore a 
hallmark of mature naïve cells. Using the antibody panel at discrete time points throughout 
reprogramming has allowed an unprecedented insight into the early molecular events leading to 
naïve cell formation, and permits the direct comparison between different naïve reprogramming 
methods. Taken together, the identified state-specific surface markers provide a robust and 
straightforward method to unambiguously define human PSC states, and reveal for the first time 
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Cells of the early mammalian embryo retain the remarkable ability to generate all of the cell 
types found within the adult body, a potential referred to as pluripotency. As embryonic 
development progresses, pluripotent cells progressively differentiate into specialised cell types. 
The transient nature of pluripotency during embryonic development presents a challenge for 
researchers with the desire to stabilise and maintain this cell type in-vitro. Nonetheless, 
pluripotent stem cell (PSC) lines have been derived from multiple sources such as germ cell 
tumours, both the pre- and postimplantation-stage embryo, and via somatic cell reprogramming 
to an induced pluripotent state. These PSCs can be propagated indefinitely in-vitro in an 
undifferentiated state, whilst retaining the capacity to differentiate into all cell lineages of the 
body. PSCs therefore provide an attractive model to study early embryonic development and 
subsequent cell fate commitment. The attribute of indefinite self-renewal, whilst retaining the 
potential to differentiate, is one of the foremost reasons that stem cells receive so much 
attention. It is hoped that one day they will provide a limitless supply of cells for disease 
modelling, drug discovery, and the treatment of degenerative diseases. In the subsequent 
sections, I will provide a brief overview of the different pluripotent cell types and their 
relationship to embryonic development.    
 
1.1 Mouse Pluripotency and Stem Cells  
 
1.1.1 Mouse Embryonal Carcinoma Cells 
 
In 1954, Stevens and Little hypothesised the existence of pluripotent cells. This statement was 
based upon the observation that tumours of germ cell origin could be serially transplanted and 
contained both differentiated and undifferentiated cell types (Stevens and Little, 1954). Further 
experiments corroborated this finding, and revealed that a single teratocarcinoma cell possessed 
the capability of deriving a new tumour upon transplantation, which contained cell types from 
all three germ layers – ectoderm, endoderm and mesoderm (Kleinsmith and Pierce, 1964; Pierce 
and Verney, 1961). Moreover, the discovery that grafting mouse embryos into adult mice 
resulted in teratocarcinoma formation, underpinned the concept that pluripotent cells are 
present in the early embryo (Solter et al., 1970; Stevens, 1970). The putative pluripotent cells 
within teratocarcinomas were designated Embryonal Carcinoma Cells (ECCs) (Pierce and 
Verney, 1961). ECCs were subsequently isolated and maintained under culture conditions, 
serving as the first platform to study embryonic development of mice in-vitro (Evans, 1972; 
Kahan and Ephrussi, 1970; Rosenthal et al., 1970). Further testament to their pluripotent 
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identity, ECCs were also able to contribute to chimeras upon blastocyst injection (Mintz and 
Illmensee, 1975; Papaioannou et al., 1975).   
 
1.1.2 Mouse Embryonic Stem Cells  
 
The pioneering work on ECCs laid a foundation for the subsequent isolation of PSCs directly 
from mouse blastocyst-stage embryos. In 1981, two teams described the ability to derive 
pluripotent mouse embryonic stem cells (mESCs), by either culturing intact preimplantation 
mouse blastocysts (Evans and Kaufman, 1981), or from the inner cell mass (ICM) (Martin, 
1981); both of which required the support from a layer of mitotically-inactivated mouse 
embryonic fibroblasts (MEFs). Mouse ESCs are derived from the early epiblast and are able to 
self-renew indefinitely in-vitro. Similar to ECCs, mESCs form teratocarcinomas when 
ectopically grafted and contribute to chimeric embryos upon blastocyst injection (Bradley et 
al., 1984; Evans and Kaufman, 1981; Martin, 1981). Importantly, a single mESC was able to 
generate a chimeric embryo displaying a contribution to multiple germ layers (Beddington and 
Robertson, 1989), highlighting an essential feature that pluripotent cells retain the ability to 
differentiate when exposed to different growth conditions. Perhaps the most stringent 
demonstration of pluripotent potential is via the tetraploid complementation assay. This showed 
that mESCs can form a whole embryo when aggregated with a tetraploid host, whereby the 
tetraploid cells contribute to the extraembryonic tissues, whilst the embryo itself and subsequent 
mouse is derived exclusively from the injected diploid mESCs (Nagy et al., 1993).  
 
1.1.3 The relationship of signaling pathways and alternative pluripotent states in the context 
of mouse embryonic development 
 
The initial culture conditions used to derive mouse ECCs and ESCs was reliant on the support 
provided by a layer of MEFs and undefined serum-containing media. Efforts were subsequently 
taken to understand what factors contained within the serum, or that were produced by MEFs, 
enabled mESCs to remain in a pluripotent state. These studies revealed that MEFs produce the 
cytokine leukemia inhibitory factor (LIF), which suppresses spontaneous mESC differentiation 
(Smith et al., 1988; Williams et al., 1988), and the serum component acts to stimulate the BMP 
signaling pathway (Ying et al., 2003). LIF is a member of the Interleukin-6 family and acts via 
the LIF receptor (LIFR), which forms a heterodimer with the LIF coreceptor, GP130. This event 
triggers the activation of Janus Kinase (JAK), which results in the phosphorylation and 
activation of the transcription factor Signal Transducers and Activators of Transcription 3 
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(STAT3) (Boeuf et al., 1997; Niwa et al., 1998). Phosphorylated STAT3 (p-STAT3) can 
subsequently translocate to the nucleus to activate the transcription of target genes. Serum/LIF 
conditions are frequently used to maintain mESCs in a pluripotent state; however, a degree of 
transcriptional heterogeneity has been described within these cultures. Subpopulations of cells 
co-express pluripotency and lineage-priming genes to varying amounts, which may therefore 
alter their pluripotent potential (Canham et al., 2010; Hayashi et al., 2008; Toyooka et al., 2008).  
 
To overcome the limitation of using undefined growth conditions, efforts towards maintaining 
mESCs in defined serum and feeder-free conditions were taken. This identified a combination 
of low-doses of bone morphogenetic protein 4 (BMP4) and LIF to mimic the signaling cues 
provided by Serum/LIF (Ying et al., 2003). Subsequently the inhibition of MEK/ERK signaling 
was found to enhance ESC derivation and culture (Buehr and Smith, 2003; Burdon et al., 1999). 
The MEK inhibitor PD0325901 blocks the phosphorylation of ERK. In a normal context, 
activated ERK results in the degradation of key pluripotency transcription factors, such as KLF2 
and KLF4 (Dhaliwal et al., 2018; Yeo et al., 2014). This approach was extended with the 3i 
media formulation that included MEK/ERK inhibition, alongside inhibitors of glycogen 
synthase kinase-3 (GSK3) and FGFR signaling (Ying et al., 2008). The GSK-3 inhibitor 
CHIR99021 results in the stabilisation of β-catenin to promote Wnt signaling, which 
consequently alleviates TCF3 repression of pluripotency factors such as Oct4, Nanog, and Rex1 
(Martello et al., 2012; Pereira et al., 2006; Sato et al., 2004; Wray et al., 2011). However, it was 
later shown that FGFR inhibition was dispensable and that culturing mESCs in 2i (dual 
inhibition of MEK and GSK3) in combination with LIF, collectively referred to as 2i/LIF, 
resulted in a homogeneous population of cells designated as reaching ‘ground-state 
pluripotency’ (Silva et al., 2008; Ying et al., 2008). Moreover, 2i/LIF culture conditions have 
made it possible to generate germline competent ESCs from rats and recalcitrant mouse strains 
(Buehr et al., 2008; Czechanski et al., 2014; Li et al., 2008; Nichols et al., 2009). Mouse ESCs 
derived from preimplantation stage blastocysts (E3.5 – E.45 developmental stage) can be stably 
maintained in cultured under 2i/LIF or serum/LIF conditions. The resultant cell lines resemble 
the preimplantation epiblast cells of origin, and have been classified as being in a ‘naïve’ state 






Conversely, an alternative pluripotent cell type can be generated from mouse embryos, termed 
epiblast stem cells (EpiSCs), which are classified as being in a ‘primed’ state of pluripotency. 
These are most commonly derived from the postimplantation-stage (Brons et al., 2007; Tesar 
et al., 2007), but it was later shown to be possible from the preimplantation-stage as well (Najm 
et al., 2011). Whilst fulfilling the criteria of pluripotency from the perspective of self-renewal 
and competent multi-lineage differentiation to all germ layers, EpiSCs are rarely able to 
contribute to chimeric blastocysts when introduced into preimplantation-stage blastocysts  
(Brons et al., 2007; Mascetti and Pedersen, 2016a; Tesar et al., 2007). EpiSCs are 
conventionally derived under culture conditions containing fibroblast growth factor (FGF) and 
Activin A (collectively F/A) (Kunath, 2011; Nichols and Smith, 2009). Unlike mESCs, EpiSCs 
cannot be maintained under 2i/LIF conditions and instead undergo widespread cell death and 
differentiation (Guo et al., 2009). EpiSCs are instead reliant on active TGFβ signalling through 
Activin/Nodal, as the inhibition of Activin/TGFB receptors results in EpiSCs differentiating 
into neuronal cell types (Tesar et al., 2007; Vallier et al., 2009). In summary, the acquisition of 
‘naïve’ mESCs and ‘primed’ EpiSCs are dependent on the extrinsic signals provided by the 
culture conditions used upon their derivation. This is therefore an important consideration to 
have in mind when deriving PSCs from other species, as the extrinsic signals may be 
developmentally stage-specific and may differ from those required for mouse pluripotency.   
 
Figure 1.1. Alternative pluripotent cell types in the context of mouse embryonic development 
A schematic depiction of the relationship between in-vivo pluripotent progression and the 




1.1.4 Interconvertible pluripotent states 
 
Both naïve mESCs and primed mEpiSCs qualify as pluripotent from the perspective of 
differentiation potential to all three germ layers, assessed either by the formation of embryoid 
bodies or teratomas. However, the two cell states are distinct in their signaling requirements 
and in their developmental potential. Nonetheless, interconversion between the two states is 
possible by manipulating the cell culture signaling cues provided. Mouse ESCs can be 
differentiated into mEpiSCs upon exposure to FGF2 and Activin (Guo et al., 2009). However, 
the conversion in the opposite direction (mEpiSCs to mESCs) can be inefficient, inferring the 
presence of a molecular barrier. This barrier can be overcome to some extent via the 
overexpression of naïve-specific transcription factors Esrrb, Klf2, Klf4, Nanog, Nr5a2, or 
Tfcp2l1, which can enhance the conversion process (Festuccia et al., 2012; Guo and Smith, 
2010; Guo et al., 2009; Hall et al., 2009; Hanna et al., 2009; Martello et al., 2013; Zhou et al., 
2010). Two further reports have indicated that it may be possible to derive mESCs from 
mEpiSCs without transgene induction; instead, the inhibition of FGF/TGF-β signaling 
combined with promoting Wnt/LIF signaling was sufficient (Bao et al., 2009b; Greber et al., 
2010). Nevertheless, the efficiency was still low, which suggests a population of mEpiSCs 
possess a selective advantage that facilitates their reprogramming, that other mEpiSCs are 
lacking.  
Given the progressive nature of embryonic development, it is conceivable that pluripotent 
epiblast cells transition through a continuum of states. Alongside the well-characterised naïve 
and primed states that correspond to the pre- and post-implantation epiblast respectively, 
various intermediate PSC types have been generated in-vitro (Han et al., 2010; Morgani et al., 
2017). Epi-like cells (EpiLCs) are one example that have been generated via the in-vitro 
differentiation of mESCs using short-term exposure to FGF/Activin/KSR conditions (Hayashi 
et al., 2011). EpiLCs exhibit an intermediate transcriptional identity between ESCs and EpiSCs, 
and are transcriptionally similar to postimplantation-stage E5.75 epiblast cells (Hayashi et al., 
2011). Interestingly, EpiLCs are proficient in generating primordial germ cell-like cells 
(PGCLCs), unlike mESCs and mEpiSCs (Hayashi et al., 2011). Moreover, Schöler and 
colleague revealed that a sub-population of cells with characteristics associated with ESCs 
exists within EpiSC cultures. Comparative analysis between the different cell types and states 
of pluripotency has collectively revealed a number of divergent molecular characteristics, 
summarised in Figure 1.2. Taken together, the ability to transition between the different PSC 
types provides an important model to understand the molecular changes that occur during 




Figure 1.2. Overview of mouse pluripotent states and their associated characteristics  
Alterations in the signaling environment permits the conversion between naïve, primed, and 
formative pluripotent states. Pluripotent state-specific transcription factors are highlighted, 
alongside epigenetic characteristics that vary between the cell states. Repressive DNA 
methylation and H3K27me3 histone modifications are acquired along the developmental 
progression, which is recapitulated in-vitro. X-chromosome status is indicated: active (green) 
and inactive (red).  
 
 
1.2 Molecular hallmarks of mouse pluripotent states   
 
Collectively, the experiments summarised in the previous three segments emphasise the notion 
that naïve mESCs and primed mEpiSCs are developmentally distinct, require different 
signaling cues, and possess divergent molecular features (Figure 1.2). In the subsequent 
sections, I will discuss in more detail several molecular features that can be used to distinguish 




1.2.1 Transcription factor networks and gene regulation  
 
In line with the notion that mESCs and mEpiSCs qualify as pluripotent, both cell types express 
the core pluripotency transcription factors Oct4, Sox2, and Nanog. Yet the two cell types adopt 
state-specific transcriptional identities. Mouse ESCs highly express markers of pre- and peri-
implantation epiblast cells. Examples include Esrrb, Rex1, Klf4, Stella/Dppa3, Tbx3, and 
Tfc2pl1 (Boroviak et al., 2015; Ghimire et al., 2018; Ying et al., 2008); many of which are 
essential to maintain naïve pluripotency (Dunn et al., 2014). Conversely, EpiSCs exhibit 
minimal expression of these factors, and instead upregulate postimplantation epiblast markers 
such as Fgf5, Foxa2, Nodal and Sox1 (Ghimire et al., 2018; Kojima et al., 2014; Tesar et al., 
2007).  
 
Alongside different utilisation of transcription factors, the regulatory mechanisms that govern 
their expression are altered depending on the pluripotent state. For instance, expression of the 
core pluripotency factor Oct4 is differentially controlled by two cis-regulatory enhancer 
elements: the distal enhancer (DE) and the proximal enhancer (PE). The distal enhancer is 
preferentially engaged during naïve pluripotency (both in-vivo and in-vitro), whilst the 
proximal enhancer controls Oct4 expression after implantation and in mEpiSCs (Brons et al., 
2007; Choi et al., 2016; Tesar et al., 2007; Yeom et al., 1996). Further reports indicate that 
enhancer rewiring is a widespread phenomenon that occurs during this pluripotent state 
transition (Buecker et al., 2014; Factor et al., 2014; Novo et al., 2018), and is therefore a useful 
hallmark to distinguish the two pluripotent states.   
 
1.2.2 Epigenetic landscape  
 
During mammalian embryogenesis the epigenome is dramatically remodeled. This includes a 
genome-wide reorganisation of DNA methylation levels and histone modification occupancy, 
together with the silencing of an X-chromosome in female cells. Many of these events can be 
recapitulated in-vitro and largely reflect their embryonic counterparts. The first example is 
DNA methylation, which is a covalent chemical modification of a methyl group added to the 
5’ position of cytosine residues. One of the most prevalent forms of DNA methylation occurs 
at CpG dinucleotides, and this has well established roles in transcriptional repression (Holliday 
and Pugh, 1975). The DNA methyltransferase (DNMT) family of enzymes are responsible for 
the deposition of DNA methylation. Conversely, the Ten Eleven Translocation (TET) enzymes 
are responsible for active DNA demethylation (Smith and Meissner, 2013). Throughout 
embryogenesis and mammalian development, the DNA methylation landscape undergoes 
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dramatic remodeling. The naïve state of pluripotency is characterised by a state of global 
hypomethylation; whilst transitioning to a primed state, either via embryo development or via 
the assessment of primed mEpiSCs, triggers a global increase in DNA methylation levels 
(Borgel et al., 2010; Hackett et al., 2013; Leitch et al., 2013; Senner et al., 2012; Smith et al., 
2012; Veillard et al., 2014; Wang et al., 2014b). The differential expression of DNMT enzymes 
and targeting factor UHRF1 reflects this situation, such that DNMT3A, DNMT3B and UHRF1 
are downregulated in naïve conditions relative to the primed state (Leitch et al., 2013; Veillard 
et al., 2014; von Meyenn et al., 2016). DNA methylation levels, or the factors involved in their 
regulation, can therefore be used to distinguish these two states of pluripotency. 
 
The second notable example by which epigenetic features define naïve and primed states is the 
status of the X-chromosome in female cells. Early during mouse development, the paternal X-
chromosome undergoes imprinted X-inactivation, which is maintained across extraembryonic 
cell types (Huynh and Lee, 2003; Mak et al., 2004; Okamoto et al., 2004). Cells of the epiblast 
subsequently reactivate the paternal X-chromosome during preimplantation development, 
before random X-inactivation occurs upon implantation (Rastan, 1982; Takagi et al., 1982). In 
accordance with their pre- and postimplantation status, female mESCs exhibit two active X-
chromosomes, whilst one is inactivated in mEpiSCs (Bao et al., 2009a; Guo et al., 2009). X-
chromosome inactivation (XCI) is mediated by the long non coding RNA (lncRNAs) Xist, 
which upon induction triggers X-chromosome silencing in cis (Penny et al., 1996). This event 
is followed by the exclusion of RNA pol II and active histone modifications, before the 
acquisition of repressive histone modifications H3K27me3 and H2A119ub, deposited by the 
polycomb repressive complex 2 (PRC2) and PRC1 respectively (Plath et al., 2003; Silva et al., 
2003).  
 
The third example used to distinguish alternative pluripotent states relates to the chromatin 
architecture and chromatin associated modifications of the histone tails. Genome-wide mapping 
of the chromatin landscape in 2i-cultured mESCs revealed a reduction in the number of bivalent 
domains, defined by the co-occurrence of active H3K4me3 and repressive H3K27me3 marks, 
compared to serum-cultured mESCs (Marks et al., 2012). Bivalent domains are considered to 
keep their associated genes in a poised state, ready for rapid activation or repression during 
subsequent differentiation (Azuara et al., 2006; Bernstein et al., 2006). Global H3K27me3 
levels do not differ between these two states, yet feature enrichment is distinct; promoter 
regions in 2i-cultured mESCs are frequently devoid of H3K27me3, and instead exhibit an 
enrichment at satellite repeat elements (Marks et al., 2012). This could be an alternative strategy 




In summary, the molecular characterisation of naïve and primed states of mouse pluripotency 
in-vitro has provided a foundation of knowledge that can be related back to in-vivo mouse 
embryonic development. The property of indefinite self-renewal in culture permits experiments 
to be performed, which would otherwise not be possible with the low material provided by 
direct embryo assessment. Moreover, our understanding of the molecular features associated 
with mouse pluripotency can provide a framework for studying pluripotency in other species, 
such as humans.  
 
1.3 Human Pluripotency and Stem Cells  
 
1.3.1 Deriving human pluripotent stem cells from embryos 
 
After the successful isolation of mouse PSCs, efforts were taken to derive PSCs from a range 
of mammalian species, including primates. James Thomson firstly generated PSCs from two 
non-human primate species, the rhesus macaque (Thomson et al., 1995) and the common 
marmoset (Thomson et al., 1996), before deriving the first human pluripotent stem cells 
(hPSCs) in 1998 (Thomson et al., 1998). Five different hPSC lines were generated from donated 
human blastocysts acquired by in-vitro fertilisation (Thomson et al., 1998). Owing to their 
indefinite self-renewal capacity, several of these hPSCs lines are still used across the world 
today; most notably the female H9 line and the male H1 line (Löser et al., 2010). The pluripotent 
potential of hPSCs can be verified by examining the ability to generate teratomas upon injection 
into immunodeficient mice (Lensch et al., 2007). This can be further supported by the formation 
of embryoid bodies in-vitro, which are spherical structures that differentiate to contain cell types 
encompassing all three germ layers (Kurosawa, 2007). More recently, it has also been shown 
that hPSCs can form human-mouse interspecies chimeras, but only when introduced into 
postimplantation gastrula stage mouse embryos (Mascetti and Pedersen, 2016b). Conversely, 
hPSCs rarely contribute to the developing mouse epiblast when introduced into 
preimplantation-stage mouse embryos (James et al., 2006; Masaki et al., 2015). This is 
reminiscent of the poor chimeric contribution of mEpiSCs when transplanted into 
preimplantation-stage mouse embryos, yet efficient contribution is seen upon postimplantation 
transplantation (Huang et al., 2012). Collectively, this suggests that conventional hPSCs may 
have developmentally progressed compared to their mESC counterparts, and subsequently 




1.3.2 Human induced pluripotent stem cells  
 
The ability to capture and maintain hPSCs in an undifferentiated state indefinitely in-vitro, 
whilst retaining the capacity to differentiate, holds great promise for the study of human 
embryonic development, disease mechanisms and drug discovery, and ultimately the use of 
these cells in regenerative medicine. However, hPSCs are faced with several hurdles. Firstly, 
the ethical consideration that deriving hPSCs results in the destruction of human embryos, and 
this is procedure is not permitted in several countries. Secondly, if hPSCs are differentiated into 
the desired cell type and used for cell therapy, the recipient patients may elicit an immune 
response to the allogeneic cells. This second caveat can be overcome via somatic cell nuclear 
transfer (SCNT), in which patient-specific fibroblasts are injected into and fused with high-
quality enucleated human oocytes. Up to 10% of SCNT embryos were able to progress to the 
blastocyst stage and give rise to human NT-ESCs (Tachibana et al., 2013). However, the ethical 
concerns surrounding the use of human oocytes persists with this method.  
 
These concerns were subsequently addressed by the advent of induced pluripotent stem cell 
(iPSC) technology, which was pioneered by Shinya Yamanaka’s lab. It was shown that the 
forced expression of four pluripotency factors (OCT4, SOX2, KLF4 and c-MYC or OCT4, 
SOX2, LIN28, and NANOG) was sufficient for the reprogramming of adult human fibroblasts 
to an induced state of human pluripotency, giving rise to hiPSCs (Takahashi et al., 2007; Yu et 
al., 2007). Fulfilling the criteria of pluripotency, hiPSCs are able to generate teratomas in-vivo 
and embryoid bodies in-vitro containing cell types from all three lineages. Ensuing this 
discovery, a range of different adult cell types have been successfully reprogrammed to an iPSC 
state, including dermal fibroblasts, hepatocytes, keratinocytes and human peripheral blood cells 
(Aasen et al., 2008; Giorgetti et al., 2009; Liu et al., 2010; Loh et al., 2009; Maherali et al., 
2008). Assessment of the transcriptional changes during iPSC reprogramming from different 
somatic cell types has highlighted a cell of origin effect (Nefzger et al., 2017). This is perhaps 
unsurprising, given the different somatic transcriptional identities that must be downregulated. 
However, for those cells that successfully reprogramme the transcriptional identities ultimately 
converge (Nefzger et al., 2017).   
Importantly, there are many examples where disease phenotypes can be recapitulated in-vitro 
from patient-specific reprogrammed fibroblasts (Shi et al., 2012; The Hd iPsc Consortium, 
2012; Zhang et al., 2011). This exemplifies the potential of iPSC technology for disease 
modelling and drug discovery (Figure 1.3). Furthermore, a variety of alternative iPSC 
reprogramming methods have been devised that extend beyond the original use of integrating 
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retroviral, or lentiviral delivery of reprogramming factors. These include safer non-integrating 
Sendai virus (Fusaki et al., 2009), episomal vectors (Yu et al., 2009), excisable transposons 
(Kaji et al., 2009; Soldner et al., 2009; Woltjen et al., 2009) and synthetic modified mRNAs 
(Warren et al., 2010).  
 
 
Figure 1.3. Overview of induced pluripotent stem cell reprogramming (iPSC) and subsequent 
applications  
Reprogramming factors are delivered to the somatic cell to induce iPSC reprogramming. 
Human iPSCs can be subsequently differentiated into the desired cell type of interest, either 
from a healthy or disease-specific iPSC. Several disease-specific applications are highlighted.   
 
The ability to generate PSCs from both embryos and via somatic cell iPSC reprogramming begs 
the question as to whether the resultant cell types are equivalent. Comparative transcriptional 
analysis of isogenic miPSCs and mESCs were indistinguishable, with the exception of several 
transcripts within the Dlk1-Dio3 imprinted gene cluster (Stadtfeld et al., 2010). More recently, 
the same has been shown for genetically matched hiPSCs and hPSCs that cannot be 
distinguished based upon their transcriptional or epigenetic profiles (Choi et al., 2015). The 
small number of genes that were differentially expressed did not affect the developmental 
potential of the PSCs. Instead, biological variability between different genetic backgrounds, 
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length of in-vitro culture, and the sex of somatic cells may be responsible for the variation 
between hPSCs and hiPSCs observed by some groups (Bock et al., 2011; Choi et al., 2015; Kim 
et al., 2010; Ohi et al., 2011). Nevertheless, the advent of iPSC reprogramming hold great 
promise for the future study of both applied research into human disease, and as a model system 
to study the mechanisms that underpin cell fate reprogramming more generally.  
 
 
1.3.3 Signaling requirements for conventional human pluripotent stem cells 
 
Whilst conventional hPSCs derived from embryos qualify as pluripotent from the perspective 
of generating cell types from all three germ layers, there are notable differences compared to 
mESCs. Human PSCs have a markedly different morphology compared to their mouse 
counterparts. When viewed under the microscope, human PSCs grow as flat colonies of tightly 
packed cobblestone cells, contrary to mESCs that grow in compact dome-shaped colonies. 
Moreover, the optimum growth conditions for the propagation and maintenance of hPSCs are 
also different to those that are required for naïve mESCs. The first culture conditions used to 
derive hPSCs were initially determined by applying the methods developed for mESC 
derivation. This included the co-culture of hPSCs supported by a MEF layer in the presence of 
an enriched serum-containing media and LIF (Thomson et al., 1998). However, hPSCs are 
distinct from mESCs, such that LIF and BMP4 signalling are not sufficient in maintaining 
hPSCs in an undifferentiated state (Dahéron et al., 2004; Gerami-Naini et al., 2004; Humphrey 
et al., 2004; Xu et al., 2002). The induction of BMP signalling instead leads to trophoblast 
differentiation (Xu et al., 2002). Contrastingly, when the agonist noggin blocks BMP signalling, 
hPSCs can be maintained in an undifferentiated state (Xu et al., 2005b), collectively suggesting 
BMP signalling induces the differentiation of hPSCs.  
 
The second disparity between mESC and hPSC culture is evident by the failure of 2i/LIF 
conditions to sustain hPSCs in a pluripotent state (Hanna et al., 2010). Instead, the optimal 
growth conditions for hPSCs are reminiscent of those used to culture mEpiSCs (Beattie et al., 
2005; James et al., 2005a; Vallier et al., 2005; Wang et al., 2005; Xu et al., 2005a). Activation 
of an alternative branch of the TGF-β signalling pathway, via TGF-β/Activin/Nodal as opposed 
to BMP, is essential for the maintenance of hPSCs. In support of this, inhibition of 
Activin/Nodal signalling via the antagonist follistatin, SB43154 and Lefty, results in a loss of 
pluripotency (Smith et al., 2008; Vallier et al., 2005). Additionally, TGF-β signalling appears 
to be important for epiblast formation in humans (Blakeley et al., 2015). Upon treatment with 
an Activin receptor inhibitor (SB-431542), the human epiblast showed an impaired formation 
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assessed by the lack of NANOG and SOX17 expression. Moreover, numerous components of 
this pathway are highly expressed in human EPI cells, including receptor expression 
(TGFBR1/ALK5 and TDGF1), receptor ligand expression (LEFTY1/2, GDF3 and NODAL), and 
downstream signal transducers (SMAD2 and SMAD4). Conversely, SMAD1 and SMAD5 are 
enriched in human trophectoderm cells, exemplifying the complex nature that the same 
signalling pathway can differentially regulate distinct lineages (Blakeley et al., 2015) 
 
In addition to TGF-β signalling, hPSCs are reliant on FGF signalling via the FGF/MAPK 
pathway, as FGF receptor inhibition cannot be tolerated whilst maintaining an undifferentiated 
state. Collectively it was shown that whilst FGF signalling is necessary for maintaining hPSCs, 
it is not sufficient without active TGF-β/Activin/Nodal signalling, and these pathways act 
cooperatively to maintain hPSCs in a pluripotent state (Vallier et al., 2005).  
 
Although human and mouse PSCs are both derived from preimplantation-stage embryos, it is 
evident that the culture conditions used to derive naïve mESCs are not adequate to capture the 
same state in humans. Instead, the conventional culture conditions used to derive hPSCs 
promotes a state of pluripotency that is reminiscent of primed mEpiSCs. Either this is owing to 
the lack of a naïve state in humans, or simply revisions must be made to the culture conditions 
such that this state can be captured and maintained. The discovery that multiple pluripotent 
states are present in the mouse embryo indicated that the same may be true for humans (Nichols 
and Smith, 2009). Moreover, the observation that both mESCs and EpiSCs can be derived from 
preimplantation mouse embryos provides evidence that in-vivo pluripotent cells will default to 
different cell types depending on the in-vitro culture methods used (Najm et al., 2011). Further 
investigation over the following years has revealed that indeed the ‘naïve’ state of pluripotency 
can be derived directly from human embryos, or more commonly via the reprogramming of 
primed hPSCs. Before elaborating on the culture conditions that permit the naïve hPSC state, I 
will discuss how the recent molecular and phenotypic studies of mouse, primate, and human 
embryos are providing clarity over the earliest stages of pluripotency. These studies have helped 
to define robust criteria by which to benchmark hPSC types against, taking into consideration 
species-specific differences (Boroviak and Nichols, 2017; Collier and Rugg‐Gunn, 2018; 






1.4 Human embryos provide a foundation to guide the characterisation of human 
pluripotent states  
 
Assigning molecular criteria to define human pluripotent states has been hindered by the 
scarcity of human embryos available for scientific research, and the technical limitations of 
working with low-cell numbers for molecular characterisation. Over the past decade there have 
been great technical improvements, and consequently the molecular characteristics of human 
embryonic development have been studied using single-cell transcriptional profiling.   
 
1.4.1 Transcriptional profiles of human preimplantation embryos 
 
One of the primary revelations from sequencing human embryos indicated the temporal 
dynamics of lineage segregation was different in primates compared to mouse. In humans, 
lineage segregation occurs simultaneously in the early blastocyst, where cells of the 
trophectoderm (TE), the epiblast (EPI) and the primitive endoderm (PrE) are specified at the 
same developmental stage (Blakeley et al., 2015; Petropoulos et al., 2016; Stirparo et al., 2017). 
Prior to this stage (≈E5), is it not possible to clearly assign a cell fate based upon their 
transcriptional profile (Stirparo et al., 2017). This observation was also true in cynomolgus 
monkeys, whereby the three lineages (TE, EPI and PrE) could only be distinguished by ≈E8 
(Nakamura et al., 2016). This is contrary to mouse lineage segregation that occurs earlier and 
in two stages; firstly the TE and EPI are specified at the morula stage, followed by EPI and PrE 
specification at the mid blastocyst stage (Figure 1.4). Interestingly, isolated and re-aggregated 
trophectoderm cells of human blastocyst-stage embryos are capable of generating an entirely 
new blastocyst, inclusive of a NANOG-expressing ICM (De Paepe et al., 2013). This further 
implies that lineage segregation occurs after the formation of the blastocyst, and at a later stage 





Figure 1.4. Overview of mouse and human embryonic development. 
Embryonic and extraembryonic cells are specified in two waves during mouse development. 
Firstly, the ICM is segregated into TE and EPI cells at the morula stage, followed by EPI and 
PrE specification at the mid blastocyst stage. Conversely, human lineage specification occurs 
simultaneously from the early blastocyst-stage E5 embryo. Figure adapted from (Niakan et al., 
2012).  
 
Yan and colleagues performed a transcriptional comparison of individual human epiblast cells 
against conventional human PSCs (Yan et al., 2013). This highlighted a substantial difference 
between the two cell types, indicating that in-vitro hPSCs have lost their cell of origin identity. 
Further extensive transcriptional profiling of human embryos has reiterated this observation, 
whilst providing a comprehensive resource of developmental stage-specific transcriptional 
profiles (Blakeley et al., 2015; Petropoulos et al., 2016; Stirparo et al., 2017). This resource 
provides a biologically relevant benchmark for assessing hPSC types. Based on these 
transcriptional studies and further molecular profiling of human embryos, several 
characteristics of naïve human pluripotency have been proposed. This provides a helpful 
framework with which to evaluate human pluripotent cell types, including conventional primed 




Figure 1.5. Hallmarks associated with naïve and primed human pluripotent states. 
(1) The core pluripotency transcription factors OCT4, SOX2, and NANOG are expressed in 
both naïve and primed hPSCs, whereas several other transcription factors show state-specific 
enrichment. (2) Naïve hPSCs have globally hypomethylated genomes compared to primed 
hPSCs. (3) Naïve hPSCs have two active X‐chromosomes in female cells, indicated by biallelic 
X‐linked gene expression alongside lncRNAs expression of XIST and XACT. Conversely, 
primed hPSCs have one inactive X-chromosome, shown by monoallelic gene expression and 
the acquisition of  the repressive histone mark H3K27me3. (4) Naïve hPSCs exhibit preferential 
activity of the OCT4 distal enhancer, whereas primed hPSCs use the proximal enhancer. (5) 
H3K27me3 is absent or reduced at >3000 Polycomb-associated genes in naïve hPSCs compared 
to primed hPSCs. (6) Identified cell‐surface markers can be used to distinguish between naïve 
and primed hPSCs. Figure from (Collier and Rugg‐Gunn, 2018). 
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Table 1.1. Characteristics of naïve and primed states of pluripotency.  
✓, presence of naïve state attribute; X, absence of naïve state attribute; −, attribute not examined. The brief media composition is noted alongside 
each publication reporting the derivation of naïve hPSCs. Conflicting results for OCT4 enhancer activity are shown, in each case the absence of 
DE activity was reported by: (Theunissen et al., 2014). Table from (Collier and Rugg‐Gunn, 2018). 
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Appearance   Domed () Flat ()           
Single cell 
survival 
High () Low ()           
Methylation 
(global CpG) 
Low (≈30%) High (≈80%) – High – – Low Low Med Med – Low 
H3K27me3  
levels 
Low at  
promoters 
High at  
promoters 
– Low Low Low Low – Low – – – 
OCT4  
enhancer 





Glycolytic () – – –  –  – – – – 
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Transcriptome profiling of human embryos has revealed both species-specific differences and 
similarities in the transcriptional markers used to assign cell types (Blakeley et al., 2015; 
Petropoulos et al., 2016; Stirparo et al., 2017). The core pluripotency transcription factors OCT4 
(POU5F1), SOX2 and NANOG are well-conserved EPI markers expressed in mouse, primates 
and humans. Further conservation exists for additional mouse EPI pluripotency factors such as 
Klf4, Sall4 and Tfcp2l1 (Boroviak et al., 2015; Takashima et al., 2014).  However, the mouse 
EPI factors Klf2, Nr0b1 and Esrrb are not expressed in the human epiblast. Instead, an 
alternative Krueppel-Like Factor, KLF17, is exclusively expressed in primate EPI cells, 
alongside additional EPI-enriched genes such as DPPA5, FGF4, GDF3, LEFTY and NODAL. 
All of these are either absent or lowly expressed in conventional hPSCs (Stirparo et al., 2017), 
exemplifying the point that upon derivation these cells may have progressed.  
 
The first studies that derived naïve-like hPSCs were published prior to the reports that revealed 
the molecular features of human preimplantation-stage embryos. Consequently, the initial 
reports may have generated cell types to match the perceived naïve properties bestowed by 
mESCs. Retrospective transcriptional comparisons of human EPI cells against the various naïve 
hPSC types has been performed (Huang et al., 2014). This revealed a considerable range in the 
expression levels of naïve-associated genes across the different naïve hPSC types. This suggests 
that some culture conditions are better than others, from the perspective of generating a cell 
type that aligns to the transcriptional profile of human epiblast cells (Huang et al., 2014; Pastor 
et al., 2016; Stirparo et al., 2017; Theunissen et al., 2016). For several of the earliest reports, a 
shift in transcriptional profiles towards a human preimplantation state is rather minor (Chan et 
al., 2013; Gafni et al., 2013; Huang et al., 2014; Ware et al., 2014). However, there are two 
conditions in particular, 5iLA and t2iL+PKCi, which reliably induce a global transcriptional 
profile that correlates with both human and monkey preimplantation-stage embryos (Guo et al., 
2016b; Huang et al., 2014; Nakamura et al., 2016; Takashima et al., 2014; Theunissen et al., 
2014). Moreover, these two conditions generate naïve hPSCs that express LTR5-HERVK and 
SINE-VNTR-Alu classes of transposable elements. Both classes are expressed in the human 
embryo between the 8-cell stage through to blastocyst formation, and therefore act as a useful 






1.4.2 Naïve-specific gene regulatory elements are present in human blastocysts  
 
Asides from the transcriptional rewiring of gene regulatory networks (GRNs), the mechanisms 
that govern transcription factor expression are altered depending on the pluripotent state. Gene 
activation frequently requires cis-regulatory DNA sequences, such as enhancers or promoters, 
to be accessed by trans factors. Akin to naïve mESCs, hPSCs under some naïve culture 
conditions utilise pluripotent state-specific enhancer elements for genes such as POU5F1 
(encoding OCT4), KLF4, LEFTY1 and NANOG (Table 1.1) (Ji et al., 2016; Pastor et al., 2018; 
Theunissen et al., 2016). In the same manner that transcriptional expression can provide a useful 
marker of cell identity, reporter systems coupled to state-specific enhancer engagement can be 
engineered and used to distinguish naïve and primed hPSCs.  
 
Perhaps owing to technical difficulties, few studies have directly examined the chromatin 
landscape of human embryos until recently (Gao et al., 2018; Pastor et al., 2018). This revealed 
that naïve hPSC-specific open chromatin regions were also accessible in human blastocyst stage 
embryos, whereas primed hPSC accessible regions were not conserved (Pastor et al., 2018). 
Moreover, naïve hPSCs mimic mESCs cultured under 2i conditions with respect to their 
chromatin landscape. This shows a dramatic loss of bivalent domains at >2,000 Polycomb target 
genes in naïve hPSCs cultured under 5iLAF conditions (Marks et al., 2012; Theunissen et al., 
2014). However, there have yet to be studies that examine the genomic distribution and feature 
enrichment of histone modifications in human embryos. It is therefore not possible to conclude 
whether this phenomenon exists in-vivo.  
 
1.4.3 The DNA methylation landscape of human embryos provides a hallmark characteristic 
of naïve pluripotency     
 
Analogous to mouse embryo development, there are substantial genome-wide modifications to 
the DNA methylation landscape during human embryogenesis (Guo et al., 2014; Okae et al., 
2014; Smith et al., 2014). CpG DNA methylation levels decline upon fertilisation, reaching 
their lowest levels in the human ICM. Upon implantation, the genome is globally remethylated 
and post-implantation fetal tissue samples are hypermethylated, exhibiting >70% methylation 
levels (Figure 1.6). DNA hypomethylation is therefore a conserved hallmark of naïve 
pluripotency in both mouse and humans. Comparative DNA methylation analysis of 
conventional human PSCs reveals a striking difference compared to the ICM cells of origin, 
with methylation levels of ≈80% observed for hPSCs (Okae et al., 2014). Moreover, it was 
shown that rapid global remethylation occurs when deriving hPSCs from human blastocysts, 
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indicating that the conventional culture conditions used are not sufficient to apprehend 
pluripotent cells in their naïve state (Smith et al., 2014).  
 
As for the transcriptional readouts, the magnitude of DNA hypomethylation is variable between 
the different naïve hPSC lines (Table 1.1). Naïve-like formulations that show minimal 
transcriptional changes also retain global DNA methylation levels close to 70%, which is the 
same as primed hPSCs (Gafni et al., 2013; Pastor et al., 2016). Yet those cells maintained under 
5iLA and t2iL+PKCi culture conditions show the closest resemblance to DNA methylation 
levels observed in the embryo (Figure 1.6) (Guo et al., 2017; Pastor et al., 2016; Theunissen et 
al., 2016). Despite this similarity, there are differences in the distribution of methylated CpG 
sites. For instance, imprinted control regions maintain methylation levels in the human embryo, 
but this methylation is lost in naïve hPSCs upon long-term culture (Guo et al., 2017; Pastor et 
al., 2016; Theunissen et al., 2016). Nevertheless, global DNA hypomethylation appears to be a 




Figure 1.6. DNA methylation distribution across human embryonic development  
Global CpG methylation levels are reduced upon fertilisation and the first cell division. The 
lowest methylation levels are observed within the ICM. Upon implantation, the genome is 
globally remethylated and post-implantation tissues samples exhibit >70% methylation. 
Conventional primed hPSCs are hypermethylated (70-80%), whereas naïve hPSCs under 
5iLA(F) or t2iL+PKCi culture are hypomethylated (≈30%). Figure adapted from (Guo et al., 




1.4.4 X‐Chromosome activity is a hallmark of naive human pluripotency   
 
Whilst the DNA methylation dynamics are comparable between mouse and human 
development, there are divergent strategies to achieve X-chromosome dosage compensation in 
females (Figure 1.7). Unlike the mouse system, the paternal X-chromosome is not transiently 
silenced in human epiblast cells. Instead, there appears to be a gradual dampening of the two 
X-chromosomes to halve the transcriptional output whilst remaining active. The next difference 
relates to the lncRNA control mechanisms behind X-chromosome inactivation. Human epiblast 
cells express XIST from both chromosomes without triggering inactivation (Petropoulos et al., 
2016; Sahakyan et al., 2017; Vallot et al., 2017). Whilst speculative, the proposed mechanisms 
behind this is via the primate-specific lncRNA XACT, which antagonises XIST to prevent XIST-
mediated silencing of the X-chromosome (Vallot et al., 2017). Upon embryo implantation, 
random X-chromosome inactivation is thought to take place, akin to mouse implantation.  
 
 
Figure 1.7. Schematic of X-chromosome status during human embryo development.  
Preimplantation-stage epiblast cells contain two active X-chromosomes that exhibit biallelic 
expression and are associated with the lncRNAs XIST and XACT. After blastocyst implantation, 
random X-inactivation occurs. The silent X-chromosome condenses and is enriched with 
H3K27me3, whilst the active X-chromosome ceases to express XIST, but retains XACT 
expression.  
 
Conventional hPSCs typically have one active and one inactive X-chromosome in female cells. 
This infers that upon derivation from the naïve human epiblast, a developmental progression 
may have occurred as cells exhibit post-implantation characteristics. Reassuringly, the inactive 
X-chromosome can be reactivated upon reprogramming of primed hPSCs to a naïve state, but 
only under certain naïve culture conditions (Table 1.2). In addition to naïve hPSCs showing 
biallelic X-linked gene expression, the lncRNAs XIST and XACT are expressed from both 
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chromosomes in a proportion of cells. This recapitulates the observed status of X-chromosome 
activity and regulation seen in human embryos. Consequently, naïve hPSCs will provide a 
valuable in-vitro model to study X-chromosome silencing in human cells with a more suitable 
transcriptional and epigenetic landscape that is akin to human epiblast cells.   
 
Several of the initial papers where naïve hPSCs had been generated using female cells, 
described the reactivation of the previously silenced X-chromosome (Gafni et al., 2013; Ware 
et al., 2014). This conclusion was based upon the absence of XIST expression and a lack of 
H3K27me3 foci, which at the time was thought to indicate the presence of two active X-
chromosomes. Subsequently the experiments that directly examined human embryos revealed 
that XIST and XACT are expressed from both chromosomes whilst remaining active. Therefore, 
the absence of XIST or lack of H3K27me3 foci is not a reliable readout of reactivation. Based 
on these recent discoveries, it is important to define X-chromosome status in hPSCs by 
evaluating biallelic gene expression for XIST, XACT and other genes on the X‐chromosome that 
do not escape silencing by erosion. Following this criteria, the status of X-chromosomes in 
female cells can be used as a reliable hallmark to distinguish naïve pluripotent stem cells. 
 
Table 1.2. X-chromosome status associated with naïve and primed hPSCs. 
Note that X-chromosome status was not reported by: (Chan et al., 2013; Duggal et al., 2015; 
Qin et al., 2016). In some cases not all X-chromosome attributes were examined. Table from 
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1.5 Developing culture conditions to sustain hPSCs in a preimplantation‐like 
state 
 
The ability to derive and maintain naïve human PSCs in-vitro would provide a valuable tool to 
investigate pluripotent state transitions and early human development. There are now greater 
than ten reports that described the methodologies and growth conditions to derive human 
pluripotent stem cells, which share characteristics comparable to the epiblast cells of human 
preimplantation‐stage embryos. The predominant approach used to generate naïve hPSCs is by 
reprogramming primed hPSCs. The cell types generated have collectively been termed ‘naïve’ 
hPSCs, even though some fulfil more of the hallmark characteristics of naïve pluripotency than 
others (Collier and Rugg‐Gunn, 2018). Many of these attempts to derive and characterise naïve 
hPSCs were based upon the knowledge of mouse studies, which may account for the spectrum 
of pluripotent states that have been reported (Table 1.1).  
 
1.5.1 Varying growth conditions induce a spectrum of human pluripotent states 
 
The first studies that derived naïve-like hPSCs were published prior to the reports that define 
the molecular characteristics of human preimplantation-stage embryos. Consequently, cell 
types with features akin to naïve mESCs were initially derived (Buecker et al., 2010; Hanna et 
al., 2010; Li et al., 2009b). Whilst the cell types generated qualify as pluripotent, assessed by 
teratoma formation and in-vitro differentiation, only Hanna and colleagues induced a naïve-
specific feature – the preferential use of the OCT4 distal enhancer. These cells were derived by 
the ectopic expression of three pluripotency factors (OCT4, KLF2, and KLF4), in combination 
with 2i/LIF. However, upon transgene withdrawal the cells could not be maintained in an 
undifferentiated state, demonstrating that 2i/LIF alone is not sufficient to maintain hPSCs in a 
naïve state, contrary to mESCs (Hanna et al., 2010).  
 
To overcome the hurdle of using transgenes to generate naïve hPSCs, multiple reports have 
subsequently derived stable, transgene-free naïve-like hPSCs (Chan et al., 2013; Chen et al., 
2015; Gafni et al., 2013; Ware et al., 2014). The resultant cell lines exhibit several properties 
of naïve-like hPSCs, such as increased clonogenicity and the upregulation of several naïve-
associated transcriptional markers (Chan et al., 2013; Gafni et al., 2013). However, a global 
shift in transcriptional profile towards a human preimplantation state has not been 
demonstrated; moreover, the degree of DNA demethylation is negligible where documented 
and biallelic X-linked expression has not been reported (Chan et al., 2013; Chen et al., 2015; 




These four studies exploit 2i/LIF as a foundation with additional supplementation (Table 1.3) 
(Chan et al., 2013; Chen et al., 2015; Gafni et al., 2013; Ware et al., 2014). Interestingly, the 
naïve-like hPSCs had transitioned to a state of LIF dependency, as withdrawal or inhibition of 
LIF signalling resulted in their differentiation or impaired self-renewal (Chan et al., 2013; Gafni 
et al., 2013; Ware et al., 2014). Chen and colleagues further demonstrate the requirement of 
LIF signalling by reinforcing STAT3 activation in the presence of 2i/LIF, which facilitated 
primed to naïve-like reprogramming (Chen et al., 2015). This is contrasting to conventional 
primed hPSCs that do not require exogenous LIF to maintain their pluripotent state (Dahéron 
et al., 2004; Humphrey et al., 2004). Naïve-like hPSCs may develop LIF-dependency in order 
to maintain the expression of naïve-specific transcription factors, KLF4 and TFCP2L1 
(Martello et al., 2013; Niwa et al., 1998; Ye et al., 2013). These are known to be regulated by 
LIF/STAT3 signalling in naive mESCs, which appears to be a conserved feature in naïve-like 
hPSCs (Figure 1.8) (Chan et al., 2013).  
 
Following on from these studies, additional signalling pathways have been targeted in order to 
derive hPSCs with naïve-like characteristics, including PKA and HIPPO inhibition. However 
these cells have not been well characterised, particularly for their epigenetic or global 
transcriptional profiles, and subsequently it is difficult to evaluate where they fall on the 
spectrum of primed to naïve pluripotency (Duggal et al., 2015; Qin et al., 2016; Zimmerlin et 
al., 2016). Moreover, a commercially available media has subsequently been developed 
(RSeT), which is based upon the ‘NHSM’ formulation, to generate transgene-free naïve-like 
hPSCs (Gafni et al., 2013). Interestingly, cell lines derived under RSeT conditions exhibit 
variable transcriptional profiles, with some lines clustering with primed hPSCs, whilst others 
are more similar to human epiblast cells. The disparity between the RSeT lines is unclear, but 
it appears that a spectrum of pluripotent states can be generated under these conditions (Kilens 
et al., 2018). To summarise the naïve-like hPSC lines describe above, it is clear that a 
progression from the conventional primed hPSC state has been made; yet this collection of 
naïve culture conditions generates cell types that do not fully satisfy the hallmark characteristics 
of naïve human pluripotency found within the early embryo.  
26 
 
 Table 1.3. Media compositions associated with the induction of naïve hPSCs. 
 ✓, addition to media; *, short-term induction / addition to the culture media; ¥, choice between two components;/, optional addition of a 
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(Guo et al., 
2017) 
LIF LIF signalling           
PD0325901 MEK inhibition           
CHIR99021 GSK3 inhibition           
IM-12 GSK3 inhibition           
BIO GSK3 inhibition           
Gö6983 PKC inhibition           
Y-27632 ROCK inhibition           
WH-4-023 SRC inhibition           
SB590885 RAF inhibition           
SP600125 JNK inhibition           
SB203580 p38/MAPK 
inhibition 
          
TGFβ TGFβ signalling           
Activin A TGFβ signalling           
FGF FGF signalling     /      
SAHA HDAC inhibition    *       
Sodium Butyrate HDAC inhibition    *      * ¥ 
Valproic Acid HDAC inhibition          * ¥ 
Dorsomorphin BMP inhibition           
Forskolin  PKA inhibition           
Ascorbic Acid Demethylation           
Lysophosphatidic 
acid 
HIPPO inhibition           
Base medium  (1) (2) (3) (4) (1) (1) (1)(4)¥ (4) (1)(3) (1) 
O2 level  20% 
20% or 
5% 





    
NANOG* 
KLF2* 




Figure 1.8. Signalling pathways in naïve and primed human pluripotent states 
The different cocktails of inhibitors and growth factors used to induce naïve pluripotency are a likely cause of the reported spectrum of pluripotent 
states. It is important to note that additional pathways that are not highlighted here are also likely to be involved. Moreover, many of the chemical 
inhibitors used will non‐specifically inhibit additional targets, even extending to components of different signalling pathways. Dashed lines indicate 
likely indirect effects. Figure from (Collier and Rugg‐Gunn, 2018). 
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1.5.2 Identified culture conditions capture naïve hPSCs with preimplantation embryo 
hallmarks 
 
Two culture conditions stand out as deriving naïve hPSCs with the closest resemblance to 
human epiblast cells thus far; these are the 5iLA(F) and t2iL+PKCi formulations (Table 1.1 and 
Table 1.2) (Guo et al., 2017; Guo et al., 2016b; Takashima et al., 2014; Theunissen et al., 2016; 
Theunissen et al., 2014). In the first instance, a chemical screen was performed to identify 
kinase inhibitors that could sustain naïve pluripotency in the presence of 2i/LIF upon transgene 
withdrawal (-DOX), using a doxycycline inducible NANOG and KLF2 system. This identified 
the components that gave rise to 5iLA(F) media. Alongside classical 2i (dual inhibition of MEK 
and GSK3), three additional inhibitors targeting ROCK (rho-associated protein kinase), SRC 
and BRAF were combined with Activin A and the optional addition of FGF2 (Theunissen et 
al., 2016; Theunissen et al., 2014). Transgene-free naïve hPSCs derived using 5iLA(F) 
transcriptionally resemble cells of the late-morula and early-blastocyst stage of human and 
primate development (Huang et al., 2014; Nakamura et al., 2016; Theunissen et al., 2016; Wang 
et al., 2018). 
 
On the other hand, naïve hPSCs generated using t2iL+PKCi may resemble more closely human 
ICM cells or later epiblast cells (Huang et al., 2014; Nakamura et al., 2016; Takashima et al., 
2014; Theunissen et al., 2016; Wang et al., 2018). The t2iL+PKCi formulation consists of 
titrated levels of classical 2i, in addition to LIF and a PKC inhibitor. This combination is able 
to maintain naïve hPSCs that have been generated by NANOG and KLF2–induced, KLF4–
induced, or OCT4, KLF4, SOX2 and MYC‐induced primed to naïve reprogramming (Kilens et 
al., 2018; Liu et al., 2017; Takashima et al., 2014). Alternatively, t2iL+PKCi has been used in 
combination with transient HDAC inhibitor treatment, termed chemical resetting, to generate 
transgene-free naïve hPSCs (Guo et al., 2017), and finally t2iL+PKCi with the further addition 
of ROCK inhibitor (t2iL+PKCi+Y) can be used to capture naïve hPSCs directly from human 
preimplantation blastocysts (Guo et al., 2016b).  
 
Collectively, both 5iLA and t2iL+PKCi cultured cells also exhibit an epigenetic profile that 
best represents the human epiblast, including a globally hypomethylated genome and two active 
X-chromosomes in female cells (Table 1.1 and Table 1.2). However, there are drawbacks with 
both of these culture conditions. Their long-term culture (≥ ten passages) results in the 
irreversible loss of DNA methylation at the majority of imprinted loci (Guo et al., 2017; Pastor 
et al., 2016; Theunissen et al., 2016), and frequent karyotype abnormalities have been reported 
using 5iLA(F) and t2iL+PKCi+Y (Liu et al., 2017; Theunissen et al., 2016). Nonetheless, these 
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two formulations have captured cells in a state that closely resembles many aspects of human 
preimplantation epiblast cells. This therefore provide an expandable in-vitro model to 
functionally explore the role of naïve-specific transcription factors, the mechanisms that govern 
X-chromosome inactivation in a context with an appropriate epigenetic landscape, and lastly to 
explore the reprogramming process itself to understand pluripotent state transitions.  
 
1.6 Methods to identify and isolate naïve human pluripotent stem cells   
 
The predominant approach to derive naïve hPSCs is by the reprogramming of primed hPSCs. 
The efficiency of this method is often low and variable between protocols used, typically 
generating a heterogeneous population of cells during the reprogramming process. The most 
common approach to purify naïve hPSCs is via continued passaging of the cultures over time 
(Collier and Rugg‐Gunn, 2018). This bulk passaging approach is dependent on reprogrammed 
naïve hPSCs having a competitive advantage compared to populations of cells that are 
refractory to reprogramming. In cases where the culture conditions permit the survival of 
primed and non-reprogrammed cell types, this approach is not suitable. Furthermore, this 
method does not easily allow the heterogeneous early stages during reprogramming to be 
molecularly characterised, unless single-cell approaches are used (Collier and Rugg‐Gunn, 
2018).  
 
1.6.1 Transgene reporter systems for the identification and isolation of naïve hPSCs  
 
Moving away from the bulk-passaging approach, several alternative isolation strategies have 
been devised to prospectively isolate naïve hPSCs, by capitalising on aforementioned 
knowledge of the molecular hallmarks of naïve pluripotency. A key feature of naïve mESCs is 
the preferential use of the Oct4 distal enhancer, whereas primed mEpiSCs utilise a proximal 
enhancer (Brons et al., 2007; Choi et al., 2016; Tesar et al., 2007; Yeom et al., 1996). Several 
groups have subsequently devised a reporter system that exploits this pluripotent state-specific 
cis-regulatory mechanism. In cell lines that contain a deletion of the OCT4 proximal enhancer, 
endogenous OCT4 expression is coupled to GFP (OCT4‐ΔPE‐GFP), and therefore GFP 
expression acts as a readout of alternative enhancer activation (Gafni et al., 2013; Theunissen 
et al., 2014). This can be detected using flow cytometry and permits live cell isolation by 




Along a similar avenue, an alternative reporter system (EOS‐GFP) has been used to identify 
naïve hPSCs (Takashima et al., 2014). EOS‐GFP expression is driven from a mouse early 
transposon (ETn) promoter, combined with mouse Oct4 enhancer elements that contain OCT4 
and SOX2 binding sites (Hotta et al., 2009). Given that EOS‐GFP expression is activated upon 
reprogramming of primed hPSCs to a naïve state, this reporter system could also be used to 
isolate naïve hPSCs. However, the timing of induction and the stringency of both EOS‐GFP 
and OCT4‐ΔPE‐GFP expression have not been examined, and may therefore isolate a broader 
population than just naïve hPSCs.   
 
Adopting a similar strategy, naïve-like hPSCs have been isolated using a reporter for the 
endogenous retrovirus HERVH expression, tagged with GFP (Wang et al., 2014a). Primed 
hPSCs expressing high levels of HERVH-GFP were isolated using FACS. These cells adopt a 
naïve-like morphology compared to HERVH-low/negative cells. Nonetheless, repeated re-
sorting is required to maintain homogeneous naïve-like hPSCs (Wang et al., 2016). Given that 
endogenous HERVH transcription is associated with primed pluripotency, and not with naïve, 
this reporter system may not be the most appropriate (Theunissen et al., 2016). Moreover, 
HERVH-high cells only display a moderate increase in naïve associated transcripts, further 
questioning the ability to sort naïve hPSCs exclusively on this property (Wang et al., 2014a). 
 
Although reporter systems can provide a simple and reliable readout of cell state, they all 
possess several drawbacks. Firstly, there is the requirement to genetically modify each primed 
hPSC line prior to the naïve reprogramming process. Secondly, in each case described above 
the timing and fidelity of each transgene reporter system has not been examined. These 
reporters may not necessarily be linked exclusively with the transition to a naïve state. Whilst 
the OCT4‐ΔPE‐GFP reporter system has been employed by multiple groups to identify naïve 
hPSCs, this is reliant on the assumption that OCT4 enhancer usage is conserved from mouse to 
human, which may not be the case (Pastor et al., 2018).   
 
1.6.2 Cell surface epitopes can distinguish primed and naïve hPSCs  
 
To overcome the limitations associated with genetically engineered reporter systems, cell 
surface antibodies have subsequently been identified that target epitopes expressed on primed, 
but not naïve, hPSCs. The technique of immunophenotyping, which involves cell type 
identification based upon protein marker expression, has been extensively used in the field of 
immunology (Morilla et al., 2017). Applying this same logic, cell surface markers are routinely 
used to identify primed hPSCs. These markers include the glycosylated epitopes SSEA-3, 
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SSEA-4, TRA-1-60 and TRA-1-81 (Andrews et al., 1984; Henderson et al., 2002). Using cell 
surface markers to identify pluripotent cell types has a number of advantages over reporter 
systems. Cell surface markers enable live cells to be isolated using FACS or magnetic-activated 
cell sorting (MACS), without any genetic manipulation of each cell line. This straightforward, 
quick and routine technique is widely accessible. Moreover, antibodies against glycosylated 
epitopes are extensively used to isolate conventional hPSCs, which reporter systems may not 
be able to capture.   
 
The first study examined the expression of CD24, which is a sialoglycoprotein (Shakiba et al., 
2015b). CD24 expression was shown to be higher in both primed hPSCs and mEpiSCs, 
compared to NHSM cultured naïve-like hPSCs and mESCs respectively. Antibodies against 
primed-specific CD24 was used in combination with the pan-hPSC antigen TRA-1-60 to isolate 
naïve-like hPSC populations: TRA-1-60+/CD24low and TRA-1-60+/CD24high. A transcriptional 
comparison between the two populations revealed that the CD24low population showed an 
enrichment of naïve-associated transcripts compared to the CD24high population. However, it 
took ten passages for the CD24low population to arise during NHSM-induced primed to naïve 
reprogramming (Shakiba et al., 2015b). This may therefore limit the ability of CD24 to isolate 
naïve hPSCs early during the reprogramming process.  
 
The second study again examined the expression of an individual surface marker, SSEA-4, 
which is routinely used to isolated primed hPSCs (Pastor et al., 2016). The author’s noticed that 
established naïve hPSCs showed morphological heterogeneity when cultured under 5iLAF 
conditions, as well as variable SSEA-4 expression. Isolation of the SSEA-4 positive and 
negative fractions revealed that naïve cells lacking SSEA4 formed dome-shaped colonies upon 
their return to culture, whereas the SSEA-4 positive fraction adopt a primed morphology. A 
transcriptional comparison between the two fractions also revealed that human epiblast-specific 
genes were upregulated in the SSEA-4 negative fraction. Furthermore, SSEA4-negative cells 
were globally hypomethylated (≈30%), compared to the positive fraction that displayed 
elevated levels (≈60%). Taken together, this shows that the lack of SSEA-4 expression can be 
used to purify naïve hPSC cultures to enrich for cells harbouring hallmark naïve characteristics 
(Pastor et al., 2016). However, the dynamics of SSEA-4 expression were not examined, so it is 
unclear as to whether this marker could also be used to isolate naïve hPSCs during the 





The third report developed a cohort of new monoclonal antibodies (O'Brien et al., 2017). Those 
targeting CDH3, GPR64, NLGN4X and PCDH1, showed a higher reactivity against primed 
hPSCs compared to naïve hPSCs derived under 5iLAF conditions. Similar to the Pastor et al. 
study, 5iLAF cultures were heterogeneous in their surface marker expression profiles, with 30 
– 50% of the naïve population expressing the four primed-enriched markers (O'Brien et al., 
2017). The heterogeneity observed indicates that the 5iLAF culture conditions permit the 
survival of non-naïve cell types. Unfortunately, it is not known whether naïve hPSCs remain in 
a homogeneous state when purified using any of the surface markers described in these three 
studies (O'Brien et al., 2017; Pastor et al., 2016; Shakiba et al., 2015a) Moreover, the ability to 
unambiguously classify naïve hPSCs within a mixed population requires naïve-specific surface 




Figure 1.9. Approaches to isolate naïve hPSCs during primed to naïve reprogramming.  
Primed to naïve reprogramming can be inefficient, often generating a heterogeneous population 
of cells during the process. Strategies to isolate and derive defined populations of naïve hPSCs 
include: (1) Bulk passaging and progressive selection, or clonal expansion of individual 
colonies that exhibit a domed naïve‐like morphology. (2) Reporter systems coupled to the 
expression of fluorescent proteins provide a read out of characteristics that are associated with 
naïve pluripotency. (3) Characterisation of the cell‐surface proteins expressed on naïve and 
primed hPSCs has identified primed state‐specific markers. Using antibodies specific to these 
markers enables the isolation of naïve hPSCs that lack primed-specific marker expression using 






1.7 Examining the routes to pluripotency   
 
Much of the knowledge that we currently have regarding the naïve and primed states of human 
pluripotency is based upon studies of the established states. Whilst this provides a valuable 
insight into the hallmark characteristics of the two cell types, very little is known about the 
transitional period or how the naïve state is acquired. We know there is a widespread 
remodelling of the epigenetic landscape and rewiring of the gene regulatory networks that 
govern pluripotency, yet the details of how these events occur and in what order were unclear 
at the onset of this work.  
 
Isolating and characterising reprogramming intermediate cell types can provide a useful insight 
into the trajectories of cell fate changes, and the mechanisms that govern the routes taken. By 
studying the intermediate populations that are refractory to reprogramming, we can begin to 
understand why some cells fail to reprogram whilst others succeed, and subsequently use this 
knowledge to coerce cells down the right trajectory. The inefficient and protracted nature of 
iPSC reprogramming is a good example of where studying intermediate populations has helped 
to identify the molecular barriers to reprogramming, and subsequently how to overcome these 
barriers (Figure 1.10). The studies that have examined iPSC reprogramming populations 
typically use cell-surface markers to track and isolate the populations for subsequent molecular 
characterisation. Generally, the surface markers are expressed on the somatic cell of origin, 
such as fibroblast markers Thy1 (CD90) and CD44 (Nefzger et al., 2014; O’Malley et al., 2013). 
Conversely, surface markers to identify mouse iPSCs include ICAM1 and epithelial markers 
EpCAM and SSEA-1 (Mikkelsen et al., 2008; O’Malley et al., 2013; Stadtfeld et al., 2008), 
whereas SSEA-3, SSEA-4, TRA-1-60, TRA-1-81 and CD30 can be used to positively identify 
human iPSCs (Abujarour et al., 2013; Cacchiarelli et al., 2015; Takahashi et al., 2014; Tanabe 
et al., 2013). However, partially reprogrammed populations can still express iPSC markers; 
therefore, additional surface markers that change during the transitional period are useful to 
delineate cells that are prone to fully reprogram from those that are not. Using mass-cytometry, 
the surface markers CD73, CD49d and CD200 were identified that are absent in both fibroblasts 
and iPSCs, but are transiently induced in cells that are prone to fully reprogram (Lujan et al., 
2015).  
 
Using surface markers to study reprogramming populations has helped to reveal that iPSC 
reprogramming is a stepwise process involving the dramatic remodeling of the transcriptional 
and epigenetic landscapes (Buganim et al., 2012; Cacchiarelli et al., 2015; Hansson et al., 2012; 
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Knaupp et al., 2017; Lujan et al., 2015; Polo et al., 2012; Zunder et al., 2015). The first wave 
of transcriptional changes relates to the loss of somatic cell identity, which is universally 
accomplished to varying degrees; however, cells that are refractory to reprogramming fail to 
fully repress the somatic identity and do not execute the second transcriptional wave, which 
involves acquiring a pluripotent transcriptional identity (Mikkelsen et al., 2008; Polo et al., 
2012). By identifying and modulating the roadblocks to iPSC reprogramming, refractory 
populations can be coerced towards an iPSC state (Ebrahimi, 2015) (Figure 1.10). This 
methodology and knowledge can be subsequently applied to facilitate alternative cell fate 





Figure 1.10. Molecular events that occur during somatic cell reprogramming.  
Somatic iPSC reprogramming is accompanied by waves of transcriptional changes and 
remodeling of the epigenetic landscape. To enhance the reprogramming efficiency, different 
strategies have been devised to overcome the barriers of reprogramming and drive refractory 





Most of the studies that generate human iPSCs have yielded cells that exhibit primed hPSC 
characteristics. There are now several reports whereby naïve hPSCs have been derived using 
iPSC reprogramming (Kilens et al., 2018; Liu et al., 2017; Wang et al., 2018). This 
demonstrates that it is possible to revert human somatic cells back to a naïve preimplantation-
like state. The authors in one study suggest that this may even be possible without going through 
a primed phase when using t2iL+PKCi conditions (Kilens et al., 2018). Further analysis would 
be required to confirm this observation, and to decipher whether skipping the primed state of 
pluripotency confers any advantage. Interestingly, naïve hiPSCs derived by OSKM and cultured 
in 5iLAF or t2iL+PKCi+Y conditions are virtually indistinguishable from their counterpart 
naïve hPSCs derived by primed to naïve reprogramming (Liu et al., 2017). Moreover, this study 
identified that KLF4 alone could reprogram primed hPSCs to a naïve state under t2iL+PKCi+Y 
culture. This is reminiscent of mEpiSC to mESC conversion induced by Klf4 under 2iL 
conditions, which indicates a species-conserved role of KLF4 in the induction of naïve 
pluripotency (Liu et al., 2017).  
 
As previously mentioned, mEpiSC to mESC conversion is possible at low efficiencies when 
naïve pluripotency factors are introduced. Testing whether the exogenous addition of specific 
transcription factors can facilitate mEpiSC to mESC conversion has identified essential 
transcription factors required for the reprogramming process. However, an in-depth analysis of 
the reprogramming trajectory or a systematic identification of naïve promoting factors has yet 
to be performed. The same is true with human primed to naive reprogramming, given that the 
current methods used to identify and isolate naïve hPSCs preclude the study of the early stages 
of the reprogramming process. Without a means to examine the earliest stages of 
reprogramming, it is not possible to decipher the molecular trajectories of primed to naïve 
reprogramming, and the mediators of this process. These are areas that I aim to address during 
this thesis.  
 
1.8 Thesis aims  
 
Naïve hPSCs are predominantly generated via the reprogramming of primed hPSCs. The 
efficiency of this method is often low and variable between naïve reprogramming protocols 
used, thereby generating a heterogeneous mix of cells at the early stages. Common approaches 
to purify naïve hPSCs rely on the continuous passaging of the cultures over time, reporter 
systems coupled to naïve state attributes, or primed-enriched surface markers. However, the 
current reporter systems and surface markers have not been examined for their fidelity, nor 
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whether the timing of induction would permit naïve hPSCs to be isolated early during 
reprogramming. Consequently, our current understanding of primed and naïve human 
pluripotent states is based upon long-term in-vitro cultured naïve hPSCs.  
Whilst studying the established primed and naïve states has identified reliable transcriptional 
markers to distinguish the two cell types, we know very little about the transitional period, the 
transcription factors required, or the route(s) taken between the two states. This also applies to 
our knowledge of how the epigenetic landscape is remodelled; we know that naïve hPSCs 
undergo X-chromosome reactivation and a genome-wide remodelling of the DNA methylation 
landscape occurs, however much is unknown about the timing and regulation of these events.  
Establishing a method to study cell populations as they transition from a primed to a naïve state 
would provide important new insights into the order of molecular changes and their possible 
regulatory mechanisms. Given that many of these molecular changes also occur during other 
cellular transitions or at the onset of disease, and may share similar pathways and targets, 
understanding primed to naïve transitioning may have wider implications. In order to accurately 
track the early stages of reprogramming, and the emergence of nascent naïve hPSCs, a new 
approach must be taken.  
To this end, I sought to identify cell surface markers capable of positively distinguishing both 
naïve hPSCs and primed hPSCs, and most importantly nascent naïve hPSCs early during 
reprogramming. The following aims form the contents of this thesis:  
 To produce a comprehensive resource of cell surface markers expressed on naïve and 
primed human pluripotent stem cells. Using this resource, identify and validate 
pluripotent state-specific surface markers using different naïve reprogramming methods 
to ensure their fidelity.  
 Formulate a multiplexed antibody panel that is able to track the dynamics of primed to 
naïve reprogramming. 
 Using the multiplexed antibody panel, isolate and characterise nascent naïve hPSCs 
early during reprogramming and track their subsequent maturation.  
 Perform transcriptional and epigenomic profiling of nascent naïve hPSCs throughout 
primed to naïve reprogramming to decipher the order or molecular changes.  
 Perform a comparative transcriptional analysis of nascent naïve hPSCs at an early time 
point using different reprogramming methods, in order to understand the route(s) to 









































2.1 Cell Culture Reagents 
 
2.1.1 Cell Lines  
 
All hPSC lines used in this study meet the ‘ethically sourced’ criterion (as defined by the 
National Institute for Health Registry and International Stem Cell Forum) and all work was 
carried out with appropriate approval from the UK Stem Cell Bank Steering Committee and the 
Babraham Institute Health and Safety and Human Tissue Ethics Committees. 
 
H9 (primed) 
Human pluripotent stem cell line (WA09) (WiCell Research Institute). (Thomson et al., 1998) 
 
H9 NK2 (primed) 
Derived from H9 hPSCs with the inclusion of a doxycycline inducible NANOG and KLF2 
construct. Obtained from Austin Smith (WT-MRC Cambridge Stem Cell Institute) with 
permission from WiCell. (Takashima et al., 2014). 
 
H9 NK2 (naïve) 
Derived from H9 NK2 primed hPSCs after transgene induced resetting cultured in t2iL+PKCi 
media. Obtained from Austin Smith (WT-MRC Cambridge Stem Cell Institute) with 
permission from WiCell. (Takashima et al., 2014). 
 
FiPSC  (primed) 
FiPSCs were derived from fibroblasts by iPSC reprogramming and cultured in primed (KSR) 
hPSC media. Obtained from Austin Smith (WT-MRC Cambridge Stem Cell Institute). 
(Takashima et al., 2014).  
 
FiPSC (naïve) 
Naïve FiPSCs  were derived from primed FiPSCs and cultured in t2iL+PKCi medium. Obtained 






WIBR3 OCT4-ΔPE-GFP (primed) 
Derived from WIBR3 hPSCs containing an OCT4-GFP reporter on the same allele that has had 
the OCT4 proximal enhancer (PE) removed. OCT4-GFP expression is subsequently indicative 
of distal enhancer activity. Obtained from Rudolph Jaenisch (Whitehead Institute for 
Biomedical Research). (Hockemeyer et al., 2011) 
 
WIBR3 OCT4-ΔPE-GFP (naïve) 
Derived from WIBR3 OCT4-ΔPE-GFP primed hPSCs after primed-to-naïve reprogramming 
using 5iLAF. Obtained from Rudolph Jaenisch (Whitehead Institute for Biomedical Research). 
(Theunissen et al., 2014)  
 
2.1.2 Cell Culture Media  
 
Mouse embryonic fibroblast (MEF) media: 
DMEM (ThermoFisher, 41965039)  
10% Fetal Bovine Serum (FBS) (Sigma-Aldrich, F7524) 
2mM L-Glutamine (ThermoFisher, 25030024) 
50U/ml Penicillin-Streptomycin (ThermoFisher, 15140122) 
0.1mM β-mercaptoethanol (ThermoFisher, 31350010) 
1mM Sodium Pyruvate (ThermoFisher, 11360070) 
1X MEM Non-Essential Amino Acids (ThermoFisher, 11140035) 
 
Primed (KSR) hPSC medium: 
Advanced DMEM (ThermoFisher, 12491015)  
20% Knockout Serum Replacement (KSR) (ThermoFisher, 10828028) 
2mM L-Glutamine (ThermoFisher, 25030024) 
50U/ml Penicillin-Streptomycin (ThermoFisher, 15140122) 
0.1mM β-mercaptoethanol (ThermoFisher, 31350010) 





N2B27 basal medium for t2iL+PKCi media:  
1:1 mixture of DMEM/F12 (ThermoFisher, 21331020) and Neurobasal (ThermoFisher, 
21103049) 
0.5x N2 supplement (ThermoFisher, 17502048) 
0.5x B27 supplement (ThermoFisher, 17504044) 
2mM L-Glutamine (ThermoFisher, 25030024) 
50U/ml Penicillin-Streptomycin (ThermoFisher, 15140122) 
0.1mM β-mercaptoethanol (ThermoFisher, 31350010) 
 
N2B27 basal medium for 5iLA(F) media:  
1:1 mixture of DMEM/F12 (ThermoFisher, 21331020) and Neurobasal (ThermoFisher, 
21103049) 
0.5x N2 supplement (ThermoFisher, 17502048) 
0.5x B27 supplement (ThermoFisher, 17504044) 
2mM L-Glutamine (ThermoFisher, 25030024) 
50U/ml Penicillin-Streptomycin (ThermoFisher, 15140122) 
0.1mM β-mercaptoethanol (ThermoFisher, 31350010) 
50μg/ml Bovine Serum Albumin (ThermoFisher, 15260037) 
0.5% KSR (ThermoFisher, 10828028) 
   
Complete t2iL+PKCi media:   
N2B27 basal medium for t2iL+PKCi media 
1µM PD0325901 (WT-MRC Cambridge Stem Cell Institute) 
1µM CHIR99021 (WT-MRC Cambridge Stem Cell Institute) 
2µM Gö6983 (Tocris, 2285) 








Complete 5iLA(F) media:  
N2B27 basal medium for 5iLA(F) media 
1µM PD0325901 (WT-MRC Cambridge Stem Cell Institute) 
1µM IM-12 (Cell Guidance Systems, SM04) 
1µM SB590885 (Cell Guidance Systems, SM48) 
1µM WH-4-023 (Cell Guidance Systems, SM16) 
10μM Y-27632 (Cell Guidance Systems, SM02) 
20ng/ml human LIF (WT-MRC Cambridge Stem Cell Institute) 
20ng/ml Activin A (WT-MRC Cambridge Stem Cell Institute) 
8ng/ml basic fibroblast growth factor (WT-MRC Cambridge Stem Cell Institute) (omitted in 
5iLA) 
 
2iL+DOX media:   
N2B27 basal medium for t2iL+PKCi media 
1µM PD0325901 (WT-MRC Cambridge Stem Cell Institute) 
1µM CHIR99021 (WT-MRC Cambridge Stem Cell Institute) 
1µg/ml Doxycycline (Sigma-Aldrich, D9891) 
20ng/ml human LIF (WT-MRC Cambridge Stem Cell Institute) 
 
2.1.3 Additional Cell Culture Reagents  
 
PBS - Dulbecco's PBS w/o Calcium and magnesium (Sigma-Aldrich, D8537) 
Reagents for passaging:  
200U/ml Collagenase type IV (ThermoFisher Scientific, 17104019) in Advanced DMEM   
Accutase (ThermoFisher Scientific, A1110501) 
Gentle Cell Dissociation Reagent (GCDR) (StemCell Technologies, 07174) or 0.5mM EDTA 








Reagents for cell culture surface treatment: 
  
0.1% Gelatin (Sigma-Aldrich, G1890) in PBS  
5µg/ml Vitronectin (ThermoFisher Scientific, A14700) in PBS  
Matrigel Basement Membrane Matrix, Growth Factor Reduced (Corning, 354230) diluted 
1:100 in DMEM/F12 
Irradiated MEFs (30 Grays) prepared in-house from active MF1 MEFs (WT-MRC Cambridge 
Stem Cell Institute). 
 
2.1.4 Human Embryos 
 
Immunofluorescent microscopy was performed on human blastocysts by Fredrik Lanner and 
colleagues (Karolinska Institute) and these data are presented in Chapter 3.2.3. Human embryos 
were obtained from the Karolinska University Hospital, Huddinge and from the Carl von Linne´ 
Clinic, Uppsala, either frozen at embryonic day (E) 2 or from preimplantation genetic diagnosis 
testing at E4, with informed consent from donating couple and with ethical approval for these 
experiments to Fredrik Lanner from the Regional Ethics Board, Stockholm (2012/1765-31/1). 
Frozen embryos were thawed with ThawKit Cleave (Vitrolife) into G-1 Plus medium (Vitrolife) 
covered with Ovoil (Vitrolife) and from E3 embryos were cultured in G-2 Plus medium until 
E6-7 in 5% O2, 5%CO2 at 37°C. 
 
2.2 Cell Culture Techniques 
 
All cells were cultured at 37°C in humidified incubators at 5% CO2 and 5% O2. 
 
2.2.1 Preparation of MEF Plates 
 
For cells cultured on irradiated MEFs, the MEF plates were prepared as follows: Tissue culture 
plates were coated with 0.1% gelatin for ≥ 1 hour at 37°C. Excess gelatin was aspirated before 
MEFs were plated. MEFs were plated in MEF medium at a density of 2x106 cells per 6-well 






2.2.2 Preparation of Vitronectin Coated Plates 
 
Primed hPSCs cultured under feeder-free conditions were plated on Vitronectin coated plates. 
Plates were coated with vitronectin for ≥ 1 hour at room temperature. Excess Vitronectin was 
aspirated before cells were seeded.  
 
2.2.3 Preparation of Matrigel Coated Plates 
 
Naïve hPSCs cultured under feeder-free conditions were plated onto Matrigel coated plates. 
Plates were coated with Matrigel for ≥ 1 hour at room temperature or at 4°C overnight. Excess 
Matrigel was aspirated before cells were seeded. 
 
2.2.4 Primed Human Pluripotent Stem Cell Culture 
 
Primed hPSCs were either maintained in primed hPSC medium on a MEF-layer, or feeder-free 
on Vitronectin coated plates in either TeSR-E8 (StemCell Technologies, 05990) or mTeSR1 
(StemCell Technologies, 85850). Primed hPSCs cultured on MEFs were typically passaged 
every 4 days at a 1:4 – 1:6 ratio. Primed hPSCs cultured on Vitronectin were typically passaged 
every 4-6 days at a 1:6 – 1:18 ratio. Media was changed daily. 
 
 
2.2.5 Passaging Primed Human Pluripotent Stem Cells 
 
Passaging primed hPSCs cultured on MEFs was conducted as follows:  
Cell culture medium was aspirated and the culture vesseles were washed gently with PBS, 
followed by incubation with collagenase for 5 minutes at 37°C. Collagenase was aspirated and 
primed hPSC medium was added. Using a 5ml stripette, cells were manually dissociated from 
the culture vessels and collected for centrifugation at 200xg for 5 minutes. Medium was 
aspirated and cell pellets were resuspended in primed hPSC medium and passaged to freshly 
prepared MEF plates.  Cells were passaged every 4 days at a 1:4 – 1:6 ratio.  
 
Passaging primed hPSCs cultured on Vitronectin was conducted as follows:  
Cell culture medium was aspirated and the culture vesseles were washed gently with PBS, 
followed by incubation with GCDR for 5 minutes at room temperature. GCDR was aspirated 
and TeSR-E8 or mTeSR1 was added. Using a 5ml stripette, cells were manually dissociated 
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from the culture vessels, collected and passaged to freshly coated Vitronectin plates. Cells were 
passaged every 4-6 days at a 1:6 – 1:18 ratio. 
 
2.2.6 Naïve Human Pluripotent Stem Cell Culture 
 
Naïve hPSCs cultured in t2iL+PKCi medium or 5iLA medium were maintained as previously 
described (Takashima et al., 2014; Theunissen et al., 2014). Both t2iL+PKCi and 5iLA naive 
hPSCs were typically maintained on a MEF-layer. Complete cell culture medium was made 
and used within 2 days of the addition of cytokines and growth factors. Cell culture medium 
was replaced daily on all cells. For feeder-free culture of t2iL+PKCi naive hPSCs, cells were 
transfered to Matrigel coated plates for at least 2 passages before any experimental work. Both 
t2iL+PKCi and 5iLA naive hPSCs were passaged every 3-4 days. 
 
2.2.7 Passaging Naïve Human Pluripotent Stem Cells 
 
Cell culture medium was aspirated and cells were incubated with Accutase for 3-5 minutes at 
37°C. Cells were collected for centrifugation and Accutase was diluted at least 1:1 with 
DMEM/F12 before centrifugation for 3 minutes at 300xg. Medium was aspirated and cell 
pellets were resuspended in complete medium. t2iL+PKCi naive hPSCs were passaged at a 1:4 
– 1:5 ratio, whereas 5iLA naive hPSCs were passaged at a 1:3 ratio. 
2.2.8 Freezing Cells  
 
Naive hPSCs were typically harvested from confluent (day 3 or day 4) 6-well plates using 
Accutase. Approximately 3x105 naive hPSCs (one confluent well of a 6-well plate) were frozen 
in complete t2iL+PKCi medium containing 10μM Y-27632 and 10% DMSO (Sigma-Aldrich, 
D2650). Primed hPSCs cultured on MEFs were harvested using Collagenase type IV and 
approximately 5x105 primed hPSCs were frozen in complete hPSC medium containing 10μM 
Y-27632 and 10% DMSO. Primed hPSCs cultured under feeder-free conditions were harvested 
using GCDR and approximately 5x105 primed hPSCs were frozen in complete TeSR-E8 or 








 2.2.9 Naïve to Primed Differentiation Protocol  
 
For transition to primed hPSCs, t2iL+PKCi-cultured naïve hPSCs maintained on Matrigel were 
dissociated to single cells with Accutase for 5 minutes. Naïve hPSCs were seeded in t2iL+PKCi 
medium on Matrigel-coated 6-well plates at a density of 2x105 cells per well. Two days later 
(termed day 0 of the differentiation protocol), media was changed to complete mTeSR1 
medium. Cells were passaged on day 4 using Accutase for the first passage, and Collagenase 
type IV for subsequent passages. 
 
2.2.10 Primed to t2iL+PKCi Naïve hPSC reprogramming  
 
The original transgene dependent method of primed-to-naïve reprogramming (NK2 
t2iL+PKCi), takes approximately 28 days (Figure 2.1A), including two weeks of NANOG and 
KLF2 induction (Takashima et al., 2014). Takashima and colleagues also present a condensed 
version of the protocol by reducing NANOG and KLF2 induction down to eight days, followed 
by seven days culture in t2iL+PKCi, collectively taking ≈17 days before clonal derivation and 
expansion of naïve hPSC lines (Figure 2.1B). I further optimised this protocol by reducing 
NANOG and KLF2 induction down to six days, followed by 2 days culture in t2iL+PKCi, 




Figure 2.1. Primed to naïve reprogramming protocols for NK2 t2iL+PKCi method.  
(A and B) Schematic of published primed-to-naïve NK2 t2iL+PKCi reprogramming protocols 
(Takashima et al., 2014). Doxycycline-inducible NANOG and KLF2 transgenes activated by 
doxycycline treatment, followed by maintenance of the naïve state under t2iL+PKCi culture. 
Culture media replaced daily.  
(C) Schematic of further optimised primed-to-naïve NK2 t2iL+PKCi reprogramming protocol 
used throughout this body of work (Collier et al., 2017).  
 
Optimised NK2 t2iL+PKCi reprogramming protocol: 
Primed H9 NK2 hPSCs were dissociated into single cells with Accutase. Primed hPSCs were 
seeded in primed hPSC medium containing 10μM Y-27632 at a density of 2x105 cells per well 
of a MEF-coated 6-well plate. The following day (day 1), media was changed to primed PSC 
media containing 1 µg/ml doxycycline (DOX). On Day 2, media was changed to 2iL+DOX 
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media and replaced daily until day 8 where media was changed to t2iL+PKCi. Cells were 
passaged using Accutase on day 3 at a 1:5 ratio and again on day 7 at a 1:3 ratio. Cells were 
subsequently passaged every 3-5 days with Accutase.  
 
2.2.11 Primed to 5iLA Naïve hPSC reprogramming  
 
Primed hPSCs were dissociated into single cells with Accutase. Primed hPSCs were seeded in 
primed hPSC medium containing 10μM Y-27632 at a density of 2x105 cells per well of a MEF-
coated 6-well plate. The following day (day 1), media was changed to 5iLA media. Dome-
shaped naïve colonies appeared after 4 days of culture in 5iLA. Cells were passaged with 
Accutase on day 5 at a 1:2.5 ratio and again on Day 10. Cells were subsequently passaged every 
4 days with Accutase at a 1:2 – 1:3 ratio. 
 
2.2.12 Colony Formation Assay  
 
Colony formation assays were performed to assess the ability of reprogramming populations to 
form undifferentiated colonies from single cells. 2x104 cells were sorted using Fluorescence 
Activated Cell Sorting into 15ml falcon tubes. Cells were centrifuged and resuspended in either 
t2iL+PKCi containing 10μM Y-27632 or 5iLA and transferred into a well of a MEF-coated 6-
well plate. After 4-5 days of culture the colony number and morphology of each were scored. 
Colony formation assays were performed for at least 3 biological replicates.  
 
2.3 Flow Cytometry  
 
All cells used for flow cytometry were dissociated into single cells using Accutase for 5 minutes 
at 37°C. Cells were washed with PBS containing 2% FBS (flow buffer) and passed through 
30µm cell strainers. Conjugated antibodies were mixed in 50µl Brilliant Stain Buffer (BD 
Biosciences, 563794) and added to 50µl cell suspension containing 1x106 cells. Cells were 
incubated in the dark for 30 minutes at 4°C. Cells were subsequently washed with flow buffer 
and centrifuged at 300xg for 3 minutes. Cell pellets were resuspended in either flow buffer 
alone or with the inclusion of 0.2µg/ml DAPI (Sigma-Aldrich). Where DAPI was not used as 
a live-dead stain, cells were instead stained with a Fixable Viability Dye-eF780 according to 
the protocol followed for standard conjugated antibodies.  
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Single antibody-stained cells or OneComp eBeads (eBioScience, 01-1111-42) were used for 
compensation calculations. Unstained cells, live human cells and Fluorescence Minus One 
(FMO) controls were used in cytometer and gating set up.  
Table 2.1. Antibodies used for flow cytometry and FACS  
 
Reagent Conjugation Source Volume/assay*  
CD130 PE BD Biosciences, 555756 20µl 
CD24 BV650 BD Biosciences, 563720 5µl 
CD24 BUV395 BD Biosciences, 563818 5µl 
CD57 BV605 BD Biosciences, 563895 5µl 
CD57 BV421 BD Biosciences, 563896 5µl 
CD7 PE BioLegend, 343106 1µl 
CD7 PE-Cy7 BioLegend, 343114 5µl 
CD75 eF660 eBioscience, 50-0759-42 5µl 
CD77 PE-CF594 BD Biosciences, 563631 5µl 
CD90 BUV395 BD Biosciences, 563804 5µl 
CD90 PE-Cy7 BD Biosciences, 561558 5µl 
CD90.2 (anti-mouse) APC-Cy7 BioLegend, 105328 5µl 
HLA-ABC BV711 BD Biosciences, 565333 5µl 
Fixable Viability Dye eF780 eBioscience, 65-0865-18 0.6µl 
Donkey anti-mouse  AF568 ThermoFisher Scientific, A10037 1:200 
CD229  R&D Systems, MAB1898 2.5µl 
Hoechst 33342  ThermoFisher Scientific, H3570 1:10000 
DAPI  Sigma-Aldrich, D9542 1:200 
*All antibodies used were first titrated. Optimised concentrations are shown for staining 1x106 
cells in 100µl staining buffer. 
 
Flow Cytometry analysis was performed using a BD LSRFortessa cell analyser (BD 
Biosciences). The machine parameters used are shown in Table 2.2.  
 
Table 2.2. Flow Cytometry machine settings used for analyser acquired data.   
 
Laser(s) Filter(s) BP Filter(s) LP Antibody and fluorophore 
355 379/28  CD90-BUV395 or CD24-BUV395 
488 530/30 505 GFP 
405 450/50  CD57-BV421 
 660/20 630 CD24-BV650 
561 585/15  CD130-PE 
 610/20 600 CD77-PE-CF594 
 780/60 750 CD7-PE-Cy7 
640 670/14  CD75-eF660 
 780/60 750 Cd90.2-APC-Cy7 and Fixable Viability Dye eF780 
 
Fluorescence activated cell sorting (FACS) was performed using a BD FACSAria Fusion Sorter 




Table 2.3. Flow Cytometry machine settings used for FACS. 
 
Laser(s) Filter(s) BP Filter(s) LP Antibody and fluorophore 
355 379/28  CD90-BUV395 or CD24-BUV395 
488 530/30 502 GFP 
405 450/50  CD57-BV421 
 670/30 630 CD24-BV650 
561 582/15  CD130-PE 
 610/20 600 CD77-PE-CF594 
 780/60 735 CD7-PE-Cy7 
640 670/14  CD75-eF660 
 780/60 765 Cd90.2-APC-Cy7 and Fixable Viability Dye eF780 
 
2.3.1 High-Throughput Flow Cytometry Antibody Screening (BioLegend LEGENDScreen) 
 
H9 NK2 primed hPSCs and H9 NK2 t2iL+PKCi naïve hPSCs cultured under feeder-free 
conditions were dissociated into single cells with Accutase. Cells were washed and passed 
through 30µm cell strainers. Cell concentrations were adjusted to 1.8x106 cells/ml in a total 
volume of 30ml. 75µl containing 1.5x105 cells was aliquoted into each well of a 96 well 
LEGENDScreen plate (BioLegend, 700001), containing 25µl reconstituted PE-conjugated 
antibody. Cells were incubated for 20 minutes in the dark at 4°C. Plates were washed twice 
with 200µl Cell Staining Buffer (BioLegend) per well. Cells were resuspended in 160µl Cell 
Staining Buffer containing 1µg/ml DAPI used as a live-dead stain. Samples were analysed 
using a BD LSRFortessa cell analyser (BD Biosciences) containing a high-throughput sampler. 
The BioLegend LEGENDScreen was performed in biological duplicate for both primed and 
naïve hPSCs.  
 
2.3.2 Fluorescence Activated Cell Sorting (FACS) 
 
Cells cultured in t2iL+PKCi were sorted directly into 15ml falcon tubes containing t2iL+PKCi 
medium containing 10μM Y-27632. Cells were washed and transferred onto MEF-coated plates 
in ti2L+PCKi+ Y-27632. After 12-24 hours medium was replaced with t2iL+PKCi medium 
without Y-27632. When sorting cells cultured in t2iL+PKCi medium a strong autofluorescent 
signal in several channels occurs, therefore unstained H9 NK2 naïve hPSCs were used to setup 
the flow cytometers in order to provide an accurate autofluorescent baseline.  
Cells cultured in 5iLA were sorted directly into 15ml falcon tubes containing 5iLAF medium. 
Cells were washed and transferred onto MEF-coated plates in 5iLAF. After two passages, cells 
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sorted into 5iLAF were transferred back to 5iLA. The addition of FGF2 and performing two-
third media changes for the first two passages improved initial cell expansion.  
 
2.4 Flow Cytometry Data Analysis  
 
2.4.1 Flow Cytometry Data Quality Control Analysis (FlowAI) 
 
FCS files were run through FlowAI V1.2.4, a quality control package that filters events affected 
by technical variation, such as abrupt flow rate fluctuations (Monaco et al., 2016). Gating was 
performed in FlowJo V10.1 (FlowJo, LLC) to examine the data and to export live, human cells 
for subsequent FlowSOM analysis.  
 
2.4.2 FlowSOM Analysis 
 
Flow cytometry data was analysed using FlowSOM (V1.2.0), an R bioconductor package that 
uses self-organising maps for dimensional reduction visualisation of flow data (Gassen et al., 
2015). Data was scaled and logicle transformed on import. Cells were assigned to a Self-
Organising Map (SOM) with a 10x10 grid, which groups similar cells into 100 different 
clusters. To visualise similar clusters a minimal spanning tree (MST) was constructed and cell 
counts were log scaled. For the time course experiments, live, human-gated cell populations 
from each day were exported. To account for cell number variation, an equal number of cells 
were exported for each time point. The same analysis was performed for the comparison of 
naïve and primed hPSCs. For the analysis of cell sorted samples, the N4+, N3+ and N4- 
populations were additionally exported and visualised on the MST constructed using day 10 
live, human cells. 









2.5 Molecular Biology  
 
2.5.1 RNA extraction and cDNA synthesis 
 
RNA for RT-qPCR analysis was extracted using the RNeasy Mini kit (QIAGEN, 74106). 1µg 
RNA was reverse transcribed using either SuperScript III (ThermoFisher Scientific, 11732020) 
or QuantiTect Reverse Transcription Kit (QIAGEN, 205311).  
RNA for RNA-sequencing was extracted by lysing cells in TRIzol LS Reagent (ThermoFisher 
Scientific, 10296028) and performing phenol-chloroform RNA extraction according to the 
TRIzol LS protocol for isolation of RNA from Small Quantities.  
 
2.5.2 Reverse Transcription Quantitative Real Time Polymerase Chain Reaction (RT-qPCR) 
 
RT-qPCR was performed using JumpStart SYBR Green ReadyMix (Sigma-Aldrich, S4438) in 
the following reaction: 6µl SYBR Green, 0.24µl 10mM forward primer, 0.24µl 10mM reverse 
primer, 5µl DNA at 50ng/µl concentration, 0.52µl water to a total volume of 12µl. RT-qPCR 
was performed on Bio-Rad CFX96 RT-qPCR machine. RT-qPCR experiments were always 
performed using at least 3 independent biological replicates.  
Table 2.4. Primers for RT-qPCR analysis  
 
Target  Forward Primer Reverse Primer 
GAPDH CGCTGAGTACGTCGTGGAGT GGGCAGAGATGATGACCCTTT 
HMBS AGGAGTTCAGTGCCATCATCCT CACAGCATACATGCATTCCTCA 
POU5F1 GGATATACACAGGCCGATGTGG ATGGTCGTTTGGCTGAATACCT 
SOX2 AACCAGCGCATGGACAGTTAC GTTCATGTAGGTCTGCGAGCTG 
NANOG TCCAGCAGATGCAAGAACTCTC GGTTCTGGAACCAGGTCTTCAC 
DUSP6 TTCCCTGAGGCCATTTCTTT AGTGACTGAGCGGCTAATG 
OTX2 CACTTCGGGTATGGACTTGC GGTACCGGGTCTTGGCAAA 
ZIC2 GATGTGCGACAAGTCCTACAC TGGACGACTCATAGCCGGA 
KLF17 CTGCAACTACGAGAACTGCG GCAAGAATATGGCCTCTACC 
KLF4 GCTGCCGAGGACCTTCTG GCGAACGTGGAGAAAGATGG 
TFCP2L1 TTTGTGGGACCCTGCGAAG TGCTTAAACGTGTCAATCTGGA 
DPPA3 AGACCAACAAACAAGGAGCCT CCCATCCATTAGACACGCAGA 







2.5.3 Western Blotting 
 
RIPA buffer:      10X Tris Buffered Saline (TBS) 1L 
150 mM NaCl      150mM NaCl 
1% NP-40      20mM Tris-HCL 
0.5% sodium deoxycholate        
0.1% SDS      TBS-T: 
50 mM Tris pH 8     1X Tris Buffered Saline 
       0.05% Tween-20 
 
Whole cell lysates were extracted in RIPA buffer with 1x cOmplete Mini EDTA-free Protease 
Inhibitor Cocktail (Sigma-Aldrich, 04693159001). Proteins were separated by electrophoresis 
using 12% SDS-polyacrylamide gels and transferred to 0.45 µM PVDF membranes (Amersham 
Hybond). Membranes were blocked for ≥ 3 hours in TBS-T 5% milk and hybridized to primary 
antibody overnight at 4°C. Membranes were washed three times for 10 minutes in TBS-Tween 
5% milk at room temperature, followed by a 1 hour incubation with HRP-conjugated secondary 
antibodies at room temperature. Detection was performed using Clarity Western ECL reagent 
(Bio-Rad, 1705060). Precision Plus Protein Dual Colour Standards (Bio-Rad, 1610374) was 
used to assess protein molecular weights.  
 
Table 2.5. Antibodies for western blotting   
 
Reagent Source Concentration   
TFCP2L1 R&D Systems, AF5726 1:500 
KLF17 Atlas Antibodies, HPA024629 1:200 
POU5F1 Santa Cruz, sc5279 1:500 
β-ACTIN Sigma-Aldrich, A5441 1:1000 
HRP-conjugated goat-anti-mouse Bio-Rad, 1721011 1:5000 
HRP-conjugated goat-anti-rabbit Bio-Rad, 1706515 1:5000 





2.5.4 Immunofluorescence  
 
Cells were fixed with 2% formaldehyde (Agar Scientific, AGR1026) for 15 minutes and 
permeabilised and blocked overnight with 0.1% Triton X-100 (Sigma-Aldrich, T9284) in PBS 
containing 5% FBS (blocking buffer) at 4°C. Cells were subsequently incubated overnight with 
primary antibodies diluted in blocking buffer at 4°C. Cells were washed with 0.1% BSA and 
0.1% Triton X-100 in PBS three times. Secondary antibodies diluted in blocking buffer were 
then applied and incubated for 4 hours at 4°C, or 1 hour at room temperature. Cells were washed 
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three times in 0.1% BSA and 0.1% Triton X-100 in PBS, with the final wash including 0.2µg/ml 
DAPI or 1µg/ml Hoechst 33342 for 10 minutes.  
 
Images were collected on a Zeiss LSM710-NLO point scanning confocal microscope with a 
20x water immersion objective, and on a NIKON A1-R confocal microscope with a 40x oil 
objective. Z stack images were processed with ImageJ.  
 
Table 2.6. Antibodies used for immunofluorescence microscopy  
 
Reagent Source Concentration   
CD130 BD Biosciences, 555756 1:200 
CD229 R&D Systems, AF1898 1:200 
CD24 BD Biosciences, 555426 1:200 
CD320 R&D Systems, AF1557 1:200 
CD57 BD Biosciences, 555618 1:200 
CD7 BD Biosciences, 555359 1:200 
CD75 Abcam, ab77676 1:400 
CD77 BD Biosciences, 551352 1:200 
CD90 BD Biosciences, 555593 1:200 
HLA-ABC BD Biosciences, 555551 1:200 
KLF17 Atlas Antibodies, HPA024629 1:300 
KLF4 R&D Systems, AF3158 1:200 
NANOG Abcam, ab21624 1:500 
NANOG ReproCELL, RCAB0004P-F 1:200 
POU5F1 Santa Cruz, sc5279 1:300 
SOX2 R&D Systems, MAB2018 1:200 
SSEA4 R&D Systems, MAB1435 1:200 
TFCP2L1 R&D Systems AF5726 1:400 
Donkey anti-mouse AF568 ThermoFisher Scientific, A10037 1:1000 
Donkey anti-mouse AF555 ThermoFisher Scientific, A31570 1:1000 
Donkey anti-mouse AF647 ThermoFisher Scientific, A31571 1:1000 
Donkey anti-mouse AF594 ThermoFisher Scientific, A21203 1:1000 
Donkey anti-rabbit AF647 ThermoFisher Scientific, A31573 1:1000 
Donkey anti-rabbit AF488 ThermoFisher Scientific, A21206 1:1000 
Donkey anti-goat AF555 ThermoFisher Scientific, A21432 1:1000 
Hoechst 33342 ThermoFisher Scientific, H3570 1:10000 
DAPI Sigma-Aldrich, D9542 1:200 
 
 
2.5.5 RNA-Sequencing  
 
RNA-sequencing libraries were constructed from 500ng total RNA using the NEBNext Ultra 
RNA Library Prep Kit for Illumina (NEB, E7530), with the Poly(A) mRNA Magnetic Isolation 
Module (NEB, E7490). Libraries were indexed using NEBNext Multiplex Oligos for Illumina 
(Index Primers Set 1 and Set2) (NEB, E7335 and E7500). Library fragment size and 
concentration was determined using an Agilent Bioanalyzer 2100 and KAPA Library 
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Quantification Kit (KAPA Biosystems, K4828). Samples were sequenced on an Illumina 
NextSeq500 instrument as 150bp single-end libraries at the Babraham Institute Sequencing 
Facility.  
 
2.5.6 RNA-Sequencing Analysis   
 
RNA-sequencing reads were trimmed using trim galore v0.4.2 using default parameters to 
remove the standard Illumina adaptor sequence. Reads were mapped to the human GRCh38 
genome assembly using HISAT 2.0.5 guided by the gene models from the Ensembl v70 release 
(Aken et al., 2017). Quality control checks were performed using FastQC (Andrews, 2014). 
Samtools (Li et al., 2009a) was used to convert to BAM files that were imported to SeqMonk 
v36.0. Further QC of the sequencing data was performed in SeqMonk to ensure an enrichment 
of read counts mapping to exons, that genomic DNA contamination was not present, and more 
generally that the overall distribution of counts was similar between samples. Raw read counts 
per transcript were calculated using the RNA-sequencing quantitation pipeline on the 
Ensemblv70 gene set using directional counts. Differentially expressed genes were determined 
using DESeq2 (Love et al., 2014). Regularised log transformation was applied prior to 
visualization to correct for library size and variance among counts.  
 
Principal component analysis (PCA) was performed using the top 1000 most variable genes 
across all samples. The first and second principal components were plotted. Gene Ontology 
(GO) analysis was performed using AmiGO 2 (Carbon et al., 2009) or EnrichR (Chen et al., 
2013; Kuleshov et al., 2016) with default settings.  
 
2.5.7 Transposable Element Analysis   
 
To analyse the expression of transposable elements, probes were generated in SeqMonk over 
the locations of hg38 repeats and then filtered to remove those which were within 2kb of a gene. 
Raw counts for all of the reads that overlapped with the final probe set were exported and 
collated to generate counts for each class of repeat. Reads were globally normalised per million 
reads. Samples containing > 3% reads outside of genes were discarded due to potential DNA 
contamination that could mask the quantification of transposable elements. PCA was performed 
using the count data for repeat classes containing a minimum of 20 total reads across the 
samples. The first and second principal components were plotted using the top 1000 most 




2.5.8 Quantification of X-linked Genes 
 
To analyse allele-specific expression of X-linked genes, an N-masked genome was generated 
using the positions of heterozygous SNPs on the X chromosome of H9 or WIBR3 cells 
(coordinates kindly provided by Celine Vallot for H9 cells (Vallot et al., 2015). WIBR3 SNPs 
were identified from the GEO SNP array data file: GSM738141. R was used to identify and 
extract heterozygous SNPs (allele difference  >-0.2 and <0.2). LiftOver was used to convert the 
genomic coordinates from hg19 to GRCh38. RNA-sequencing reads were trimmed using trim 
galore v0.4.2/v0.4.4 and aligned to the N-masked genome using HISAT2 (default settings but 
without soft-clipping). The mapped data was sorted into allele-specific reads using SNPsplit 
(v0.3.1/v0.3.3, default parameters, single-end) (Krueger and Andrews, 2016). 
Genome1/genome2 reads, which corresponded to reads carrying either of the two SNPs, were 
imported into SeqMonk. Probes were designed over informative SNP annotations and 
quantified in SeqMonk using linear read counts. Read counts were exported as ‘Feature report’ 
and annotated by gene name. Replicate samples were merged. Transcripts with fewer than 10 
informative reads were classified as ‘not expressed’. Transcripts were classified as biallelic 
when 25%–75% reads originated from the minor allele (i.e., allelic ratio of 3:1). 
 
2.5.9 Comparative Transcriptional Dynamics and Clustering Analysis  
 
Raw read counts per transcript were calculated using the RNA-sequencing quantitation pipeline 
in SeqMonk V.1.40.1. Biological replicates were merged and transcripts containing fewer than 
5 reads were omitted. Integrated Differential Expression and Pathway analysis (iDEP) V0.71 
(Ge, 2017) was used for transcriptional clustering analysis. The top 4000 most variably 
expressed genes were clustered based on Euclidean distance into eight lusters. Eight clusters 
was deemed optimal as this provided eight distinct profiles of transcriptional changes. When 
greater than eight clusters were selected, multiple clusters displayed the same transcriptional 
dynamics. Z-score normalised expression values for each gene cluster were plotted as line 


















3. Comprehensive Cell Surface Protein Profiling to identify 



























3.1.1 Overview of isolation methods to enrich for naïve hPSCs  
 
The predominant method to derive naïve hPSCs is via the reprogramming of primed hPSCs to 
a naïve state. The efficiency of this method is often low and variable between protocols used, 
typically generating a heterogeneous population of cells during the reprogramming process. A 
common approach to purify the naïve hPSCs is via continued passaging of the cultures; 
however, this method relies on the assumption that naïve hPSCs have a competitive advantage 
compared to non-reprogrammed cells, and will therefore be enriched over time. Moreover, this 
approach is not suitable where the culture conditions permit the survival of primed and non-
reprogrammed cell types.  
As a result, several alternative approaches have been devised to prospectively isolate naïve 
hPSCs by capitalising on aforementioned knowledge of molecular hallmarks of naïve 
pluripotency. Examples include reporter systems that monitor OCT4 distal enhancer usage, or 
the levels of HERVH transcription. Whilst these reporter systems can provide a simple readout 
of cell state, they require each cell line to be genetically modified. Furthermore, the timing of 
reporter induction and the fidelity of expression are not always clear, and may not necessarily 
report a robust change in cell state – a point that I will address in more detail in Chapter 5. 
Consequently, there is a need for transgene-independent isolation strategies, which had not been 
reported at the onset of this work.  
During this time however, three reports have subsequently each identified either individual 
markers, or several markers that display primed-specificity (O'Brien et al., 2017; Pastor et al., 
2016; Shakiba et al., 2015a). In each case, the timing of marker expression change is unknown, 
which restricts the utility for isolating nascent naïve hPSCs early during reprogramming. 
Moreover, the lack of a known positive naïve-specific marker limits the unambiguous 







3.1.2 Current strategies to identify and isolate naïve hPSCs are unsuitable for studying the 
early stages of primed to naïve reprogramming 
 
As previously discussed in the main introduction, there are two media formulations that give 
rise to naïve hPSCs with the closest resemblance to preimplantation human blastocysts (Huang 
et al., 2014; Stirparo et al., 2017) (Table 1.1, Table 1.2); these are 5iLA(F) and t2iL+PKCi, and 
are the two methods of reprogramming that I primarily use. The naïve hPSC lines derived using 
5iLA reprogramming were established by continuous passaging. (Theunissen et al., 2016; 
Theunissen et al., 2014). Reliance on this enrichment method means that the molecular 
characterisation of 5iLA(F) hPSCs, such as the DNA methylome and transcriptional analysis, 
has been performed on cells that have undergone ten passages. (Theunissen et al., 2016). The 
same is also true for the transgene dependent method of reprogramming (NK2 t2iL+PKCi), 
which takes approximately 28 days, before the clonal derivation and expansion of naïve hPSC 
lines. Therefore, much of the characterisation of NK2 t2iL+PKCi derived naïve hPSCs has also 
been conducted on cells that have been in culture for at least 40 days (≈10 passages) (Takashima 
et al., 2014). These two reprogramming methods coupled to their current isolation strategies 
prohibit the reprogramming process itself from being studied.  
Most of what we currently know about the naïve state of human pluripotency is based upon 
long-term cultured naïve hPSCs. Therefore, the transcriptomics analysis will predominantly 
highlight the gene regulatory networks (GRNs) that are utilised in maintaining the established 
primed and naïve states. Whilst this has identified reliable transcriptional markers to distinguish 
the two cell types, we know very little about the transitional period, the route(s) taken between 
the two states, and the transcription factors required. The same applies to observations made 
regarding the epigenetic landscape; we know that naïve hPSCs undergo X-chromosome 
reactivation and a genome-wide remodelling of DNA methylation levels, however much is 
unknown about the timing and regulation of these processes.  
Establishing a means to study cell populations as they transition would provide a new insight 
into the order of molecular changes that occur, including the identification of mediators of these 
processes. Many of these molecular changes, such as the rewiring of gene regulatory networks 
and remodelling of the DNA methylation landscape, occur during other cellular transitions or 
at the onset of disease, and may share similar pathways and targets. Therefore, understanding 






Accurately tracking the early stages of reprogramming, and the emergence of nascent naïve 
hPSCs, requires a new approach of identifying and isolating these cells that current methods 
do not permit. To this end, I sought to identify cell surface markers capable of distinguishing 
naïve hPSCs, primed hPSCs, and most importantly nascent naïve hPSCs early during 
reprogramming. 
 
1. Conduct a comprehensive cell surface marker screen on naïve and primed hPSCs  
2. Identify pluripotent state-specific cell surface markers  
3. Validate the state-specificity of candidate surface markers  
i. Using naïve hPSCs derived using different reprogramming methods 
ii. Using preimplantation-stage human embryos  
4. Examine the utility of candidate markers for tracking naïve to primed transition  


















The gold standard technology for detecting and isolating live cell populations is via flow 
cytometry and fluorescent activated cell sorting (FACS). This technology can be used in 
combination with recently developed antibody library screens that contain hundreds of titrated 
antibodies. Individual antibodies are allotted to each well of a 96-well plate to enable high-
throughput screening of your desired cell type. These antibody library screens present an 
opportunity to examine a large quantity of antibodies, many of which have not previously been 
associated with pluripotent stem cells. Even so, our knowledge of markers expressed on the cell 
surface of naïve hPSCs is very limited; therefore, a wider screening approach is sensible.  
 
3.2.1 Comprehensive cell surface marker screen of naïve and primed hPSCs 
 
Naïve and primed hPSCs were profiled using two different antibody library screens to identify 
pluripotent state-specific surface markers. These were the BioLegend’s LEGENDScreen that I 
performed, and the BD-Lyoplate conducted by our collaborators at the Karolinska Institute. 
Both screens were used in order to increase the number of cell surface markers that could be 
examined, as some were unique to one screen. The LEGENDScreen contained 135 unique 
antibodies, whereas the BD-Lyoplate contained 45 unique antibodies. The overlapping number 
of antibodies covered by both screens was 197, with 109 surface markers covered by different 
antibody clones and 88 antibodies being the same clone. H9 primed and H9 naïve hPSCs were 
reprogrammed and maintained under two different naïve culture conditions (5iLA and NK2 
t2iL+PKCi) to identify robust state-specific markers, and to capture any variation related to the 
reprogramming method and maintenance culture media used. Our collaborators at the 
Karolinska Institute profiled H9 primed and naïve hPSCs cultured under 5iLA conditions, 
whilst I profiled H9 NK2 primed and NK2 t2iL+PKCi naïve cultured cells. Primed and naïve 
hPSC samples were analysed by high-throughput flow cytometry, and state-specific markers 






Figure 3.1. Schematic of the experimental design.  
Human primed (cultured in Primed (KSR) medium on MEFs and TeSR-E8 on Vitronectin) and 
naïve (cultured in 5iLAF and t2iL+PKCi conditions) H9 hPSCs were profiled by two antibody 
library screens that targeted 377 cell surface markers. Samples were analysed by high-
throughput flow cytometry. State-specific surface markers were identified according to the 
fluorescence intensity of each marker.  
 
The percentage of positive cells for each cell type was determined for each surface marker after 
replicate values were averaged (Figure 3.2). The results have identified more than 50 primed-
specific markers, 40 shared markers, and 8 naïve-specific markers (Figure 3.2). Reassuringly, 
the dataset includes previously reported cell surface markers that are known to be expressed in 
both primed and naïve hPSCs, such as TRA-1-60 and TRA-1-81 (Chen et al., 2015; Gafni et 
al., 2013; Pastor et al., 2016; Qin et al., 2016; Shakiba et al., 2015a; Ware et al., 2014). In line 
with previous reports of displaying primed-specificity, CD24 and SSEA-4 were 
heterogeneously or lowly expressed in naïve hPSC cultures (Pastor et al., 2016; Shakiba et al., 
2015a). The results have also revealed cell surface markers that are newly identified as being 
expressed in human PSCs; examples include CD46, CD151, MCAM (CD146) and PDPN 
which were uniformly expressed in both primed and naïve hPSCs and provide a useful set of 
common markers. More than 50 primed state-specific markers were identified, such as THY1 
(CD90), B3GAT1 (CD57), HLA-A-B-C, and members of the NOTCH family of receptors. 
However, far fewer naïve-specific surface markers were identified with only 8 being uniquely 
expressed in naïve hPSCs. These include LY9 (CD229), CD77 and CD75 that are glycosylated 





Figure 3.2. Identification of pluripotent state-specific cell surface markers  
Each dot represents a different cell-surface marker and their position along the XY axis is 
determined by the percentage positive in naïve and primed hPSCs. Results are averaged from 
one to three independent assays per cell type. One BD-Lyoplate screen was conducted on 
5iLAF cultured H9 naïve hPSCs and parental H9 primed hPSCs. Two biological replicates of 
H9 NK2 t2iL+PKCi naïve hPSCs and parental H9 NK2 primed hPSCs were independently 
screened using BioLegend’s LEGENDScreen. Based on their position in the chart, a subset of 
cell surface proteins have been categorised as naïve-specific (blue), primed-specific (red), and 
common to both naïve and primed hPSCs (green).  
 
The previous studies that examine surface marker expression between naïve and primed hPSCs 
rely exclusively on primed-specific markers (O'Brien et al., 2017; Pastor et al., 2016; Shakiba 
et al., 2015a). This approach is limited by the assumption that surface marker expression 
changes accurately reflect a change in pluripotent state; however, it is possible that surface 
markers may change in response to the signaling cues provided when the culture media is 
changed at the onset of primed to naïve reprogramming. In this instance, the primed-specific 
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markers would be unable to discriminate reprogramming populations, including nascent naïve 
hPSCs. With this in mind, I set out to validate a cohort of primed and naïve specific markers; 
each conjugated to different fluorophores, with the overarching aim to generate a multiplexed 
panel of antibodies that could be used simultaneously.   
 
3.2.2 Validation of state-specific surface markers 
 
One of the drawbacks to using flow cytometry or FACS to identify and isolate cell types is the 
requirement for high-quality antibodies. The selection of candidates that could be validated was 
restricted by the availability of antibodies with compatible conjugations. Many of the antibodies 
were only available in common conjugations, such as phycoerythrin (PE), or fluorescein 
(FITC). Due to the OCT4-ΔPE-GFP reporter construct integrated into hPSC lines that I 
commonly use during primed to naïve reprogramming, FITC antibodies would not be 
compatible. This therefore limited the selection of antibodies down to four compatible 
conjugations for naïve-specific markers targeting CD7, CD75, CD77 and CD130. The selection 
of primed-specific markers was based upon a newly identified hPSC marker CD57, and two 
additional primed-specific markers CD24 and CD90. Verification of the state-specificity of the 
individual markers is shown in Figure 3.3 using H9 NK2 primed and H9 NK2 Naïve hPSCs 
cultured under t2iL+PKCI conditions.  
Consistent with the expression profiles seen from the antibody screen, all predicted primed 
state-specific antibodies exhibit a good separation in fluorescence intensity by flow cytometry 
when comparing primed and naïve hPSCs (Figure 3.3). It is clear that naïve hPSCs are 
uniformly negative for all primed-specific markers examined. Similarly, the four naïve-specific 
markers tested were consistently absent in primed hPSCs; but were all expressed in naïve 
hPSCs, confirming their state-specificity. The variation and magnitude of expression for some 
of the markers was variable. For example, CD77 was unevenly expressed across the naïve hPSC 
population. By comparison, CD130 was uniformly expressed, however the magnitude of 







Figure 3.3. Validation of individual cell surface markers in Naïve H9 NK2 cells cultured in 
t2iL+PKCi and parental Primed H9 NK2 cells.  
Histograms of flow cytometry data using conjugated antibodies for primed cells (red) and naïve 
cells (blue). Representative phase-contrast image (left); scale bars indicate 100µm. 
 
It is possible that the state-specific markers identified could be specific to the H9 hPSC line and 
could also vary between naïve culture conditions used. I therefore sought to examine additional 
primed and naïve hPSC lines and naïve culture conditions. Shown in Figure 3.4 is the flow 
cytometry data for an iPSC derived line from human fibroblasts (FiPSC), with the primed cells 
cultured in KSR media and naïve cells cultured in t2iL+PKCi. Similar state-specific expression 
profiles could be seen for most of the markers; however, CD24 expression failed to clearly 
distinguish primed and naïve hPSCs, in contrast to the prior results using H9 hPSCs. Likewise, 
CD77 expression was observed in a proportion of primed FiPSCs, as well as being highly 
expressed in naïve FiPSCs.  
 
Figure 3.4. Validation of individual cell surface markers in Naïve FiPSCs cultured in 
t2iL+PKCi and parental Primed FiPSCs. 
Histograms of flow cytometry data using conjugated antibodies for primed cells (red) and naïve 
cells (blue). Representative phase-contrast image (left); scale bars indicate 100µm. 
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To exclude the possibility of variation between culture conditions, 5iLAF cultured H9 naïve 
hPSCs were examined by our collaborator, Fredrik Lanner (Figure 3.5). In agreement with 
t2iL+PKCi cultured naïve hPSCs (Figure 3.3), all naïve-sate specific markers displayed 
comparable expression profiles. Primed state-specific markers also displayed concordant 
expression, with CD24 exclusively expressed in primed cells. An additional primed-specific 




Figure 3.5. Validation of individual cell surface markers in Naïve H9 cells cultured in 5iLAF 
and parental Primed H9 cells.  
Histograms of flow cytometry data using conjugated antibodies for primed cells (red) and naïve 
cells (blue); Flow cytometry data provided by Sarita Panula. Representative phase-contrast 
image of naïve and primed cells (left); scale bars indicate 100µm. 
 
As previously discussed within the introduction, 5iLA(F) and t2iL+PKCi naïve hPSCs are 
maintained in culture media targeting similar signaling pathways, and ultimately exhibit very 
similar naïve hallmark characteristics. I therefore sought to examine the state-specific 
expression of our surface markers on naïve hPSCs generated using commercially available 
RSeT medium, which is based upon the NHSM formulation (Gafni et al., 2013). As noted in 
Table 1.1, the naïve hPSCs derived under these conditions generate an alternative type of naïve-
like hPSCs with dissimilar properties. Perhaps unsurprisingly, RSeT naïve-like hPSCs fail to 
express any of the naïve-specific markers, but two primed-specific markers (CD24 and CD90) 






Figure 3.6. Validation of individual cell surface markers in Naïve-like H9 cells reprogrammed 
and maintained in RSeT medium and parental Primed H9 cells.  
Histograms of flow cytometry data using conjugated antibodies for primed cells (red) and 
naïve-like cells (blue). Representative phase-contrast image of naïve and primed cells (left); 
scale bars indicate 100µm. 
 
3.2.3 Human embryo validation of state-specific surface markers 
 
To investigate the relevance of the identified surface markers to human embryo development, 
embryonic day 6-7 human embryos were stained with each antibody (Figure 3.7). This stage of 
embryonic development represents the preimplantation-stage, which naïve hPSCs share many 
characteristics with (Table 1.1). At this time point, all three lineages of the human blastocyst 
(the trophectoderm, epiblast and primitive endoderm) should be established (Petropoulos et al., 
2016). This is confirmed by the presence of both NANOG-positive cells of the epiblast and 
NANOG-negative cells of the primitive endoderm found within the inner cell mass, (indicated 
in Figure 3.7 - ICM zoom-in for CD7 and CD130 staining). Whilst CD7 signal was not detected, 
CD75, CD77 and CD130 were detected at the cell surface of human blastocyst cells. Of note, 
CD130 was particularly enriched within the cells of the ICM; whereas CD75 and CD77 were 
expressed in the majority of the cells, including the ICM. This indicates that their specificity is 
not restricted to cells of the human epiblast. By contrast, all of the primed-specific surface 
markers were undetectable, except for HLA-A,B,C which was present in a small number of 







Figure 3.7. Immunofluorescent microscopy validation of candidate cell surface markers in 
human blastocysts.  
Cross-sections of embryonic day 6 human blastocysts labelled with candidate naïve-specific 
and primed-specific surface markers together with NANOG, to reveal the location of the 
epiblast, and hoechst to stain DNA in all cells. Scale bars, 50µm. Embryo immunofluorescent 
microscopy data provided by members of Fredrik Lanner’s lab (Sarita Panula, John Paul Schell, 
Alvaro Plaza Reyes and Sophie Petropoulos).  
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3.2.4 Multiplexed antibody panel to distinguish naïve and primed human PSCs  
 
Given the encouraging results obtained during the individual antibody validation studies, I 
decided to compile a multiplexed antibody panel consisting of three primed-specific markers 
(CD24, CD57, CD90), and four naïve-specific markers (CD7, CD75, CD77 and CD130) 
(Figure 3.8A). Whilst there may be individual markers that are capable of distinguishing 
established primed from naïve hPSCs, the expression of each marker throughout 
reprogramming is unknown. Moreover, primed to naïve reprogramming generates a 
heterogeneous population of cells at the early stages, therefore using a multiplex antibody panel 
containing primed and naïve-specific markers will be more reliable for accurate cell type 
identification.  
 As reprogramming of primed hPSCs to a naïve state is conducted on a layer of mouse 
embryonic fibroblasts, I additionally included an APC-Cy7 conjugated anti-CD90.2 antibody 
that recognises MEF cells, so that these could be excluded; a viability dye was also included on 
the same channel. This reduced the number of channels to compensate during multi-parameter 
flow analysis, as cells positive for APC-Cy7 were either MEFs or dead cells (Figure 3.8B). 
Moreover, primed-specific marker HLA-A,B,C was not included in the final panel. The weaker 
HLA-A,B,C expression in combination with a BV711 conjugation could not be accurately 
compensated for whilst using CD24 conjugated to BV650. Nonetheless, a combination of seven 








Figure 3.8. Flow cytometry gating scheme to isolate live-human single cells.  
(A) A list of antibodies that are combined to form a multiplexed panel. The information in 
brackets shows the fluorophore conjugation of each antibody. See Table 2.1 for antibody details 
and Table 2.2 for flow cytometer parameters used. 
(B) Flow cytometry dot plots show the gating scheme for H9 Naïve hPSCs. The first panel 
enables the isolation of cells versus debris, and the subsequent two panels identify single cells. 
The fourth panel allows live and human cells to be identified by excluding MEF cells that are 
positive for CD90.2 conjugated to APC-Cy7, and dead cells that are positive for an eF780 
viability dye. The final panel proves an example to show the final gated population of live-
human naïve PSCs that are positive for naïve-state markers CD75 and CD130.   
 
To ensure that all conjugation were compatible when run simultaneously in a single panel, naïve 
and primed hPSCs were stained with all seven state-specific antibodies. Shown are the pairwise 
expression profiles for all seven markers in the format of contour plots (Figure 3.9). CD57, a 
primed specific marker, is plotted on the y axis for all combinations. The results indicate a clear 
state-specific expression profile for all markers, in line with the individual marker validations 
performed previously. Encouragingly, there is a clear separation between naïve and primed 
hPSCs, which will be critical when using the antibody panel to isolate naïve hPSCs at low 





Figure 3.9. A Multiplex antibody panel to distinguish between naïve and primed hPSCs.  
Flow cytometry contour plots of pairwise antibody combinations. The primed-specific marker 
CD57 is on the y axes, and the different primed-specific markers and naïve-specific markers 
are on the x axes. H9 NK2 Primed (red) and H9 NK2 t2iL+PKCi cultured naïve hPSCs (blue) 
are shown for each antibody combination.  
 
A caveat with using conventional analysis methods for flow cytometry data is the inability to 
examine more than two markers simultaneously. For a panel with seven markers, 21 unique 
pairwise comparison plots would be required to examine all of the data. Even then, further 
gating and additional plotting would be required to examine the expression profiles of any sub-
populations. Therefore, to overcome this limitation I used a dimensional reduction visualisation 
package called FlowSOM (Van Gassen et al., 2015). FlowSOM works by clustering the cells, 
typically into 100 different clusters, based on similar expression profiles obtained via flow 
cytometry. A self-organizing map (SOM), which is a type of artificial neural network, performs 
unsupervised clustering to order the different clusters; these are subsequently plotted as a 
minimal spanning tree (MST). This approach has the advantage of providing a clear overview 
of the expression levels of each marker across all cells. Moreover, subpopulations can be 
identified in an unsupervised manner. FlowSOM analysis was performed and is shown in Figure 
3.10, using the same flow cytometry data plotted in Figure 3.9. The results again show two 
well-separated populations that correspond to naïve and primed hPSCs. This reiterates the 
finding that the antibody panel is capable of discriminating between the two cell types, (Figure 
3.10B - right panel). The expression levels for each marker can be overlaid onto the MST and 













Figure 3.10. A Multiplex antibody panel to distinguish between naïve and primed hPSCs. 
(A) Schematic of the experimental design and dimensional reduction visualisation of Flow 
cytometry data. The multiplexed panel of antibodies was applied to pluripotent cell types and 
flow cytometry data is obtained. FlowSOM visualisation enables the visualisation of all cells 
and multiple markers simultaneously by clustering cells of similar expression profiles together.  
 (B) FlowSOM visualization of flow cytometry data for all antibodies in the panel. An 
unsupervised self-organising map arranges the cells into clusters (represented by circles) 
according to similarities in their cell surface marker expression profiles (right). Overlaying the 
identity of the cell type within each cluster reveals a clear separation of H9 NK2 naïve hPSCs 
cultured under t2iL+PKCi conditions (blue) and H9 NK2 primed (red) populations. The 
heatmap panels (left) show the expression level of each cell surface marker in the cell clusters. 
Clusters are arranged in the same position as for the minimal spanning tree of the self-
organising map.  
 
To ensure the robustness of the multiplexed antibody panel, two additional naïve and primed 
hPSC lines were examined; primed and naïve FiPSCs cultured in t2iL+PKCi (Figure 3.11A), 
and primed and naïve WIBR3 cells cultured in 5iLA (Figure 3.11B). As before, there is a good 
separation between the two cell types, particularly for the FiPSC line. Of note, the WIBR3 
hPSC line contains an OCT4-ΔPE-GFP reporter that is active in naïve hPSCs (Theunissen et 
al., 2014). The FlowSOM results showed a good overlap in GFP expression with the naïve-
specific surface markers, providing further authentication for the antibody panel. Curiously, 
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there is some overlap between the WIBR3 primed and 5iLA naïve hPSCs, with clusters 
containing both cell types. This is not so surprising, given that ≈40% of 5iLA cultured naïve 
hPSCs have been shown to express primed-specific marker SSEA-4, and display a primed or 
differentiated morphology (Pastor et al., 2016).  These clusters could therefore correspond to a 
differentiated cell type, as both primed and naïve state-specific markers are lowly expressed, or 
absent.  
 
Figure 3.11.  Multiplexed antibody panel enables robust distinction between naïve and primed 
hPSCs cultured under different naïve conditions.  
(A and B) FlowSOM visualisation of flow cytometry data for all antibodies in the panel. (A) 
FlowSOM visualisation of FiPSC primed and FiPSC naïve hPSCs cultured under t2iL+PKCi 
conditions (right) exhibit clear separation according to cell type. (B) FlowSOM visualisation of 
WIBR3 primed and WIBR3 naïve hPSCs cultured under 5iLA conditions.   
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To further test the sensitivity of the antibody panel to discriminate naïve and primed hPSCs, I 
performed a spike-in experiment where primed and naïve hPSCs were mixed together to contain 
90% primed and 10% naïve cells (Figure 3.12 – right panels). The bottom left panel shows the 
expression profiles of naïve hPSCs stained with two naïve-specific markers (CD75 and 
CD130). The same gating was used to demonstrate that primed hPSCs are not detected by this 
gating (top left panel), but importantly the spike-in naïve population could be identified with 
just these two markers. Moreover, these cells were almost exclusively negative for primed 
specific markers CD57 and CD24, as would be expected. This reiterates the previous findings 
that the antibody panel is capable of discriminating between the two cell types, and opened up 




Figure 3.12. Assessing the sensitivity of identified state-specific markers to discriminate 
between primed and naïve hPSCs.  
Flow cytometry contour plots show that the identified panel of state-specific markers can 
discriminate between primed and naïve hPSCs when the cells are mixed together. Left: the 
expression levels of two naive-specific markers (CD75 and CD130) in H9 primed (top) and 
naïve (bottom) hPSCs. Top right: the expression levels of the same markers in a sample of 90% 
primed hPSCs mixed with 10% naïve hPSCs. Bottom right: Cells positive for both CD75 and 
CD130 do not express the primed-specific markers CD57 and CD24. Gates were drawn based 









3.2.5 Time course naïve to primed differentiation 
 
To further test the utility of the antibody panel, it was important to examine whether the state-
specific markers tracked the changes in cell state, rather than a direct response to changes in the 
signaling environment. I thereby examined the cell surface expression profiles of all markers 
across a state transition experiment, firstly by transitioning naïve cells to a primed state. To 
initiate naïve to primed conversion, naïve hPSCs cultured under feeder-free conditions in 
t2iL+PKCi were switched into TeSR-E8 medium, containing high levels of TGFβ and FGF. 
Naïve hPSCs progressively changed in their morphology from compact spherical colonies to a 
flattened, cobblestone primed appearance (Figure 3.13A). I monitored the cells every two days 
by flow cytometry using the multiplexed antibody panel. Example dotplots for two naïve-
specific and two primed-specific markers are shown across the time-course (Figure 3.13B). The 
expression of naïve-specific markers CD75 and CD130 gradually reduced as the time-course 
progressed. Likewise, CD57 displayed a progressive upregulation as cells transitioned from a 
naïve to primed state, with the onset of expression at day four onwards. By contrast, primed-
specific marker CD90 was rapidly induced two days into the conversion protocol, to similar 
levels observed in primed hPSCs. This strongly indicates that CD90 is responsive to the 
signaling cues provided by the culture media, rather than a pluripotent state change (Figure 
3.13B).  
FlowSOM analysis was subsequently performed to obtain a complete overview of the dynamics 
of all markers across the conversion experiment. The flow cytometry data collected for each 
time-point was merged into a single file. Importantly, FlowSOM has the ability to retain all 
labelling information, and expression values for each individual cell. Consequently, the 
FlowSOM MST output can be readily labelled to indicate the cell origin, in this case the 
transitional time-point. The FlowSOM clustering results show a sequential transition from the 
naïve to primed state (Figure 3.13C – right panel). Interestingly, the individual cell surface 
markers exhibit different dynamics during the ten-day time course.  However, the majority of 
markers encouragingly track the change in cell state (Figure 3.13C – left panel). From the 
FlowSOM clustering results it is also notable that by day 10, CD7 and CD130 have yet to be 
fully downregulated, and CD24 and CD57 fully upregulated. This infers that more than 10 days 




Figure 3.13. Cell Surface marker expression levels track the dynamics of naïve-to-primed hPSC 
transition. 
(A) Phase contrast images of H9 hPSCs reveal the morphological changes that occur during 
naïve-to-primed state transition by switching t2iL+PKCi culture conditions to TeSR-E8. Scale 
bars, 100 µm. 
(B) Flow cytometry dotplots of pairwise antibody combinations over the time course. Primed-
specific markers are shown on the y-axis (CD57, top; CD90, bottom) and naïve-specific 
markers are shown on the x-axis (CD75, top; CD130, bottom). 
(C) FlowSOM visualization of the flow cytometry time course data for H9 hPSCs. The minimal 
spanning tree of the self-organising map displays unsupervised clustering of the samples based 
on their cell surface marker expression levels (right). The results reveal a progressive change 
in cell surface protein expression during conversion from the naïve state to the primed state. 
The heatmap shows the expression level of each cell surface marker in the cell clusters (left). 




The next crucial stage of the analysis was to examine the surface marker expression dynamics, 
this time going from a primed state to a naïve state. As discussed in the main introduction, all 
reprogramming protocols typically require >30 days to establish naïve hPSCs at a sufficient 
purity and cell number for subsequent experiments. The transgene dependent method (NK2 
t2iL+PKCi) of reprogramming take approximately 28 days before clonal isolation, or ≈17 days 
using the condensed protocol (Figure 2.1). As mentioned in section 2.2.10, I further modified 
this protocol by reducing NANOG and KLF2 induction down to six days, followed by two days 
culture in t2iL+PKCi (Figure 3.14A). Phase contrast images show the morphological changes 
during this transition (Figure 3.14B), with dome-shaped naïve colonies formed by day 10.  
 
Figure 3.14. Optimisation of NK2 t2iL+PKCi primed to naïve reprogramming method. 
(A) Schematic of primed-to-naïve reprogramming protocol. Doxycycline-inducible NANOG 
and KLF2 transgenes were activated for the first 8 days, and then doxycycline was withdrawn 
and PKCi was added; culture media was replaced daily.  
(B) Phase contrast images of H9 hPSCs reveal the morphological changes that occur during 
primed-to-naïve reprograming by switching primed (KSR) cultured hPSCs to t2iL+PKCi 






To examine whether the surface markers tracked the change in cell state going from a primed 
to naïve state, I again performed flow cytometry every two days for a period of ten days (Figure 
3.15). Primed-specific marker CD57 shows a gradual decrease in expression across the 10 days. 
Conversely, CD24 displays a more notable decline as early as day 2. Overall, primed-specific 
markers are silenced in the majority of the population (Figure 3.15A). By contrast, naïve-
specific markers CD75 and CD130 are only upregulated in a sub-population of cells, with a 
clearly distinguishable negative and positive fraction evident by day 10 (Figure 3.15A).   
The global overview provided by FlowSOM again exhibits a stepwise transition from the 
primed to naïve state, largely recapitulating pseudotime. However, along the trajectory are 
several branch points of divergence at day 8 and day 10. The majority of day 8 reprogramming 
cells express naïve-specific markers CD7 and CD130; just over half express CD77, but very 
few cells additionally express CD75 (Figure 3.15B and Figure 3.16). The profile observed for 
day 10 reprogramming cells is markedly different, with CD75 now detectable in 50-60% of the 
cells. Perhaps surprisingly, CD130 expression reduces from ≈85% on day 8, to ≈55% by day 
10; similarly, CD7 expression declines from ≈90% positive down to ≈40% (Figure 3.16). It 
appears that the naïve-specific markers are resolved into positive and negative fractions, 
perhaps attributed to the removal of doxycycline and the addition of the PKC inhibitor between 
days 8 –10. Alternatively, the cells that a refractory to reprogramming could have a growth 
advantage and begin to dominant the cultures. Conversely, the naïve culture media may present 
a selection pressure to induce senescence in the refractory reprogramming populations.   
Nonetheless, the FlowSOM results highlight that day 10 cells cluster closely to established 







Figure 3.15. Cell Surface marker expression levels track the dynamics of primed-to-naïve hPSC 
reprogramming.  
(A) Flow cytometry dotplots of pairwise antibody combinations over the time course. Primed-
specific markers are shown on the y-axis (CD57, top; CD24, bottom) and naïve-specific 
markers are shown on the x-axis (CD75, top; CD130, bottom). 
(B) FlowSOM visualization of the flow cytometry time course data for H9 hPSCs. The minimal 
spanning tree of the self-organising map displays unsupervised clustering of the samples based 
on their cell surface marker expression levels (right). The results reveal a progressive change 
in cell surface protein expression during conversion from primed to naïve pluripotency. The 












Figure 3.16. Cell Surface marker expression levels resolve upon the transition to the final stages 
of naïve pluripotency.  
Flow cytometry dotplots of pairwise antibody combinations highlighting day 8 (top row) and 
day 10 samples (bottom row). Naïve-specific markers show different dynamics between the 
two time points.  
 
 
3.2.7 Time course primed to 5iLA naïve reprogramming  
 
Given the low efficiency of primed to naïve reprogramming observed with the NK2 t2iL+PKCi 
method, I wondered whether this would additionally apply to alternative methods, such as 5iLA. 
I therefore profiled cells in a similar manner, performing flow cytometry with the multiplex 
antibody panel every two days. Interestingly, the phase contrast images taken throughout 
reprogramming indicate that the efficiency may be higher using 5iLA. Numerous compact, 
dome-shaped colonies formed per field of view by day 10 – notably more frequent than 
observed for NK2 t2iL+PKCi reprogramming (Figure 3.17). In line with this observation, 
FlowSOM analysis shows that day 10 cells and established 5iLA naïve hPSCs formed well-
integrated clusters (Figure 3.18B). The cell surface marker expression profiles display different 
dynamics between the two reprogramming methods. Markers CD7 and CD77 increase in a 
proportion of cells as early as day 4. Moreover, CD75 and CD130 are expressed in >50% of 
cells from day 6 onwards (Figure 3.18A). The OCT4-ΔPE-GFP reporter system has previously 
been used to identify naïve hPSCs. Providing further validation, a high overlap between the 
naïve-specific surface marker expression profiles and OCT4-ΔPE-GFP expression occurs 




In summary, the state-specific surface markers collectively track the dynamics of pluripotent 
state transitions, in both directions. By examining the temporal dynamics of expression onset 
(for naïve-specific) and expression silencing (for primed-specific markers), the earliest window 
in which to prospectively identify and isolate putative naïve hPSCs has been identified as day 
10 for NK2 t2iL+PKCi reprogramming, and as early as day 8 for 5iLA. These are both much 
earlier time points that previously possible.  
 
 
Figure 3.17. Morphological changes associated with primed to naïve reprogramming under 
5iLA culture.  
(A) Schematic of 5iLA primed-to-naïve reprogramming protocol. Cells were passaged on day 
5; culture media was replaced daily.  
(B) Phase contrast images of WIBR3 primed hPSCs reveal morphological changes that occur 
during primed-to-naïve reprograming by switching primed (KSR) cultured hPSCs to 5iLA 







Figure 3.18. Cell Surface marker expression dynamics during primed to naïve reprogramming 
under 5iLA culture conditions. 
(A) Flow cytometry dotplots of pairwise antibody combinations over the time course. Primed-
specific markers are shown on the y-axis (CD57, top; CD90, bottom) and naïve-specific 
markers are shown on the x-axis (CD75, top; CD130, bottom).  
(B) FlowSOM visualization of the flow cytometry time course data for WIBR3 hPSCs. The 
minimal spanning tree of the self-organising map displays unsupervised clustering of the 
samples based on their cell surface marker expression levels (right). The heatmap shows the 














3.3 Discussion  
 
Employing antibody library screens enabled the cell surface marker expression profiles of naïve 
and primed hPSCs to be comprehensively studied. The approach of using two different naïve 
culture systems ensured that the classification of state-specific markers was robust and not 
biased by the culture medium used. Collectively the screens identified over 50 primed-specific 
markers, 8 naïve-specific markers, and 40 common markers; many of these have not been 
previously associated with pluripotent stem cells. One of the main advantages to using an 
antibody library screen was the inclusion of antibodies that detect glycosylated epitopes. 
Amongst the state-specific surface markers were a large number of glycosylated epitopes, such 
as CD77, CD75, and several SSEA family members. An alternative method of predicting 
surface-markers by analysing transcriptional data would have identified naïve-specific markers 
CD7 and CD130 (IL6ST), which both have assigned genes that are upregulated in naïve hPSCs. 
However, identifying modified epitopes would not be possible unless the enzymes involved in 
their catalysis are known. A second benefit is the quantity and diversity of antibodies that were 
screened, with 377 surface markers examined, a selection of which were tested by two different 
antibody clones to collectively cover 486 unique antibodies in total. Concordant results were 
obtained for different clones targeting the same surface-marker, which provided additional 
verification.  
The screens identified eight naïve-specific surface markers that are the first described 
candidates that can positively distinguish naïve from primed hPSCs. The three previous reports 
that use surface markers to distinguish these two cell types rely only on primed-enriched surface 
markers (O'Brien et al., 2017; Pastor et al., 2016; Shakiba et al., 2015a). It is still unknown 
whether these markers accurately track the dynamics of primed to naïve conversion, by which 
expression is lost specifically and only once primed cells have reprogrammed. The lack of a 
known positive marker for human naïve PSCs has restricted the ability to unambiguously 
identify and isolate naïve hPSCs within a heterogeneous reprogramming population. To resolve 
this, I developed a multiplexed panel of antibodies consisting of three primed and four naïve-
specific markers. By testing the panel on different PSC lines, I could detect line-specific 
differences. Similarly, I examined three different culture mediums: t2iL+PKCi, 5iLA and ReST 
medium (based upon NHSM). The results for t2iL+PKCi and 5iLA were comparable, and the 
state-specific markers were clearly able to distinguish between naïve and primed cell types. 
However, RSeT naïve-like cells showed a peculiar expression profile in that none of the naïve-
specific markers were expressed. Interestingly, primed-specific marker CD24 had been 
downregulated by passage 4 under RSeT conditions (Figure 3.6). However, Shakiba and 
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colleagues found that it took ten passages under NHSM conditions, indicating that RSeT 
medium may induce naïve-like characteristics earlier than NHSM. Even so, it is clear that this 
naïve formulation does not derive cells with the desired naïve hallmark characteristics, such as 
a hypomethylated genome and the presence of two active X-chromosomes (Table 1.1, Table 
1.2)(Pastor et al., 2016; Vallot et al., 2017). For this reason, I continue the focus of this body of 
work using t2iL+PKCi and 5iLA. 
Given the encouraging results that the multiplexed antibody panel could distinguish naïve and 
primed hPSCs, our collaborators at the Karolinska Institute examined their expression in 
blastocyst stage E6 human embryos. Three of the naïve-specific markers, CD75, CD77 and 
CD130, were detected in the epiblast, whereas all primed-specific markers were absent. Naïve-
specific markers CD75 and CD77 were also expressed in the extraembryonic cells of the 
embryo. This indicates that their specificity is not restricted to pluripotent cells, and that naïve 
hPSCs may encompass properties of both embryonic and extraembryonic cell types – a point 
that I will discuss further in later sections. Contrary to this, naïve-specific marker CD7 was not 
expressed in human embryos, inferring that naïve hPSCs may possess characteristics that do 
not fully equate to the epiblast cells of human preimplantation embryos.  
Whilst the roles of CD7 are not well characterised, the promoter region of CD7 interestingly 
contains a transcription factor binding site for STAT3 (Zhang et al., 2013); it is therefore 
possible that JAK/STAT signaling may be utilised more in naïve hPSCs than in human 
blastocysts, thus the discrepancy in CD7 detection. Alternatively, CpG sites within the first 
exon of CD7 are methylation sensitive (Röhrs et al., 2010). Treatment with the DNA 
demethylating agent Aza-2'deoxycytidine induced CD7 expression in human CD7- acute 
myeloid leukemia and T cell lines (Röhrs et al., 2010). It is possible that this region could be 
hypomethylated in naïve hPSCs, but not in the human embryo. Collectively, the similarities and 
discrepancies observed with surface marker expression between naïve hPSCs and human 
embryos, provides one interesting direction for future investigation to understand their 
functional roles in pluripotency and signalling. Moreover, it would be interesting to examine 
recently developed models of postimplantation-stage embryos to validate the relevant stage-
specificity of the primed-specific markers (Deglincerti et al., 2016; Shahbazi et al., 2016). 
Similarly, these models open up the possibility to study a time point in human embryonic 
development that is otherwise inaccessible. These models, alongside human preimplantation 
embryos, might also facilitate establishing where the different naïve and primed hPSCs fall 
along the human embryonic developmental trajectory.  
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The biological role for the naïve-specific markers CD75 and CD77 are largely uncharacterised, 
especially in the context of pluripotency, with no previously reported indications to their 
function. Little is known for each surface marker, asides for both being glycosylated epitopes 
that mark germinal centre B cells and B cell lymphomas (Arends et al., 1999; Billian et al., 
1996). The surface of mammalian cells are decorated by complex and diverse protein and lipid 
linked glycan structures, which vary between different cell types (Berger et al., 2016). One of 
the first markers to identify mouse embryonal carcinoma and mouse embryonic stem cells was 
the carbohydrate-based epitope SSEA1 (Solter and Knowles, 1978). Subsequently, a range of 
antibodies against glycosylated epitopes such as SSEA3, SSEA4, TRA-1-60 and TRA-1-81, 
are all commonly used to identify human embryonic stem cells (Kannagi et al., 1983; Wright 
and Andrews, 2009), and were all expressed in primed cells in the antibody screen, with TRA-
1-60 and TRA-1-81 also expressed in naïve hPSCs. However, the biological role for these four 
glycosylated epitopes are also not well understood, perhaps owing to their dispensability in the 
maintenance of human pluripotency in-vitro (Fenderson et al., 1993; Wright and Andrews, 
2009). The lacking mechanistic insight into the function of glycoproteins presents an 
interesting, yet challenging avenue for further investigation. Possible experiments to decipher 
their function and requirement could include the use of neutralising antibodies against their 
epitopes. Alternatively, it may be possible to use antibody‐mediated immunoprecipitation in 
combination with mass spectrometry to identify their interacting proteins, which might provide 
an insight into their target pathways and subsequent biological function in pluripotency.  
The identified markers provide not only a means by which to distinguish primed from naïve 
hPSCs, but they also reveal potential differences in signaling pathways between the pluripotent 
states. An interesting example being CD130, otherwise known as the LIF co-receptor. The role 
of LIF in embryonic development was first recognised when several reports showed that LIF 
was required for the propagation of mESCs, through the activation of the JAK-STAT signaling 
pathway (Smith et al., 1988; Williams et al., 1988). However, this was not the case for the 
derivation and propagation of human PSCs (Reubinoff et al., 2000; Thomson et al., 1998). 
Moreover, hPSCs could not be maintained by the activation of LIF signaling in the absence of 
mouse embryonic feeder cells (Carpenter et al., 2003; Dahéron et al., 2004; Humphrey et al., 
2004). Similarly, low expression levels of CD130 (IL6ST) indicated that LIF signaling was not 
active in hPSCs (Brandenberger et al., 2004). This observation is likely attributable to the 
derivation of hPSCs under primed culture conditions, whereas we now know that LIF/STAT3-
dependent signaling is required for the maintenance of naïve hPSCs (Chan et al., 2013; Gafni 
et al., 2013; Hanna et al., 2010; Ware et al., 2014). Given that all the culture formulations to 
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derive naïve hPSCs contain 2i/LIF, perhaps it is not surprising to see enrichment of CD130.  
Nonetheless, future work is necessary to clarify the role of LIF signaling during human 
embryonic development and pluripotent state transitions.  
Other interesting signaling proteins identified include the NOTCH family of receptors and 
NOTCH ligand JAGGED2, expressed only in primed hPSCs. Whilst I see that NOTCH1-3 are 
expressed in undifferentiated primed hPSCs, previous analysis of the downstream targets 
reveals that NOTCH signaling is inactive in this state (Yu et al., 2008). However, upon exposure 
to differentiation cues, NOTCH signaling is both activated and required for lineage 
commitment to the three germ layers (Yu et al., 2008). This suggests to me that NOTCH 
receptors are present on the surface of primed hPSCs to poise the cells for efficient entry into 
lineage specification. Perhaps it is therefore not surprising that NOTCH proteins are absent in 
the naïve state if their function is not imminently required.  
To further test the utility of the state-specific markers, I examined whether the panel could be 
used to identify a small population of naïve hPSCs which had been mixed with primed cells. 
Reassuringly, the naïve hPSCs could be captured under gating for CD75+/CD130+ expression. 
However, these are both established cell states, which will not be the case during 
reprogramming. It was therefore necessary to examine the dynamics of each marker during 
primed to naïve state interconversion to check their ability in a heterogeneous setting. The 
results firstly reiterated their state-specificity, but secondly revealed that most could accurately 
track the change in pluripotent state. For example, CD57 and CD130 changed in their 
expression gradually during reprogramming, inferring these are coupled to a progressive 
change in cell state. By contrast, CD90 is rapidly downregulated at the onset of reprogramming. 
THY1 (CD90) is a predicted FGF target gene and expressed accordingly in primed hPSCs 
cultured in media containing high levels of FGF (Choi et al., 2001; Kaufman et al., 2001). The 
switch to t2iL+DOX media that contains a potent FGF/MEK/ERK inhibitor (PD0325901) is 
likely responsible for the rapid downregulation. Consequently, CD90 is less reliable as an 
individual marker. 
An interesting observation was made when comparing the different primed to naïve 
reprogramming methods, 5iLA and t2iL+PKCi; the proportion of day 8 - day10 reprogramming 
cells that clustered with established naïve hPSCs was greatly increased using 5iLA, compared 
to t2iL+PKCi (FlowSOM results: Figure 3.16 and Figure 3.18) . This suggests that 
reprogramming may be more efficient using 5iLA. A possible explanation for this could be the 
addition of inhibitors that collectively target more signalling pathways than under t2iL+PKCi 
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culture. Alternatively, the selection pressure to reprogram may be much stronger in 5iLA, 
consequently cells that do not reprogram undergo programmed cell death, which could be 
misinterpreted as being more efficient. Even so, it would be of interest to further examine the 
two reprogramming methods and the different routes to naïve human pluripotency.  
Whilst the focus of the antibody library screening was to identify markers that can distinguish 
between naive and primed human hPSCs, the availability of an extensive catalogue of markers 
present on the cell surface of hPSCs should be valuable for the study of human pluripotency 
and differentiation more generally. Moreover, surface markers enable the straightforward 
isolation of live cells that can be coupled with downstream functional assays. This has several 
advantages over current methods that rely on an “expert eye” to handpick individual colonies 
for expansion, or by long-term propagation to purify the cultures. Applying the antibody panel 
to reprogramming populations will provide a new insight into the earliest stages of naïve cell 
formation; this will help to unveil the temporal dynamics of molecular changes that occur, and 




























4. Cellular and Molecular Characterisation of Human 



























Much of the knowledge that we currently have regarding the two states of human pluripotency 
is based upon studies of the established states. Whilst this provides a valuable insight into the 
gene regulatory networks for primed and naive cell types, we know very little about the 
transitional period. Isolating and characterising reprogramming intermediate cell types can 
provide a useful insight into the trajectories of cell fate changes and the mechanisms that govern 
the routes taken. Several reports have used cell surface markers to examine the transcriptional 
waves and alterations in the epigenetic landscape that facilitate iPSC reprogramming 
(Cacchiarelli et al., 2015; Knaupp et al., 2017; O’Malley et al., 2013; Polo et al., 2012). By 
studying the intermediate populations that are refractory to reprogramming, we can begin to 
understand why cells fail to reprogram, and subsequently use this knowledge to coerce cells 
down the right trajectory. Moreover, we can identify the order of molecular events and 
regulators that lead to successful reprogramming.  
As previously discussed, the current methods used to isolate naïve hPSCs preclude the study of 
the early stages of reprogramming. Primed to naïve reprogramming generates a heterogeneous 
mix of cells, of which only a small proportion will be successfully transitioning. It is therefore 
necessary to enrich for this population of cells to faithfully track the order of molecular changes 
that occur during reprogramming. To address this gap in knowledge, I have identified cell-
surface markers that I believe will be capable of isolating naïve hPSCs as early as day10 during 
primed-to-naïve reprogramming. Under t2iL+PKCi culture, a small population of day 10 cells 
clustered with established naïve hPSCs based upon their cell surface expression profile. I 
hypothesise that this population will be the nascent naïve hPSCs that will ultimately progress 
to form the reprogrammed population. If this is true, it would offer an opportunity to isolate 
naïve hPSCs at a time point far earlier than previously studied. Moreover, it would be possible 
to track this population at time points throughout reprogramming to examine how and when 




1. Isolate early naïve hPSCs and reprogramming populations using FACS 
2. Characterise early naïve hPSCs and reprogramming populations  
i. Assess the ability to form colonies from single cells  
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ii. Examine the expression of known naïve and primed state-specific 
markers – both transcriptionally and at the protein level   
iii. Examine global transcriptional profile of early naïve hPSCs and 
reprogramming populations  
iv. Examine epigenetic hallmarks of naïve pluripotency in early naïve 
hPSCs and reprogramming populations – X-chromosome status and 




Defining and characterising reprogramming and intermediate cell states can provide a useful 
insight into the mechanisms of cell fate changes. I therefore sought to use the state-specific 
surface markers to isolate nascent naïve hPSCs and reprogramming intermediates at an early 
time point during reprogramming.  
 
4.2.1 Using cell surface marker expression profiles to define reprogramming populations 
under NK2 t2iL+PKCi culture  
 
The earliest time-point at which I could hope to isolate nascent naïve hPSCs using the NK2 
t2iL+PKCi method is 10 days into reprogramming (Figure 3.15). Focusing specifically on the 
surface marker expression profiles of day 10 cells, several distinct populations were apparent. 
The first, designated N4+ corresponds to the most “naïve-like” population, defined by high 
expression of all four naïve-specific markers, combined with low expression of primed-specific 
marker CD24 and CD90 (Figure 4.1). This population represents ≈2% of all live-human day 10 
cells. The next population, termed N3+ expresses three naïve-specific markers: CD77, CD7 and 
CD130, but not CD75. Similarly, gating isolates the CD24 and CD90 low fraction. This 
population represents a larger proportion of cells at ≈6%. Finally, a third population with low 
or absent expression of naïve specific markers is apparent, designated N4- representing ≈22% 
of day 10 cells. I opted to isolate this population irrespective of primed-specific marker 
expression, as only 3% of cells lowly express CD24 and CD90. The same gate shown on all 
three plots is to emphasize the selection of cells that I deemed lowly expressing primed-markers 
(Figure 4.1 - right). This is more apparent when displaying N4- cells, as a clear CD24 positive-




To gain an overview of all potential sub-populations amongst day 10 cells I performed 
FlowSOM analysis; this time highlighting the populations described above (N4-, N3+ and N4+) 
onto the MST. The three populations are distinct from each other and largely represent the 
predominant clusters observed using this unbiased analysis.    
 
 
Figure 4.1. Flow cytometry gating scheme to isolate early-naïve reprogramming populations 
by FACS. 
Flow cytometry dotplots of day 10 cells during primed to naïve-state reprogramming of H9 
hPSCs under t2iL+PKCi culture conditions. Left: Expression levels of two naïve specific 
markers, CD75 and CD77. Gates were constructed based on control live, human stained day 10 
samples. Three gates on the left correspond to CD75+/CD77+ (green box), CD75–/CD77+ 
(orange box), and CD75–/CD77– (purple box) cell populations. Middle: the levels of CD7 and 
CD130 proteins for the same three gated 
cell populations. Right: Expression levels of two primed specific markers, CD24 and CD90. 
Boxed areas indicate the N4+ (green) and N3+ (orange) that were gated based on low 
expression of these markers. N4– (purple) cell populations included all cells irrespective of 
primed-marker expression. The cells highlighted in each gate were used for subsequent 
experiments. The percentage of cells within each cell sorting gate relative to all live-human 







Figure 4.2. Prospective isolation of day 10 naïve reprogramming populations by FACs.   
FlowSOM visualisation of the flow cytometry data for day 10 cells during primed to naïve 
reprogramming. The minimal spanning tree of the self-organising map displays an 
unsupervised clustering of the sample based on the cell surface protein expression levels (right). 
The cells corresponding to each cell sorted population, N4+, N3+, and N4–, are indicated. The 
















Whilst using a multiplexed panel with four naïve and two or three primed-specific markers is 
likely to identify a more stringent naïve-like population, there are a number of caveats to its 
utility. Firstly, there is the requirement for a high-end flow analyser or FACS machine with five 
lasers, which may impose a restriction on usability. Moreover, users must be familiar with 
multi-parameter flow cytometry compensation. Secondly, the degree of flexibility over 
compatible conjugations is restricted, as discussed in section 3.2.2. It could be problematic if 
users wish to examine additional surface markers or reporter expression. Finally, purchasing 8-
9 antibodies required for the complete antibody panel may be financially unappealing to wider 
usability. With these factors in mind, I opted to compile a minimised antibody panel containing 
two naïve-specific and two primed-specific surface markers. The naïve-specific markers chosen 
were CD75 and CD130, based upon the previous panel and time-course results. CD75 is one of 
the most stringent naïve-specific markers, and CD130 has well-established biological 
importance as the LIF co-receptor. I selected CD24 and CD57 as the primed-specific markers, 
as they both appear to be more indicative of a pluripotency state change than CD90.  
The population of interest using the minimised panel is designated N2+, a population positive 
for both naïve-specific markers and negative for primed markers. Shown are the flow cytometry 
results of day 10 cells after NK2 t2iL+PKCi reprogramming (Figure 4.3A). The N2+ population 
represents 4-5% of live-human cells. As anticipated, the minimal panel identifies a broader 
population compared to N4+. FlowSOM analysis of day 10 cells reveals N2+ cells cluster 

















Figure 4.3. A minimised antibody panel to isolate early-naïve reprogramming cells.  
(A) Flow cytometry dotplots of day 10 cells during primed to naïve-state reprogramming of H9 
PSCs under t2iL+PKCi culture conditions. Left: Expression levels of two primed-specific 
marhkers, CD24 and CD57. The double negative population (CD24-/CD57-) was gated (blue 
box). Right: The expression levels of two naïve-specific markers CD75 and CD130. The double 
positive population (CD75+CD130+) was gated (blue box) and corresponds to N2+ cells that 
was used for subsequent experiments. The percentage of cells within each cell sorting gate 
relative to all live, human cells is shown. 
(B) FlowSOM visualisation of the flow cytometry data for day 10 cells during primed to naïve 
reprogramming. Right: the cells corresponding to the N2+ cell sorted population is indicated 
on the minimal spanning tree (blue). Left: the heatmap shows the expression level of each cell 
surface marker in the cell clusters. 
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4.2.2 Characterisation of reprogramming populations 
 
4.2.2.1 Colony formation assay to examine clonogenicity of reprogramming intermediates 
 
One of the hallmarks of naïve pluripotency is the attribute of high clonogenicity compared to 
their primed counterparts. I examined this attribute by isolating each reprogramming population 
(N4+, N3+, N4- and N2+) and comparing their ability to form colonies from single cells against 
established naïve hPSCs. All populations, including established naïve hPSCs, underwent the 
same FACS protocol to ensure a robust comparison. Four days after isolating the various 
populations, I counted both the number of colonies that had formed and scored their 
morphology (Figure 4.4). Both N4+ and N2+ populations have the equivalent ability to form 
colonies from single cells when compared to established naïve hPSCs. Importantly, the colonies 
formed are predominantly naïve in morphology. By contrast, N3+ sorted cells form 
significantly fewer naïve scored colonies, indicating that the expression of CD75 is a key 
marker of nascent naïve hPSCs. Moreover, N4- sorted cells have an impaired ability to form 
colonies, with only a small number of primed and differentiated colonies observed.  
 
 
Figure 4.4. Colony formation efficiency of cell sorted populations into t2iL+PKCi naïve culture 
conditions.  
Colonies scored as naïve, mixed, primed and differentiated: examples shown below. Data show 
the mean ± SD of three or four biological replicates and were compared to established naïve 
hPSCs using an ANOVA with Dunnett’s multiple comparisons test (*p < 0.05, **p < 0.005, 
***p < 0.0005). Scale bars, 100 µm. 
95 
 
4.2.2.2 Transcriptional profiling of reprogramming intermediates for pluripotent state-specific 
transcription factors 
 
One method by which to predict cell identity is to examine the transcriptional profile. This can 
be performed on a genome wide level using RNA-sequence, or via targeted RT-qPCR when 
transcriptional markers are known. To gain an insight into the fate of each reprogramming 
population and how each compare transcriptionally to established naïve hPSCs, I performed 
RT-qPCR for various genes associated with primed, naïve, and shared pluripotency (Figure 
4.5). The comparison of N4+, N3+ and N2+ populations revealed no significant difference in 
the expression of core pluripotency factors POU5F1, SOX2 or NANOG, when compared to 
established naïve cells. However, N4- cells show a decrease in POU5F1 and NANOG 
expression, combined with an increase in SOX2 transcription. This result combined with the 
inability to form colonies suggests an impairment of pluripotency. Moreover, N4- cells 
expressed primed-specific genes OTX2 and ZIC2 to higher levels than primed hPSCs. This is 
not the case for any other reprogramming intermediate, or established naïve hPSCs; none of 
which express primed-specific genes. Perhaps unsurprisingly, N4- cells also show a reduction 
in the transcription of naïve-specific genes. These findings suggest that N4- cells adopt a neural-
like expression profile, likely caused by FGF inhibition during naïve reprogramming (Greber 
et al., 2011). Conversely, the expression of naïve-specific transcription factors KLF17, KLF4, 
TFCP2L1, DPPA3 and DNMT3L is comparable for N2+, N3+ and N4+ cells to each other, and 
to established naïve hPSCs. The main exception being a ≈40 fold decrease in KLF17 expression 
in N3+ cells. This is concordant with the colony formation assay highlighting a significant 
decrease in naïve cell formation; suggesting that N3+ cells, which lack CD75 expression, 





Figure 4.5. Comparative gene expression analysis for pluripotent state-specific genes across the 
different cell-sorted populations.  
RT-qPCR analysis of gene expression levels in the different cell-sorted populations and 
established naïve hPSCs. Expression levels are shown on a log scale relative to primed hPSCs. 
Data show the mean ± SD of three or four biological replicates and were compared to 
established naïve hPSCs using an ANOVA with Dunnett’s multiple comparisons test (*p < 
0.05, **p < 0.005, ***p < 0.0005). 
 
4.2.2.3 Isolated nascent naïve hPSCs form homogeneous naïve cell cultures    
 
An additional readout of cell fate is to examine the protein expression and cellular localisation 
of key transcription factors. With this in mind, I examined the expression of core pluripotency 
factor OCT4 (POU5F1), which is common to both naïve and primed hPSCs, and naïve-specific 
factor KLF17. Representative immunofluorescence images of naïve hPSCs show a more 
compact morphology, with clear expression of both KLF17 and OCT4 (Figure 4.6). By contrast, 
primed hPSCs were negative for KLF17 and positive for OCT4. The results for two 
reprogramming intermediate populations (N4+ and N2+) are analogous to naïve hPSC results. 
A compact morphology is visible, combined with dual expression of OCT4 and KLF17.  
To ascertain whether N4+ and N2+ isolated populations are the cells that will go on to form 
stable naïve hPSCs, I cultured the cells for three passages in t2iL+PKCi after FACS isolation. 
The cultures from both populations are homogeneous in nature and do indeed form stable 
cultures. I have subsequently passaged these cells greater than 20 times without deterioration 











Figure 4.6.  Early-naïve sorted hPSCs exhibit naïve pluripotency characteristics.  
(A) Immunofluorescence microscopy for KLF17 (a naïve-specific protein) and OCT4 (a protein 
expressed by naïve and primed hPSCs) reveals that N4+ and N2+ cell-sorted populations can 
generate KLF17+/OCT4+ colonies that are similar to established naïve hPSCs. Scale bars, 100 
µm. 
(B) Phase contrast images showing representative fields of view of N4+ and N2+ cell-sorted 
populations that have been propagated under t2iL+PKCi naïve hPSC conditions for three 





4.2.2.4 Global transcriptional profiling to examine the transition from primed to naïve 
pluripotency  
 
To determine where each reprogramming intermediate falls along the trajectory of primed to 
naïve pluripotency, I performed RNA sequencing of each isolated population 10 days into 
reprogramming to obtain a global overview of the transcriptional profiles. mRNA libraries were 
generated for three independent reprogramming experiments. Read counts per transcript were 
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quantified and differentially expressed genes were identified using DESeq2 (Love et al., 2014). 
Dimensional reduction visualisation of the top 1000 most variable genes across all cell types is 
visualised using principal component analysis (Figure 4.7). The PCA plot demonstrates that the 
biological replicates for each population and cell type cluster close together with minimal 
variation. This provides confidence in the reproducibly of the identified populations based on 
their cell surface marker expression profiles. The first principal component represents the 
majority of variation (72%), and nicely separates primed and naïve hPSCs. Along this 
component, N4+ cells cluster closer to naïve hPSCs. In contrast, N4- cells cluster closer to 
primed hPSCs and appear to take a different trajectory. The second principal component, that 
captures 16% of the variation, separates day 10 isolated populations from the established primed 
and naïve hPSCs. This suggests that day 10 samples represent early-stage cell types that have 
yet to acquire a mature gene expression profile. To explore this idea further, I profiled N4+ 
cells that were maintained for five (P5) or ten passages (P10) in t2iL+PKCi. These both 
clustered with established naïve hPSCs, which additionally highlights the concept that a final 
maturation phase occurs, but also reassuringly that the N4+ cells are the nascent naïve cells.   
To further examine the variable genes that influence the clustering of samples, a loadings plot 
is shown (Figure 4.7). Known primed-specific (DUSP6, OTX2 and ZIC2) and naïve-specific 
(TFCP2L1, KLF4 and DPPA3) genes were amongst the most variably expressed and contribute 
to the separation of primed and naïve hPSCs. As alluded to previously, N4- cells exhibit a strong 
neural gene expression profile, with genes such as SOX5, DKK1 and MAP2 contributing to their 
cluster positioning. More importantly, genes that contribute to the second principal component 
(plotted in the top right quadrant of the loadings graph), are genes that provide a new insight 
into the transcriptional differences of early, nascent-naïve hPSCs compared to established naïve 
cells. Example genes associated with early naïve hPSCs include TBX3, DPPA3, GDF3, KLF5 
and FOXC1. These genes alongside many others that distinguish the early and late-stage naïve 
cell types, will be useful for establishing the temporal order of transcriptional changes between 
primed and naïve pluripotency. Genes associated with late stage naïve cell formation include 
XIST, MEG3 and a collection of zinc finger proteins.  
To explore the different biological processes that distinguish early and late stage naïve cells, I 
performed gene ontology (GO) analysis on the differentially up and down regulated genes 
between N4+ and naïve hPSCs (Figure 4.8). Genes that are upregulated in naïve hPSCs display 
enrichment for processes relating to transcriptional regulation and RNA metabolic processes. 
Strikingly, more than 100 zinc finger proteins are upregulated in naïve hPSCs and contribute to 
transcriptional regulation. This suggests an important role for this class of transcriptional 
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regulators in naïve cell fate. Conversely, transcripts that are downregulated in naïve hPSCs 
compared to N4+ cells are associated with developmental processes and cell differentiation GO 
terms. This indicates that N4+ cells have yet to silence lineage-priming genes that may be lowly 
expressed in primed hPSCs, but will be robustly silenced in late stage naïve hPSCs.  
Another method by which naïve and primed hPSCs can be distinguished is based upon the 
expression profiles of transposable element (TE) classes (Grow et al., 2015; Theunissen et al., 
2016). Different classes of TEs are upregulated during early human embryonic development 
and our understanding of their roles and regulation during this period remain largely unknown, 
but are a topic of acute interest. Theunissen and colleagues have previously classified many TE 
classes as being enriched in either naïve or primed hPSCs (Theunissen et al., 2016). With this 
in mind, I quantified the expression of TE classes accordingly and performed PCA analysis to 
display the results (Figure 4.9). The clustering profile closely mimics the trajectory seen when 
quantifying gene transcripts. N4+ cells cluster in between primed and naïve hPSCs, and these 
two established cell types are well separated along principal component 1. This reinforces the 
idea that N4+ cells represent an early stage naïve cell type, further exemplified by the finding 
that P5 and P10 samples have matured and again cluster with established naïve hPSCs. The 
loading plot highlights the transposable element classes that contribute to each sample type. 
LTR5_Hs, LTR7Y and SVA class of repeats are amongst these and have previously been labelled 
as naïve-specific (Theunissen et al., 2016); likewise, known primed-specific elements HERVH-
int and LTR7 contribute to separating these two pluripotent cell types along the first principal 
component. Moreover, the analysis identifies additional TE families that contribute not only to 
the separation of naïve and primed hPSCs, but additionally influence the separation of early 
versus late naïve stage formation. LTR7B, MER11A and LTR5B elements contribute to principal 
component two and are associated with early-stage naïve hPSCs, whereas MER47C, MER57E3 
and BSR/Beta elements distinguish late stage naïve hPSCs. Taken together, the transcriptional 
comparison of populations at an early-stage of primed to naïve reprogramming reveals the 







Figure 4.7. Transcriptional analysis of primed to naïve reprogramming populations.  
Principal component analysis of RNA-sequencing gene expression data from the different cell-
sorted populations, primed, and established naïve hPSCs (left). Right: the contribution of 




Figure 4.8. Gene Ontology analysis of differentially expressed genes between early-naïve and 
established-naïve hPSCs.  
Top GO terms of genes that were differentially expressed between N4+ and established naïve 
hPSCs. The numbers of genes contributing to each GO term are shown; example genes within 
each GO category are listed (right). Corrected p values were calculated using a modified 





Figure 4.9. Transposable element expression can recapitulate primed to naïve reprogramming 
dynamics.  
PCA of TE classes from the different cell-sorted populations (left). Right: the contribution of 
TEs to the first and second principal component. Selected TEs are labelled as having a 
previously defined naïve (blue) or primed (red) TE signature (Theunissen et al., 2016). 
 
4.2.2.5 X-chromosome status  
 
One of the hallmark characteristics of naïve pluripotency is the presence of two active X-
chromosomes in female cells. As discussed in the main introduction, the methodologies of 
inferring X-chromosome activity are controversial. To examine the status of X-chromosome 
activity, I utilised the RNA-sequencing datasets generated throughout the primed to naïve 
reprogramming time-course. Using SNP information for the H9 line enabled the quantification 
of X-linked gene expression from each X-chromosome. Genes classed as biallelic infer the 
presence of two active X-chromosomes (XaXa), whereas mono-allelic expression is indicative 
of XaXi status. This analysis reveals that X-chromosome reactivation occurs predominantly 
during the late stage of naïve cell formation (Figure 4.10). All day 10 reprogramming 
intermediates have yet to reactivate the X-chromosome, even though N4+ and N2+ cells already 
exhibit a naïve-like transcriptional profile. However, the culturing of N4+ cells for an additional 
for five or ten passages results in X-chromosome reactivation. This narrows down the window 
whereby the inactive X-chromosome will reactivate to somewhere between day 10 to day 30 of 
reprogramming. A peculiar observation from this analysis reveals a handful of genes on the p-
arm of the X-chromosome were monoallelically expressed in established naïve hPSCs 
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(Takashima et al., 2014). The cause of this is unclear, but it could indicate an erosion of X-
chromosome activation during long-term maintenance of naïve hPSCs. Nevertheless, N4+ cells 
cultured for five (P5) and ten (P10) passages undergo X-chromosome reactivation and display 
uniform biallelic expression. I believe this analysis supports the notion that X-chromosome 
reactivation is a robust molecular marker, and perhaps one of the most faithful indicators of 
bona-fide mature naïve hPSCs.  
 
 
Figure 4.10. X-chromosome reactivation is a late event during primed to naïve reprogramming.   
Schematic of X chromosomes that summarise the results from an allelic analysis of RNA-seq 
data for the indicated cell types. Informative SNPs within X-linked genes of the H9 PSC line 
(Vallot et al., 2017) were used to classify expression as monoallelic (brown, <25% from minor 
allele), biallelic (orange, 25%–75% from minor allele), or not expressed (gray, <10 
reads/sample). The number of monoallelic and biallelic genes is shown below. 
 
4.2.2.6 DNA methylation analysis  
 
Global DNA hypomethylation is an additional characteristic of human ICM cells that naïve 
hPSCs also share. Typically, primed hPSCs exhibit uniformly high CpG methylation levels 
(≈80% globally), whereas long-term cultured naïve hPSCs reduce to 30% globally (Guo et al., 
2017; Pastor et al., 2016). The DNA methylation dynamics have yet to be examined at intervals 
during this state transition. Therefore, we examined the methylome status at several time-points: 
N4+ cells at day 10, and passage 10 (day 50) (Figure 4.11). There is a notable decrease (30%) 
in global CpG DNA methylation as early as 10 days into reprogramming compared with 
parental H9 primed cells. A further decrease occurs by passage 10, with global levels dropping 
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to ≈30%. This is the equivalent level to established naïve hPSCs that have been cultured for 
>20 passages. Unfortunately, samples at an intermediate time-point (passage 5) did not provide 
sufficient coverage for reliable quantification. However, the rapid loss of DNA methylation 
between primed cells and day 10 precedes the reactivation of the X-chromosome. This infers 
that the removal of DNA methylation may be required for X-chromosome reactivation.  
We further examined the DNA methylation levels at imprinted loci where sufficient coverage 
was obtained (n=36). Of these, 30/36 showed retention of DNA methylation 10 days into 
reprogramming; However, by passage 10 only 10/36 were still methylated. This phenomenon 
has been previously highlighted, also in naïve hPSCs cultured for >10 passages (Guo et al., 
2017; Pastor et al., 2016).  
 
 
Figure 4.11. Global CpG DNA Methylation levels across primed to naïve reprogramming 
populations.  
(A) Global CpG methylation levels (%) from three independent biological replicates which 
were pooled after sequencing.  
(B) Classification of imprinted loci methylation status between day 10 and passage 10 samples. 
Methylation was either maintained or lost (classified according to a ≥50% loss in CpG 











4.3 Discussion  
 
Flow cytometry analysis of day 10 t2iL+PKCi reprogrammed cells revealed several distinct 
populations. The most “naïve-like” population, designated N4+, is defined by the high-
expression of all four naïve-specific markers, and low expression of primed-specific markers. 
After 10 days of reprogramming, between ≈2% of all live-human cells are classed as N4+, 
highlighting the inefficient nature of t2iL+PKCi reprogramming. Alongside N4+ cells, I 
additionally sorted two other reprogramming intermediates, N3+ that expressed CD7, CD77, 
CD130, but not CD75, and N4- that failed to express any naïve-specific markers. N3+ and N4- 
populations represented 6% and 22% of the live-human population respectively. Collectively, 
the populations represent 30% of cells at this time-point; this highlights one of the caveats to 
the gating strategy used, as many cells were unable to be characterised. Nonetheless, the 
FlowSOM results reveal three predominant cell clusters which N4+, N3+ and N4- are 
embedded within (Figure 4.2). These populations should therefore provide a good overview 
and capture the variation in reprogramming populations.  
Whilst multiplexing a large panel of antibodies provides a high-resolution insight into different 
cell populations, it is not without challenges. Users will require a good knowledge of antibody 
panel design to ensure appropriate compensation is applied. Moreover, the current panel design 
requires a high-end FACS machine with five lasers. Finally, the availability of high-quality 
antibodies in a range of conjugations is necessary. For commonly used markers this is normally 
not an issue; however, the choice of infrequently studied naïve-specific markers CD77, CD75, 
and CD130, was restricted to common conjugations. To improve the usability of our approach, 
I refined the set of antibodies down to a combination of two naïve-specific (CD75 and CD130) 
and two primed-specific markers (CD24 and CD57). These could largely recapitulate the full 
antibody panel, isolating a slightly wider population that corresponded to 4-5%, and was 
designated as N2+.  
An increase in clonal efficiency is one of the hallmark characteristics of naïve pluripotency 
compared to their primed counterparts. I was pleasantly surprised to see that both N4+ and N2+ 
populations possess the ability to form colonies with a naïve-morphology that equates to the 
standard of established naïve hPSCs. Contrary to this, the N3+ population performed poorly by 
comparison and generated far fewer naïve colonies. This suggests that N3+ cells represent a 
partially reprogrammed population, and that CD75 is a crucial marker of naïve hPSCs. CD75 
is a glycosylated epitope purportedly catalysed by the sialytransferase ST6GAL1 (Munro et al., 
1992). Sialyation is known to be involved in a variety of cellular processes, such as cell 
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adhesion, cell signalling, and the regulation of glycoprotein stability (Pshezhetsky and 
Ashmarina, 2013; Schauer, 2009). Whilst the role of CD75 and sialyation has not been 
examined in the context of naïve pluripotency, the perturbation of the sialytransferase 
ST6GAL1 caused a reduction in iPSC reprogramming efficiency and led to the impaired self-
renewal of primed hPSCs (Wang et al., 2015). Moreover, the deletion of an enzyme responsible 
for sialic acid biosynthesis (UDP-GlcNAc 2-epimerase) resulted in embryonic lethality, 
supporting the notion that sialyation is important for embryonic development in mice 
(Schwarzkopf et al., 2002). It would be interesting in the future to isolate the N3+ population 
at day 10 of reprogramming and subsequently re-evaluate whether subpopulations can mature 
to an N4+ state – or whether a failure to upregulate CD75 by day 10 is a defining criterion to 
distinguish nascent naïve hPSCs from refractory populations.  
To further characterise the different reprogramming populations, I examined their 
transcriptional profiles, and several epigenetic hallmarks that distinguish primed and naïve 
pluripotent states. Firstly, the transcriptional analysis revealed N4+ and N2+ populations 
represent an early-stage naïve cell type and have yet to acquire a mature naïve gene expression 
profile. To determine whether these populations represent nascent naïve hPSCs, I continued to 
culture N4+ isolated cells and reassessed five or ten passages later. By passage five, the cells 
had acquired a fully mature naïve expression profile, providing evidence that N4+ cells are 
indeed nascent naïve hPSCs. Moreover, N4+ cells can be maintained long-term for more than 
20 passages whilst retaining a homogeneous naïve morphology. Collectively this shows the 
antibody panel provides an opportunity to study naïve hPSC formation at a time point far earlier 
than previously possible. 
Importantly, analysis of early-stage naïve hPSCs provided a new insight into the temporal order 
of gene expression changes. Of note, transcription factors TBX3, DPPA3, GDF3 and KLF5 are 
strongly upregulated by day 10 of reprogramming, to near maximum levels observed, 
suggesting these play a crucial role during reprogramming. Whilst TBX3 and DPPA3 have not 
been studied during human pluripotent state transitions, several groups have emphasised the 
connection between the two in mouse pluripotency. TBX3appears to maintain steady levels of 
DPPA3 to prevent the premature exit from pluripotency, and is strongly downregulated upon 
the transition from naïve mESCs to primed mEpiSCs states (Buecker et al., 2014; Russell et al., 
2015; Waghray et al., 2015). The co-expressed nature of TBX3 and DPPA3 in this context infers 
a conserved relationship in human pluripotency. Moreover, TBX3, DPPA3, GDF3 and KLF5 
are all highly expressed within the ICM cells of human embryos assessed by single-cell RNA-
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sequencing (Stirparo et al., 2017). This provides additional support to their biological relevance 
in naïve human pluripotency.  
The transcriptional analysis of the reprogramming populations additionally highlighted a set of 
genes that are associated with established naïve hPSCs and N4+ cells that had been passaged 
five or ten times. Several interesting examples include KLF17, DPPA5, and a large number of 
zinc finger proteins. Both KLF17 and DPPA5 are transcriptionally present in the epiblast cells 
of both primate and human embryos. However, the function and targets of KLF17 in human 
pluripotency are largely unknown, and provides an interesting avenue for future studies. 
DPPA5 - another member of the developmental pluripotency-associated protein family - has 
been shown to post-transcriptionally regulate NANOG stability in primed hPSCs (Xu et al., 
2016). Moreover, DPPA5 (Esg1 in mouse) is a small RNA binding protein that has been shown 
to bind over 900 transcripts in mouse ESCs. Notable validated examples include the chromatin 
remodelling factor Ezh2, and transcriptional activator Nr5a2 (Tanaka et al., 2006). Future 
studies employing enhanced sequencing technologies for the identification of RNA-binding 
protein target RNAs, such as iCLIP, will help to reveal the function of DPPA5 in human 
pluripotency. Collectively, KLF17, DPPA5 and zinc finer proteins - particularly KRAB-ZFPs 
- have all been implicated in transcriptional repression, amongst other roles (Gumireddy et al., 
2009; Tanaka et al., 2006; Yang et al., 2017a). It is possible that given the predominantly blank 
epigenetic landscape of naïve hPSCs, as far as repressive marks at promoter regions are 
concerned (Ji et al., 2016; Theunissen et al., 2014), ZFPs and other transcription factors may 
act as transcriptional repressors to thwart precarious gene activation and silence transposable 
elements (TEs).  
Different transposable element classes exhibit developmental stage-specific expression profiles 
during embryogenesis. The mode of action for transposable elements are also variable; 
examples include cis-regulation of nearby gene expression, chimeric transcript formation by 
developing splice donor sites, or acting as long-range enhancer elements (Peaston et al., 2004; 
Thompson et al., 2016; Xie et al., 2010). Based upon the expression of various TE classes, it is 
possible to distinguish naïve and primed hPSCs (Theunissen et al., 2016). PCA analysis of TE 
expression for the various day 10 reprogramming intermediates, alongside established primed 
and naïve hPSCs (Figure 4.9), was able to recapitulate the PCA clustering observed by assessing 
mRNA transcript levels (Figure 4.7).  
Whilst I observe concordant classification of TE classes previously implicated in human naïve 
and primed pluripotency, I detected additional TE classes with state-specific enrichment. For 
example, β-satellite repeats which are highly enriched in naïve hPSCs, but were not described 
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in naïve hPSCs under 5iLA culture (Theunissen et al., 2016); possibly owing to PSC line-
specific differences, or the different naïve reprogramming methods. Moreover, I found 
LTR5_Hs elements to be enriched in N2+, N3+ and N4+ day 10 reprogramming cells, as well 
as being highly expressed in naïve hPSCs. Both LTR5_Hs and HERVK are expressed in 8-cell 
stage human embryos through to blastocyst formation, and exert their function to modulate 
mRNA levels via the accessory protein Rec (Grow et al., 2015). Wysocka and colleagues show 
the hypomethylated state of LTR5_Hs in human embryonic carcinoma cells and naïve-like 
hPSCs results in LTR5_Hs upregulation (Grow et al., 2015). We also examined the DNA 
methylation profile of N4+ nascent naïve hPSCs at day 10 and passage 10 (Figure 4.11); from 
this, we see a global decrease in CpG methylation of 30% by day 10. Whilst further examination 
is necessary to decipher loci-specific DNA demethylation dynamics, the transcriptional 
upregulation of LTR5_Hs correlates with the loss of DNA methylation. Future work will seek 
to address the entwined relationship between the regulation of transposable elements, and how 
in turn TEs regulate gene expression in the context of human pluripotency. 
Finally, I sought to examine the status of X-chromosome reactivation (XCR) – a vital hallmark 
of naïve pluripotency in female cells. The results revealed X-chromosome reactivation had not 
occurred in any of the day 10 reprogramming intermediates; however subsequent passaging of 
N4+ nascent naïve hPSCs displayed a convincing XaXa status by passage 5. Utilising RNA-
sequencing data to examine X-chromosome status has the advantage of being matched to a 
global transcriptional profile for cell type identification; however, there are a few caveats to 
classifying the X-Chromosome status by this method. Firstly, it is only possible to examine 
allelic-specific expression for PSC lines where SNP information is available. Secondly, the 
results display a population average. This means that the details of how XCR is mediated, for 
instance by lncRNAs, cannot be observed in detail at a single cell resolution.  
Analysis of female human preimplantation-stage embryos has revealed the two active X-
chromosomes are associated with expression of both XIST and XACT lncRNAs (Petropoulos et 
al., 2016; Vallot et al., 2017). Whilst this biallelic expression is observed in established naïve 
hPSCs cultured under t2iL+PKCi and 5iLA, substantial heterogeneity of XIST expression by 
RNA-FISH is seen (Kilens et al., 2018; Sahakyan et al., 2017; Vallot et al., 2017). This 
observation would be missed by the quantification of X-linked gene expression alone. 
Regardless, this method can still serve as a reliable population status of X-chromosome activity. 
One correlation from our data that can be drawn is the upregulation of XIST that occurs at a 
late-stage of naïve cell formation, correlating with XCR. Interestingly, the rapid DNA 
demethylation observed by day 10 of naïve reprogramming occurs before XCR. This implies 
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that further DNA demethylation may be necessary for robust reactivation of the silent X-
chromosome. In line with this observation, XCR does not take place during human iPSC 
reprogramming to the primed state, perhaps unsurprisingly given their hypermethylated status 
(Mekhoubad et al., 2012). Moreover, DNA methylation persists on the inactive X-chromosome 
throughout mouse iPSC reprogramming. It is not until the very latest stages that sufficient DNA 
demethylation occurs to allow faithful XCR (Pasque et al., 2014).  
In summary, by identifying the earliest responders during reprogramming, inference towards 
an interconnected transcription factor network or hierarchy can be made, and subsequently 
tested experimentally in future studies. Our understanding of pluripotent gene regulatory 
networks and their importance has been shown extensively for mouse pluripotency (Boyer et 
al., 2005; Chen et al., 2008; Kim et al., 2008; van den Berg et al., 2010; Wang et al., 2006). 
Whilst these studies provide a valuable foundation for mammalian pluripotency, extrapolating 
to human may not always be accurate, and human or primate-specific pluripotency factors may 
be overlooked. More recent reports which examine the molecular and phenotypic 
characteristics of human, primate, and mouse embryos, will facilitate our understanding of 
human pluripotency and highlight species-specific differences (Nakamura et al., 2016; Stirparo 
et al., 2017). Nonetheless, due to the ethical restrictions and technical challenges associated 
with studying early human embryos, in-vitro models that recapitulate the developmental 
progression of human embryogenesis would be highly desirable. Accordingly, I have shown 
that the identified state-specific surface markers reliably track the dynamics of primed to naïve 
reprogramming, and enable nascent naïve hPSCs to be isolated. For the first time, this enables 























5. Comparative analysis of different primed to naïve 




























Until now, the inability to isolate nascent naïve hPSCs at an early time point during primed-to-
naïve reprogramming has precluded the study of the reprogramming process. This gap in 
knowledge means that little is known about the transitional period and consequently there are 
many unanswered questions. Primarily, are there different molecular routes from primed to 
naïve pluripotency? If so, are there benefits of one reprogramming route over another – such as 
efficiency, timing, or stability of the end naïve hPSC population? To date, all comparative 
studies that examine the molecular characteristics of naïve hPSCs derived using different 
reprogramming methods, were restricted to long-term cultured naïve hPSCs. Without a means 
to examine the earliest stages of reprogramming, it is not possible to decipher if there are 
alternative routes to naïve pluripotency. The ability to answer these questions relies upon a 
method to study the reprogramming process with frequent temporal precision, in order to 
determine with accuracy the dynamics and potential coordination of molecular changes that 
occur. A better understanding of this process may present an opportunity to coerce refractory 
reprogramming populations down the right route.  
From the comparative molecular characterisation of naïve hPSCs derived by 5iLA and NK2 
t2iL+PKCi reprogramming, we know that the resulting cell types are very similar and share a 
close transcriptional and epigenetic resemblance to preimplantation epiblast cells (Huang et al., 
2014; Stirparo et al., 2017). However, we know almost nothing about the routes taken from 
primed pluripotency to a naïve state. As previously mentioned, the cell type of origin can 
influence the molecular trajectory taken during iPSC reprogramming (Nefzger et al., 2017). 
However, in this instance both the starting (primed) and end cell type (naïve) are hypothetically 
the same; instead the reprogramming method is what differs. 5iLA reprogramming is transgene 
independent, with the addition of several chemical inhibitors that are not present in t2iL+PKCi 
conditions. Conversely, t2iL+PKCi reprogramming is reliant on the transient overexpression of 
NANOG and KLF2 transgenes, followed by continued culture in t2iL+PKCi; yet remarkably 
the resulting naïve cell types generated by each method are very similar. This infers that 
convergent signalling pathways and gene regulatory networks are utilised, at least towards the 
later stages of reprogramming, or for the maintenance of naïve pluripotency. Yet given the 
divergent methodologies employed at the onset of reprogramming, I propose that the early 




In support of this idea, I observed a substantial difference in the proportion of day 10 
reprogramming cells that cluster with established naïve hPSCs, based upon their cell surface 
expression profile, between the two reprogramming methods (Figure 3.15and Figure 3.18). 
During 5iLA reprogramming the majority of day 10 cells clustered with established naïve 
hPSCs; by contrast only ≈2% of t2iL+PKCi day 10 day cells were cluster with their 
corresponding naïve hPSCs, which is approximately 40 fold lower than 5iLA. This allows me 
to infer that the reprogramming efficiency of 5iLA may be higher, or that reprogramming may 
be faster. To address this, I propose using the multiplexed antibody panel to isolate nascent 
naïve hPSCs at early matched time-points for 5iLA reprogramming, to be compared against the 
t2iL+PKCi transition data discussed throughout chapter 4. Comparative analysis of the 
transcriptional profiles will help to reveal the similarities and differences in gene regulatory 
networks utilised when transitioning from a primed to naïve state using the different 
reprogramming methods. Moreover, it may be possible to associate the transcriptional routes 
taken to specific chemical inhibitors used in one culture medium, and not the other. 
Alternatively, common mediators that facilitate reprogramming may be identified, which would 
subsequently open up the possibility of these being experimentally tested for their requirement 
during primed to naïve reprogramming. If the identified mediators or repressors of 
reprogramming are susceptible to chemical induction or inhibition respectively, future targeted 
efforts can be taken towards improving current naïve hPSC induction media. Taken together, 
the isolation of nascent naïve hPSCs using an additional reprogramming method will help to 
address unresolved questions, whilst also highlighting the robust and versatile capability of the 





1. Isolate early naïve hPSCs using different primed to naïve reprogramming methods 
2. Characterise early naïve hPSCs 
i. Assess the ability to form colonies from single cells  
ii. Examine global transcriptional dynamics throughout primed to naïve 
reprogramming at frequent time points  
iii. Examine the dynamics of X-chromosome reactivation throughout 
primed to naïve reprogramming  
iv. Perform comparative transcriptional profile analysis of early naïve 






To gain a better understanding of the cell fate transition from primed to naïve pluripotency, I 
wished to examine different reprogramming methods in more detail. As alluded to earlier (in 
section 3.2.7) the efficiency of reprogramming is variable among the reprogramming protocols. 
Whilst NK2 t2iL+PKCi reprogramming forms a nascent naïve population of ≈2% by day 10 
(Figure 4.2), 5iLA reprogramming revealed that the majority of day 10 cells were clustered 
amongst established naïve hPSCs (Figure 3.18) – indicating that the reprogramming efficiency 
may be higher using this method.  
 
5.2.1 Using cell surface marker expression profiles to define reprogramming populations 
under 5iLA culture 
 
I first examined what intermediate reprogramming populations were present by day 10 using 
the complete multiplexed antibody panel. The results visualised using FlowSOM reveal a far 
greater percentage of N4+ cells (≈11% on average) (Figure 5.1). Curiously, the N3+ population 
(lacking CD75 induction) is considerably smaller, perhaps indicating that this population has 
progressed, or that this trajectory is infrequent with 5iLA reprogramming. As previously 
observed in naïve cells, there is a good overlap between the naive-specific markers and OCT4-
ΔPE-GFP expression. Interestingly, the vast majority of day 10 cells are positive for OCT4-
ΔPE-GFP expression, even though there is considerable heterogeneity in the morphology at this 
time point (Figure 5.2). Moreover, OCT4-ΔPE-GFP positive cells are apparent that are lowly 
expressing several naïve-specific markers, and are still positive for primed-specific marker 
CD57 (designated with black arrows, Figure 5.1). This indicates that OCT4-ΔPE-GFP 
expression may precede the expression of naïve-specific markers. Alternatively, this could 
indicate that OCT4-ΔPE-GFP is not adequately stringent for prospective isolation of 
homogeneous naïve hPSCs, and may identify a broader cell population. – a point I shall address 






Figure 5.1. Prospective isolation of 5iLA day 10 reprogramming populations by FACs.  
FlowSOM visualisation of the flow cytometry data for day 10 cells during primed to 5iLA naïve 
reprogramming. The minimal spanning tree of the self-organising map displays an 
unsupervised clustering of the sample based on the cell surface protein expression levels 
(bottom). The cells corresponding to each cell sorted population, N4+, N3+, and N4–, are 
indicated. The heatmap shows the expression level of each cell surface protein marker in the 






Figure 5.2. Representative morphology of day 10 5iLA reprogramming hPSCs 
Phase contrast image showing a representative field of view of WIBR3 hPSCs under 5iLA 
reprogramming conditions (day 10). Colonies with a naïve morphology are beginning to emerge 
(indicated by white arrows), yet considerable heterogeneity is apparent. Scale bars, 200 µm; 4x 
objective.  
 
5.2.2 Isolating nascent naïve hPSCs early during 5iLA reprogramming using a refined 
multiplexed antibody panel   
 
I next decided to further optimise the multiplexed antibody panel, by removing the naïve 
specific CD7 and the primed-specific CD90 antibodies. These two markers contribute the least 
to the panel when the objective is to identify naïve hPSCs. The majority of the cells that are 
triple positive for CD75, CD77 and CD130 are positive for CD7 (≈98%). Moreover, CD7 
expression is absent in human embryos, unlike CD75, CD77 and CD130. Likewise, CD24 and 
CD57 low populations correspond to the lowest CD90 expressing cells. Removal of these two 
markers additionally served to simplify cytometry compensation and improve the reliability, as 
is the case when fewer compensation calculations are required. I additionally considered 
removing CD130 from the antibody panel, as 97% of cells that are double positive for CD75 
and CD77 are also CD130 positive under 5iLA reprogramming; however, CD130 is a useful 
marker during NK2 t2iL+PKCi reprogramming to delineate successfully reprogrammed cells 
upon DOX-induced transgene withdrawal. I therefore decided to retain CD130 to safeguard 
future continuity in the case where additional reprogramming methods are examined.   
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As discussed previously, there is a potential caveat with the isolation strategy performed 
previously for NK2 t2iL+PKCi samples. It is possible that additional nascent naïve hPSC 
populations exist, but may not have been captured within the stringent gating strategies of N3+ 
and N4+. Moving forward with the condensed antibody panel (CD75, CD77, CD130, CD24 
and CD57), I sought to address this concern by broadening the gated populations into “Reset” 
and “Not Reset”. Gating for “Reset” cells is comparable to N4+ in that the CD75/CD77/CD130 
high and CD24/CD57 low expressing cells are isolated (Figure 5.3). However, the gating of 
“Not Reset” cells has been broadened considerably to include all cells that do not fall into the 
initial “Reset” category of CD75/CD77 high. This includes cells that will be CD77 or CD75 
high, but not those that express both markers highly. With this modified gating strategy, the 
Reset population corresponds to ≈10%, whilst the Not Reset cells corresponds to ≈55% on 
average at 10 days into reprogramming with 5iLA (Figure 5.3). If I were to apply this modified 
gating strategy to NK2 t2iL+PKCi day 10 reprogramming cells analysed previously, the Reset 




Figure 5.3. Refined gating strategy for the prospective isolation of day 10 reprogramming 
populations by FACS.  
Flow cytometry dotplots of day 10 cells during primed to naïve-state reprogramming of WIBR3 
hPSCs under 5iLA culture conditions. Left: Expression levels of two naïve-specific markers, 
CD75 and CD77. The double positive population (CD75+/CD77+) was gated (green box), and 
cells not included were gated separately and correspond to day 10 “Not Reset” cells. These cells 
can express CD77 and CD75 individually to high levels, but not together. Middle: The 
expression levels of a third naïve-specific marker CD130 was gated (CD75+/CD77+/CD130+). 
Right: Expression levels of two primed-specific markers, CD24 and CD57. The double negative 
fraction was gated and corresponds to day 10 “Reset” cells that was used for subsequent 
experiments. The percentage of cells within each cell sorting gate relative to all live, human 




The FlowSOM projection for 5iLA reprogramming highlights the both the Reset and Not Reset 
populations, and again exemplifies the previous finding that OCT4-ΔPE-GFP is expressed in 
the majority of day 10 cells (≈75%) (Figure 5.4), even though most of these cells do not display 
the appropriate surface marker expression profile indicative of naïve cells. I have further 
highlighted the OCT4-ΔPE-GFP expression across three day 10 populations: Reset, Not Reset, 
and all live-human cells (Figure 5.5). Whilst the Reset population is almost exclusively positive 
for the OCT4-ΔPE-GFP reporter, more than 50% of the Not Reset population is also positive. 
This infers that either the surface markers are too stringent and will therefore fail to capture 




Figure 5.4. Prospective isolation of 5iLA day 10 reprogramming populations by FACS. 
FlowSOM visualisation of flow cytometry data for day 10 cells during primed to naïve 
reprogramming under 5iLA conditions. Right: cells corresponding to day 10 “Reset” (green), 
and day 10 “Not Reset” (purple) cell sorted populations indicated on the minimal spanning tree. 





Figure 5.5. OCT4-ΔPE-GFP expression levels across day 10 5iLA reprogramming populations 
Representative histograms of day 10 GFP expression levels for three populations: all live-
human cells, Not Reset cells and Reset cells. Noted are the percentage of cells classified as 
GFP+ for each population.  
 
 
5.2.3 Colony formation assay to examine clonogenicity of reprogramming populations 
 
To assess whether the modified gating strategy faithfully distinguishes between nascent naïve 
hPSCs and the cells that have not reprogrammed, I performed a colony formation assay. 
Strikingly, the Reset population isolates almost all cells with the capability of giving rise to 
colonies with a naïve morphology (Figure 5.6A). On contrast, the Not Reset population fails to 
generate colonies with a naïve or mixed morphology, even though this population includes cells 
that express two out of the three naïve-specific markers, and OCT4-ΔPE-GFP positive cells. 
This result reassuringly addresses the potential concern of missing important nascent naïve 
hPSC populations, and exemplifies that the state-specific surface markers can isolate naïve 
hPSCs generated by different reprogramming methods. Moreover, 5iLA day 10 Reset cells 
isolated by FACS give rise to homogeneous naïve hPSC cultures (Figure 5.6). Taken together, 







Figure 5.6. Colony formation efficiency of cell sorted populations into 5iLA naïve hPSC 
conditions. 
(A) Colonies were scored as naïve, mixed, primed and differentiated: examples shown below. 
Data show the mean ± SD of three biological replicates. Day 10 Reset cells were compared to 
Day 10 Not Reset cells for each morphology classification using a two-tailed t-test (***p < 
0.005). Scale bars, 100 µm. 
(B) Representative phase contrast image of day 10 Reset sorted population, cultured for 4 days 
after sorting for colony morphology Scale bars, 200 µm, 4x objective. 
(C) Representative phase contrast image naïve hPSC line derived from day 10 Reset cells, 







5.2.4 Transcriptional dynamics of 5iLA primed to naïve reprogramming  
 
5.2.4.1 Global overview of the transcriptional dynamics during 5iLA reprogramming 
 
Examining the transcriptional dynamics between primed and naïve pluripotency using NK2 
t2iL+PKCi reprogramming provided an initial insight into the potential regulators of this 
process. However, I wished to elaborate upon this work in a number of ways. Firstly, the 
assessment of an earlier time point, given that emerging naïve cells appear on day 8 during 
5iLA reprogramming based upon FlowSOM clustering. Secondly, more frequent time-points 
to enhance the resolution of transcriptional dynamics and order of molecular changes. The 
transcriptional analysis performed using NK2 t2iL+PKCi reprogramming revealed that 
considerable transcriptional and epigenetic remodeling continues between day 10 and passage 
5. I therefore decided to examine each passage between these time points. Finally, I wished to 
use an alternative method of reprogramming which would enable me to decipher the similarities 
and differences in routes taken between pluripotent states at matched time points. To this end, 
I sorted “Reset” cells at the following time points: day 8, day 10, passage 1 (day 14), passage 2 
(day 18), passage 3 (day 22), passage 4 (day 26) and passage 5 (day 30). In addition, “Not 
Reset” cells were isolated at early time points of 8 and 10 days into reprogramming for a 
comparison against the “Reset” population. Cells were isolated at each time point by FACS and 
mRNA-seq libraries were generated from three independent reprogramming experiments.  
PCA was performed using the top 1000 most variable genes across all cell types. Time-point 
replicates cluster closely together and exhibit minimal variation, providing assurance in the 
reproducibility of the antibody panel to isolate nascent naïve hPSCs (Figure 5.7). Similar to the 
PCA generated for NK2 t2iL+PKCi reprogramming, PC1 separates primed and naïve hPSCs, 
representing 74% of the variation. Along this same component, there is a progressive trajectory 
from day 8 through to passage 5. Interestingly, cells appear to have acquired a mature naïve 
identity by passage 2, with little variation between P2, P3, P4, P5 and  established naïve hPSCs. 
Analogous to the trajectory observed for NK2 t2iL+PKCi reprogramming, the “Not Reset” 
population takes a divergent path that mimics the N4- population. This population similarly 
expresses neural associated genes such as MAP2, CER1 and SOX5. Likewise, genes associated 
with early-naïve hPSCs include DPPA3, GDF3, TFCP2L1 and CD7, all of which are common 
with N4+ early-naïve hPSCs; this indicates similarities in the gene expression changes and 





Figure 5.7. Transcriptional analysis of primed to naïve 5iLA reprogramming populations.  
Principal component analysis of RNA-sequencing gene expression data from the different cell-
sorted populations throughout reprogramming, primed, and established naïve hPSCs (left). 
Right: the contribution of selected genes to the first and second principal components.  
 
Whilst PCA analysis is useful for deciphering the broad similarities and differences between 
sample types, the majority of variation in gene expression occurs between primed and later 
naïve hPSC samples; therefore, the loading plot predominantly highlights genes that contribute 
to their separation, as opposed to emphasising the transcriptional changes that occur early 
during the reprogramming transition.  
 
5.2.4.2 Comparative transcriptional analysis of naïve hPSCs throughout 5iLA reprogramming 
 
To examine the reprogramming transition in more detail, I broaden the analysis by extending 
the calling of differentially expressed genes across all sample types to the top 4,000 genes, 
followed by clustering analysis (Figure 5.8). Reassuringly, the samples (columns) largely 
cluster in the time-point order of reprogramming. Each row corresponds to a cluster of genes 
that exhibit the same expression pattern. Using eight clusters for the expression dynamics 
allowed genes to be classified into distinct clusters of co-expressed genes that describe the 
major stages I would expect during a state transition; including up and downregulation of genes 






Figure 5.8. Clustering of differentially expressed genes during primed to naïve reprogramming 
reveals distinct clusters of co-expressed genes    
Heatmap showing the enrichment or depletion of the identified gene clusters during primed to 
naïve reprogramming at frequent time points. Gene clusters were generated from the top 4,000 
most differentially expressed genes across all time-points. Z-score normalized expression data 
is shown for each cluster of genes at each time-point. Co-expressed gene clusters have been 
given a short description of the transcriptional trajectory. 
 
I subsequently plotted the expression values for all genes within each cluster along the 
reprogramming time course (Figure 5.9). Presented are the number of genes within each cluster, 
a selection of representative genes, and gene ontologies associated with each gene cluster.  
The early upregulated gene cluster, which shows upregulation in day 8 Reset cells through to 
established naïve cells, contains genes that I have previously identified as being associated with 
early stage naïve hPSCs, such as CD7, IL6ST (CD130), DPPA3 and KLF4, along with >450 
additional genes, many of which are unknown in this context. The identification of genes within 
this cluster that have previous links with naïve pluripotency provides confidence in those that 
have no prior association. Moving forward more generally, this will provide new insights into 
transcriptional dynamics during primed-to-naïve reprogramming. This gene cluster provides 
several significant gene ontology categories. Examples include immune response and cellular 
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response to chemical stimuli – likely due to a number of cell surface receptor changes, including 
multiple interleukin and chemokine receptors. Moreover, several growth factors are 
upregulated during this early stage of reprogramming, such as FGF4 and PGF (placental 
growth factor). PGF is known to be expressed from trophoblast cells during human embryo 
development (Athanassiades and Lala, 1998). Similarly, FGF4 is an important growth factor 
produced throughout mouse embryonic development (Niswander and Martin, 1992; Rappolee 
et al., 1994), and found to be necessary for the derivation and maintenance of trophoblast stem 
(TS) cells (Tanaka et al., 1998). This cluster also contains notable epigenetic modifiers such as 
TET2 and DNMT3L that both have key roles in regulating DNA methylation levels that is an 
important hallmark to distinguish pluripotent states.  
Whilst the next cluster termed “middle phase upregulation” did not return any significant GO 
terms, there are a number of interesting genes with relevance to primed-naïve pluripotency. 
GDF3, a known TGFβ superfamily member and naïve-pluripotency-associated marker, follows 
this expression trajectory. Likewise, CD320 shown to be expressed in E6 blastocyst stage 
human embryos (Collier et al., 2017) is upregulated during the middle phase of reprogramming.  
The late upregulated cluster contains many genes which are common to both methods of 
reprogramming, such as KLF17, XIST, DPPA5 and many zinc finger proteins. In addition to 
these, several genes in this cluster contribute to DNA methylation and piRNA related GO terms, 
examples include ZFP57, TDRD9 and PIWIL2. Both TDRD9 and PIWIL2 mediate the 
repression of transposable elements during germline development (Aravin et al., 2009; Shoji et 
al., 2009), and may therefore be required to moderate transposable element expression in naïve 
hPSCs. 
Interestingly, >500 genes were clustered as being transiently upregulated early during primed 
to naïve reprogramming, with many significant GO terms associated with these. A few 
examples include cell-cell adhesion, driven by a collection of cadherin/protocadherin genes, 
and terms associated with the regulation of hormone levels including genes such as GATA3, 
IL6, TFAP2B and CGB3. CGB3 encodes for a beta subunit of chorionic gonadotropin, a 
glycoprotein hormone released by trophoblast cells between implantation and gestation stages 
of pregnancy (Cole, 2009). Identification of candidate small molecules or growth factors, such 
as IL6 and CGB amongst many others, can be examined for their ability to facilitate primed to 
naïve reprogramming via media supplementation. Moreover, new signalling pathways 
previously not implicated in primed to naïve reprogramming may be identified with further 
analysis of the transcriptional dynamics, and can subsequently be experimentally tested.  
123 
 
The next four clusters all exhibit a downregulated trajectory. The early downregulated gene 
cluster includes previously identified primed-specific markers DUSP6, OTX2 and ETV5, which 
are known regulators of, and/or regulated by FGF/ERK signaling (Hoch et al., 2015; Li et al., 
2007). During primed to naïve reprogramming there is silencing of lineage-priming genes that 
are expressed in subpopulations of primed hPSCs, even though these cells are still pluripotent 
(Hough et al., 2014; Takashima et al., 2014). The GO terms associated with the four 
downregulated clusters include systems development, embryo development and fate 
specification. Within the gene cluster of progressively downregulated genes include key 
mesoderm lineage specification genes such as T (brachyury), BMP7 and MESP1. Similarly, the 
middle phase and early strongly downregulated gene clusters include important lineage 
specification and stem cell differentiation genes such as LEFTY1, ZIC2/3 and ID2/3. This infers 
that silencing of the primed pluripotent state-specific and lineage-priming GRNs is required for 
conversion back to naïve pluripotency (Kalkan et al., 2017; Luo et al., 2015; Smith, 2017). 
More than 1000 genes are downregulated during the middle phase and are silenced by passage 
3, which is longer than I would have anticipated given the potent inhibitor treatment from the 
onset of reprogramming. This could mean that priming is a robust phenomenon, acting as a 
barrier to naïve conversion, or alternatively that complete silencing of the priming GRNs is not 













Figure 5.9. Transcriptional dynamics of co-expressed gene clusters during reprogramming. 
The expression (z-score normalised FPKM) of all genes within each cluster are shown for 
each reprogramming time-point. Alongside each plot are the number of genes in the cluster 
and representative genes. A selection of gene ontologies associated with each cluster are 
shown. Corrected p values were calculated using a modified Fisher’s exact test followed by 
Bonferroni’s multiple comparisons test. 
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One use of the transcriptional data could be the inference of upstream regulators that modulate 
the expression dynamics and subsequently naïve reprogramming. There are many possible 
options for further data mining in the long-term, but in the first instance I sought to identify 
candidate compounds that are known to regulate the genes within the four-upregulated clusters 
by performing DSigDB analysis (drug signatures database for gene set analysis) (Yoo et al., 
2015).  Highlighted in Table 5.1 are a selection of compounds, their target effect, and example 
genes that each compound is known to regulate. This has identified a number of conceivable 
compounds, such as the DNA methyltransferase inhibitor Decitabine (5-aza-2'-deoxycytidine), 
and the histone deacetylase inhibitor Trichostatin A. DNA demethylation occurs rapidly during 
primed to naïve reprogramming, likely via the downregulation of DNMT1, DNMT3B, and 
UHRF1, and the concurrent upregulation of TET1 and TET2. Even so, 5-aza-2'-deoxycytidine 
has been shown to promote a variety of cell fate transitions (Kim et al., 2010; Mikkelsen et al., 
2008; Yoon et al., 2006; Zhao et al., 2015), and the addition during primed to naïve 
reprogramming could enhance this process. Additionally, the compound Trichostatin A was 
identified, that is a histone deacetylase (HDAC) inhibitor. Several reports of naïve cell 
derivation by alternative reprogramming methods have used HDAC inhibitors (Guo et al., 
2017; Ware et al., 2014). This provides some reassurance for the other compounds identified, 
all of which have yet to be examined for their ability to promote primed to naïve 
reprogramming, and this offers an avenue for further experimental exploration.  
 
Table 5.1. DSigDB results identifying compounds that target genes which are upregulated 
during primed to naïve reprogramming.  
 




Prenylamine Calcium channel blocker 9.07E-07 
MT2A, MX1, MX2, MT1M, MT1X, MT1G, MT1H, 
MT1E, MT1HL1, SGK1 
Progesterone Steroid hormone 1.09E-05 
GATA6, CGA, CGB, DEPTOR, KLF4, KLF5, 





BMI1, CD70, CD80, KLF2, KLF5, KLF9, IL6, 
IL6R, IL6ST, SOX15, SOX18,  
Dexamethasone Glucocorticosteroid 8.62E-04 
 BMP6, IL6, IL6R, IL32, NFKB2, PCAM1, 





CEBPD, IL1R1, KLF9, MT1X, MT2A, OLAH, 
SPTLC2 
Prenylamine Calcium channel blocker 2.61E-03 
CDKN1A, GDF15, GPRC5A, IFIT3, IFIH1, IL6, 
KLF5, SAT1 
Mometasone Glucocorticoid 3.21E-03 
CCNA1, FKBP5, KLF9, MT1G, MT1X, MT2A, 
OLAH, SMARCA2 
Trichostatin A HDAC inhibitor 6.25E-03 
BMI1, DEPTOR, DPPA2, DPPA5, GATA2, 





hormone receptor agonist 
1.35E-02 
CGB5, CYGB, ESRRB, FGF13, IGF1, IL6, 





1.61E-02 GATA6, GDF15, IFI16, IL6ST, KLF4, STYK1 
 
 
5.2.5 X-chromosome status  
 
As previously discussed, one of the most faithful indicators of naïve hPSCs is the reactivation 
of the silenced X-chromosome in female cells. Naïve and primed hPSCs have a close 
resemblance to the transcriptional and epigenetic landscape of primate pre- and post-
implantation epiblast respectively (Boroviak and Nichols, 2017). Given that epigenetic 
mechanisms regulate X-chromosome activity, it is important to study this event in a model 
system that best resembles the in-vivo cellular context. For this reason, naïve and primed hPSCs 
offer an opportunity to obtain a better mechanistic understanding of how X-chromosome status 
may be regulated in humans. Analysis of the time-course NK2 t2iL+PKCI reprogramming 
revealed X-chromosome reactivation occurred between day 10 and day 30 (passage 5). To 
examine the X-chromosome status during 5iLA reprogramming a similar approach was taken. 
RNA-sequencing datasets were examined and using SNP information genes could be classed 
as mono- or bi-allelically expressed. This analysis again reveals that X-chromosome 
reactivation occurs predominantly during the later maturation phase of naïve cell formation, 
with reactivation occurring between passage 1 (day 14) and passage 2 (day 18) (Figure 5.10). 
It was not possible to examine as many genes for the WIBR3 line compared to H9 NK2 cells, 
because WIBR3 cells have only been genotyped by SNP array and not by sequencing. 
Therefore, the total number of informative SNPs in coding regions is reduced. Nonetheless, a 
consistent trend of reactivation during P1-P2 is observed for those genes that could be assessed. 
As observed under NK2 t2iL+PKCi reprogramming, XIST is also upregulated during the later 
stages of reprogramming concomitant with XCR. As previously discussed, the upregulation of 
XIST expression is counterintuitively indicative of X-chromosome reactivation (Sahakyan et 
al., 2017; Vallot et al., 2017). This result is therefore consistent with X-chromosome 
reactivation occurring between day 14 and day 18, and the conclusion that X-chromosome 




Figure 5.10. X-chromosome reactivation dynamics during primed to naïve reprogramming.   
Allelic analysis of RNA-seq data for X-linked genes at time-points throughout reprogramming. 
Informative SNPs within X-linked genes of the WIBR3 hPSC line were used to classify 
expression from each allele: allele 1 (red), allele 2 (blue); Log2 RPKM values for each time 




5.2.6 Comparative transcriptional analysis of the routes from primed to naïve pluripotency by 
different reprogramming methods  
 
To better understand the route from primed to naïve pluripotency I not only wanted to examined 
more intricate time points, but also to compare different reprogramming protocols to establish 
the similarities and differences in paths taken. To this end, I firstly performed a transcriptional 
comparison between the two reprogramming methods NK2 t2iL+PKCi and 5iLA (Figure 5.11). 
The PCA plot shows that the established naïve hPSCs derived by both reprogramming methods 
exhibit a remarkable transcriptional similarity; however, there are notable differences in the 
trajectory taken from primed pluripotency to get there. PC1 clearly separates primed from naïve 
hPSCs. Along this component, there is a good alignment between the matched cell types: 
Primed, Not Reset, Day 10 Reset, and Naïve hPSCs. However, the two reprogramming methods 
exhibit divergence in their trajectories from primed to naïve pluripotency shown along PC2.  
 
Figure 5.11. Comparative transcriptional analysis of 5iLA and NK2 t2iL+PKCi 
reprogramming.  
Principal component analysis of RNA-sequencing gene expression data from time points 
throughout primed to naïve reprogramming. Circles represent H9 NK2 t2iL+PKCi 




Next I chose to focus in on the differences between day 10 time points of the two 
reprogramming methods, as this is the first matched time-point that also displays some of the 
greatest divergence. PCA results show the samples cluster by reprogramming method, as would 
be expected, and the majority of variation is captured in PC1 (91%) (Figure 5.12). To examine 
the most variable genes that influence the clustering of samples, a loadings plot is shown with 
a selection of these genes. This immediately highlights some curious differences between the 
two methods. Both TET2 and TET3, which are capable of active DNA demethylation, are 
upregulated in day 10 5iLA reset cells compared to day 10 cells under NK2 t2iL+PKCi 
reprogramming. This may indicate that DNA demethylation could occur earlier, or more 
rapidly, under 5iLA reprogramming. Another gene of considerable interest and which is also 
upregulated in 5iLA samples is TFAP2C. This transcription factor is essential for naïve human 
pluripotency using both 5iLA and t2iL+PKCi reprogramming (Pastor et al., 2018). TFAP2C is 
able to bind the proximal enhancers of pluripotency related genes, including a naïve-specific 
enhancer that regulates POU5F1 (Pastor et al., 2018). Of note, day 10 5iLA cells also express 
GATA2, GATA3 and GATA6 to higher levels. All three of these GATA factors are expressed in 
both the mouse and human trophectoderm (Home et al., 2009; Koutsourakis et al., 1999; Ma et 
al., 1997; Ralston et al., 2010; Roode et al., 2012). This raises the speculative possibility that 
early reprogramming cells could transition through a TE-like state under 5iLA reprogramming. 
Alternatively, the differential expression of GATA factors may be due to cell line differences, 
and GATAs 3 and 6 are lowly expressed in WIBR3 primed cells, but not in the H9 NK2 line. 
Whilst in the first instance I have focused on these PSC lines, in the future it will be important 






Figure 5.12. Comparative transcriptional analysis of early-naïve reset cells via different 
reprogramming methods.   
Principal component analysis of RNA-sequencing gene expression data from Day 10 Reset 
cells generated using 5iLA and NK2 t2iL+PKCi reprogramming methods (top). Bottom: the 
contribution of selected genes to the first and second principal components.  
 
To examine the top 1,000 most variably expressed genes between the two reprogramming 
methods in more detail, I performed gene-clustering analysis. Genes were firstly classified as 
up regulated in 5iLA cells (n=603), or upregulated in t2iL+PKCi cells (n=397) (Figure 5.13). 
A number of distinct clusters were apparent within the two gene sets: “primed genes”, defined 
as being upregulated in primed and day 10 cells (red), “transient genes”, upregulated in day 10 
cells only (green), “naïve genes”, upregulated in day 10 and naïve cells (blue), and “unaffected 
genes” with minor expression changes between the three cell types (orange). One of the first 
notable observations is the continued expression of “primed genes” in both 5iLA and 
t2iL+PKCi cells at the day 10 time point, even though many genes associated with naïve 
pluripotency have already been induced. This indicates that it may not be necessary to silence 
lineage-priming and primed-pluripotency-specific genes before converting back to a naïve 
state. Another notable observation is a cluster of genes that are transiently upregulated in day 
10 cells under 5iLA reprogramming conditions (Figure 5.13). Within this cluster are four genes 
(GCA, CGB, CGB5, and CGB8) that encode for the alpha and beta subunits of chorionic 
gonadotropin, a hormone released by trophoblast cells (Zhuang and Li, 1991). Intriguingly 
neither CGA nor CGB genes are expressed at any stage during t2iL+PKCi reprogramming, and 
are only expressed transiently in early-naïve 5iLA cells. This could mean that chorionic 
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gonadotropin is produced during 5iLA reprogramming and may facilitate this process, 
suggesting one possible divergent pathway between the two reprogramming methods.  
Finally, a cluster of “naïve” genes that are upregulated in day 10 and naïve hPSCs exists for 
both reprogramming methods. A few interesting examples that are differentially upregulated in 
5iLA cells compared to t2iL+PKCi include GCM1, KLF3 and KLF4. GCM1 has been shown 
to bind the promoter region of all six CGB genes to promote gene expression (Cheong et al., 
2016). Moreover, a TFAP2C binding motif is also present at these promoter regions (Cheong 
et al., 2016), which may be another method by which CGB genes are upregulated, given that 
TFAP2C is also an early responder during 5iLA reprogramming. Another notable gene within 
the “naïve” gene cluster is NODAL, which encodes for a secreted protein that binds to type I 
and type II TGF-β receptors (James et al., 2005b; Massague, 1998). NODAL is not expressed 
in H9 NK2 primed cells, but is strongly upregulated by day 10 and remains expressed in naïve 
hPSCs. Related to this, GDF3, LEFTY1 and LEFTY2 exhibit this same expression pattern in H9 
NK2 cells – low in primed, but strongly upregulated in early and established naïve hPSCs, 
suggesting a potential role for Activin/Nodal signalling in naïve pluripotency. In line with this 
observation, Blakeley and colleagues found that human embryos treated with a potent TGF-β 
inhibitor resulted in the lack of NANOG expression and impaired epiblast formation (Blakeley 
et al., 2015). Interestingly, NODAL is expressed at similar levels throughout the entire 5iLA 
transition, extending to WIBR3 primed cells and established 5iLA naïve hPSCs. This again 
highlights a potential PSC line specific difference and could infer that WIBR3 primed cells 
have a head start towards the acquisition of naïve pluripotency. The PCA plot displaying both 





Figure 5.13. Clustering of differentially expressed genes between 5iLA and NK2 t2iL+PKCi Day 10 
Reset cell populations reveals distinct clusters of co-expressed genes.    
The top 1,000 differentially expressed genes between 5iLA and t2iL+PKCi Day 10 Reset cells 
were used for clustering analysis. Data from the parental primed hPSCs and established naïve 
hPSCs plotted for comparison. Left: Genes that are upregulated in day 10 5iLA compared to 
NK2 t2iL+PKCi reprogramming form three distinct clusters: genes upregulated in primed and 
day 10 cells (red), genes transiently upregulated in day 10 cells (green), and genes upregulated 
in day 10 and naïve cells (blue). Right: Genes that are upregulated in day 10 NK2 t2iL+PKCi 
compared to 5iLA reprogramming separate into three clusters: genes upregulated in primed and 
day 10 cells (red), genes with minor expression changes between the three cell types (orange), 
and genes upregulated in day 10 and naïve cells (blue). Z-score normalised FPKM expression 




In light of the unexpected observation that several trophectoderm related markers are 
upregulated transiently during 5iLA reprogramming, I subsequently assessed a broader panel 
of 500 TE-enriched genes. These 500 genes are the most differentially expressed genes between 
the trophectoderm and epiblast, determined by scRNA-seq of human embryos (Blakeley et al., 
2015). To my surprise, the transient upregulation of TE-related genes appears to be more widely 
applicable, with a significant upregulation in day 10 reprogramming samples compared to 
primed hPSCs. Example genes that exhibit some of the greatest expression changes include 
GATA2, LRP2, CDX2, SLC7A2, TEAD3 and HOOK1, which are all recognised human TE-
markers (Assou et al., 2012; Blakeley et al., 2015; Petropoulos et al., 2016). Further to this, I 
have observed colonies with a trophoblast-like morphology arising during primed to naïve 
reprogramming (Figure 5.15); however, to validate this observation it will be necessary to 
assess the protein expression of TS-markers. Even so, these results suggests it may be possible 
to derive trophoblast-like stem cells; by amending the culture conditions to enrich for their 
survival and expansion, as opposed to selecting for naïve hPSCs, it could be possible to preserve 
this population in the future.  
 
Figure 5.14. Comparative transcriptional analysis of trophectoderm-enriched genes across 
primed to naïve reprogramming time-points.  
Assessment of the top 500 differentially expressed genes (TE compared to EPI, acquired from 
scRNA-seq of human embryos (Blakeley et al., 2015), across the reprogramming time-points 
for 5iLA and NK2 t2iL+PKCi reprogramming methods. Log2 FPKM expression shown. 
Average FPKM calculated from 3 biological replicates, with the exception of WIBR3 primed 
(n=1, (Theunissen et al., 2014)). Boxplots show the median, min and max values. ANOVA with 




Figure 5.15. A subset of human PSCs adopt a trophoblast-like stem cell morphology during 
primed to naïve reprogramming.  
Representative phase contrast image of early reprogramming cells which adopt a trophoblast-
like morphology. Left and centre: NK2 t2iL+PKCi reprogramming; Right 5iLA 
reprogramming. Scale bars, 100 µm, 4x objective. 
 
KLF transcription factors are known to play an important role in regulating pluripotency 
(Bialkowska et al., 2017; Pastor et al., 2018; Takashima et al., 2014). To my surprise, most of 
the different KLF factors appear to be utilised more so during early 5iLA reprogramming, with 
the exception of KLF17 that is expressed to significantly higher levels in NK2 t2iL+PKCi day 
10 cells (Figure 5.16). Under both reprogramming methods, KLF17 is ultimately upregulated 
to similar levels in mature naïve hPSCs; however, it appears that during the early stages of 
reprogramming, there is differential utilisation of the KLF family members. Interestingly, KLF2 
was expressed to higher levels during early 5iLA reprogramming, even though NK2 t2iL+PKCi 
reprogramming requires the transient over-expression of NANOG and KLF2. This infers that 
by day 10 the transgenes are no longer induced and reprogramming resumes independently of 
transgene expression. Given the importance of KLF factors in human pluripotency, little is 
known about their target specificity and probable redundancy, and this therefore provides an 







Figure 5.16. Important regulatory genes exhibit divergent expression dynamics between 5iLA 
and NK2 t2iL+PKCi Day 10 Reset cell populations. 
Plotted are the gene expression profiles of example genes that exhibit differential expression 
between the two reprogramming methods. Data show the mean log2 FPKM ± SD of three 
biological replicates and were compared using a two-tailed t-test (*p < 0.05, **p < 0.005, ***p 








5.3 Discussion  
 
One of the first indicators that 5iLA reprogramming may be more efficient than NK2 
t2iL+PKCi came from the morphological observation that dome-shaped colonies appeared 
more frequently by day 10. In support of this idea, the flow cytometry results of day 10 
reprogramming cells revealed a population of ≈10% corresponding to Reset cells, which is far 
greater than ≈2% observed under t2iL+PKCi culture. Although this implies the efficiency of 
reprogramming may be higher, without performing lineage tracing experiments it would not be 
possible to conclude this. There is the possibility that the same efficiency is observed by both 
methods, yet expansion of naïve hPSCs under 5iLA culture is faster. Alternatively, the selection 
pressure of 5iLA culture may be greater, and subsequently the cells that are refractory to 
reprogramming do not survive, giving the illusion of enhanced efficiency. I believe this is a 
more likely outcome given the initial reports of “wide-spread cell death” in the original 
publication (Theunissen et al., 2014), and from what I experience early during 5iLA 
reprogramming.  
In a similar manner observed for NK2 t2iL+PKCi reprogramming, the day 10 Reset population 
under 5iLA culture gave rise to colonies with a predominantly naïve morphology. Furthermore, 
the Not Reset population that corresponds to >50% of all day 10 cells, struggled to form 
colonies of any morphology. This result instils confidence in the multiplexed antibody panel 
for the reliable and versatile identification of the nascent naïve hPSC population using a 
different reprogramming method. Moreover, I have shown the antibody panel is effective for 
the tracking and subsequent isolation of naïve hPSCs throughout the reprogramming process.  
The examination of early reprogramming populations under 5iLA has inadvertently highlighted 
a potential caveat to the OCT4-ΔPE-GFP reporter system. By day 10 of reprogramming, ≈75% 
of the population are GFP positive; however, only 10% of cells are classed as Reset according 
to the surface marker panel. Likewise, ≈50% of the Not Reset population – which does not form 
naïve colonies – are GFP positive. This strongly indicates that the expression of OCT4-ΔPE-
GFP is not restricted to colony forming naïve hPSCs, and is therefore not a robust method to 
isolate naïve cells under 5iLA reprogramming. The OCT4-ΔPE-GFP reporter system was 
originally devised based upon enhancer utilisation during mouse preimplantation development 
and the conserved activity seen in naïve mouse ESCs (Choi et al., 2016; Tesar et al., 2007; 
Yeom et al., 1996). However, the enhancer elements driving OCT4 expression in humans had 
not been examined in detail until recently (Pastor et al., 2018). Pastor and colleagues discovered 
a naïve-specific intronic enhancer element that is essential for OCT4 expression in human naïve 
PSCs (Pastor et al., 2018). Amending the previously used reporter system, such that GFP 
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expression is coupled to the newly identified intronic-enhancer element usage, may provide a 
more faithful readout of naïve state reprogramming, and subsequently enable using this reporter 
system to accurately isolate naïve hPSCs.  
The chemical screening approach used by Theunissen and colleagues was reliant on the 
induction of OCT4-ΔPE-GFP reporter expression. Compounds that promoted GFP expression 
were ultimately combined to form the 5iLA media formulation. However, given the finding that 
the OCT4-ΔPE-GFP reporter is not restricted to naïve hPSCs, it raises questions over their 
specificity for inducing naïve hPSCs. Adopting a similar compound library screen using a more 
reliable report system, or the surface marker panel, could prove useful for the future 
identification of compounds that induce naïve pluripotency.  
Using the antibody panel to isolate nascent naïve cells as they emerge and progress throughout 
reprogramming has provided the first detailed insight into the transcriptional dynamics across 
human pluripotent states. The clustering analysis of variably expressed genes across the 5iLA 
reprogramming time course revealed distinct clusters of co-expressed genes, many of which 
have thought-provoking biological functions. Of note, transcription factors KLF2, KLF4 and 
KLF5 are all upregulated early during reprogramming, along with >400 other genes. It is well 
established that KLFs 2, 4 and 5 work in cooperation with Nanog to maintain mESC 
pluripotency and self-renewal (Jiang et al., 2008). Furthermore, in-vitro studies of mESCs have 
highlighted MEK/ERK signalling as a negative regulator of Klf2, and upon treatment with 
PD0325901 Klf2 expression is quickly elevated (Yeo et al., 2014). Similarly, Klf4 and Klf5 are 
targets of Jak/Stat3 signalling and are upregulated in the presence of LIF (Hall et al., 2009). It 
is therefore not all that surprising that specifically these three KLF factors are induced at the 
very earliest stages of naïve reprogramming. Moreover, this infers a conserved signalling 
pathway regulation of these factors in humans. 
The importance of KLF transcription factors in relation to naïve human pluripotency has been 
touched upon in several studies. Takashima and colleagues show that shRNA knockdown of 
KLF4 in t2iL+PKCi naïve hPSCs (but not in primed hPSCs) caused a vast reduction in AP+ 
pluripotent colony formation (Takashima et al., 2014). More recently, KLF binding motifs were 
the most enriched factor found at open chromatin sites in human blastocysts and naïve hPSCs, 
signifying an overlapping and important role in both in-vitro and in-vivo naïve cell types (Pastor 
et al., 2018). Nonetheless, the target specificity and redundancy of the different KLF factors in 
human primed and naïve pluripotency are currently unknown, and this provides an interesting 
avenue for further investigation. 
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There is still an incomplete understanding of the transcriptional dynamics that drive primed and 
naïve pluripotency. Intricate analysis throughout 5iLA reprogramming has provided a 
comprehensive insight into the order of transcriptional changes. A few examples of the top most 
variably expressed genes across the 5iLA transition include DPPA5, KHDC1L, TRIM60, 
OLAH, KHDC3L, VIM, ALPP and GTSF1; alongside many other examples, these will provide 
a useful resource of transcriptional markers for the future assessment of cell identity along the 
primed to naïve axis. Furthermore, it will be interesting to utilise the time-series expression data 
for impending gene regulatory network modelling. Due to time constraints it has not yet been 
possible to perform this analysis, however recently devised tools such as dynamical GENIE3, 
that are specifically designed for GRN inference from time course transcriptional data, will help 
to reveal the GRNs utilised throughout reprogramming in the future (Huynh-Thu and Geurts, 
2018). A recent study has similarly performed time-series analysis of transcriptional profiling 
across 5iLAF reprogramming, although starting from immortalised secondary human 
fibroblasts (Wang et al., 2018). Bulk RNA-sequencing was performed at regular intervals 
throughout, revealing a transient reactivation of transcripts associated with 8-cell stage embryos 
during the later stages of reprogramming. Given that lineage segregation has not occurred at 
this stage of human embryonic development (Petropoulos et al., 2016), this again infers naïve 
hPSCs may adopt a transcriptional identity encompassing both embryonic and extraembryonic 
cell types. Further experiments are warranted to confirm whether this is the case.  
Transcriptional data is frequently used as a method to infer cell identity. However, there can be 
a disconnect between transcript levels and protein expression, particularly in the case of state 
transitions (Liu et al., 2016). There is often a time lag between transcription, transcript export 
and subsequent translation, and the mRNA sequence and a multitude of additional factors can 
influence translation rates (Liu et al., 2016). For this reason, it would be nice to perform 
additional experiments in the future employing mass cytometry (CyTOF) technology, with the 
formulation of antibody panels to study primed to naïve reprogramming at the protein level. 
Similar to flow cytometry, mass cytometry utilises antibodies conjugated to metal isotopes and 
enables the quantification of >50 different protein markers to be assessed at a single-cell 
resolution (Bendall et al., 2012). Moreover, the concurrent examination of phospho-specific 
antibodies, and antibodies for epigenetic modifiers, will provide a comprehensive overview of 
the reprogramming trajectory, and the cross talk between signalling, epigenetic, and gene 
regulatory networks.  
An unexpected outcome of the transcriptional dynamics of 5iLA reprogramming was the 
observation that multiple trophectoderm related genes were transiently upregulated. I firstly 
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noticed that GATAs 2, 3 and 6 were all upregulated by day 10 of reprogramming. All three of 
these GATA factors are strongly enriched in the trophectoderm cells of both mouse and human 
embryos compared to the epiblast (Blakeley et al., 2015; Home et al., 2009; Petropoulos et al., 
2016; Ralston et al., 2010; Roode et al., 2012). Further analysis of reported human TE enriched 
genes revealed that many were transiently upregulated under both reprogramming conditions. 
However, there were some notable exceptions which displayed 5iLA specificity, such as a 
collection of genes encoding for the alpha and beta subunits of human chorionic gonadotropin 
(hCG). As mentioned previously, both GCM1 and TFAP2C are also upregulated early under 
5iLA reprogramming, and are known regulators of CGB gene expression (Cheong et al., 2016). 
However, this may not be the mechanisms for CGB upregulation, as both GCM1 and TFAP2C 
continue to be expressed throughout both reprogramming methods, whilst CGB genes are 
silenced at later stages in 5iLA culture, and CGB genes are not expressed at any stage under 
t2iL+PKCi culture. Collectively, this infers hCG could be transiently produced during 5iLA 
reprogramming and might promote naïve state transitioning.  
Alternatively, early naïve hPSCs may possess the ability to become both naïve hPSCs with 
embryonic potential, and cell types with extraembryonic potential such as trophoblast-like stem 
cells; but with prolonged culture in 5iLA the route to naïve pluripotency may be enforced, and 
thus the trophectoderm related genes are largely downregulated at later stages. Conversely, it 
is possible that multiple cell types are isolated using the antibody panel, including a population 
with embryonic potential and a separate population with an extraembryonic identity. A similar 
phenomenon has been reported during chemical mediated iPSC reprogramming (CiPSC), 
where populations of cells can pass through an extra-embryonic endoderm (XEN)-like state 
before transitioning to form mouse CiPSCs (Li et al., 2017; Zhao et al., 2018; Zhao et al., 2015). 
It has yet to be shown whether this is also true during human iPSC reprogramming. As it 
currently stands there are no protocols to establish and maintain human XEN cells in-vitro. 
However, there has been a recent report describing human trophoblast stem cell derivation and 
maintenance (Okae et al., 2018). A chemical cocktail that promotes Wnt and EGF signalling, 
in combination with TGF-β, HDAC, and ROCK inhibition permitted the expansion of several 
trophoblast cell types. These culture conditions provide a framework to guide the amendment 
of current naïve culture conditions, which will be required to fully explore the possibility of 
deriving trophoblast-like stem cells during primed to naïve reprogramming. Furthermore, the 
surface marker KRT7 was used to positively assess the human TS cells, in combination with a 
lack of HLA-A,B,C expression (Okae et al., 2018). The addition of these two markers to the 
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current multiplexed antibody panel offers an alternative method to enrich for potential TS-like 
cells during primed to naïve reprogramming.    
An additional aim of this chapter was to characterise the transcriptional dynamics of primed to 
naïve reprogramming, with the intent to identify candidates that could be added to the culture 
media to facilitate naïve cell formation. The first example of this is human chorionic 
gonadotropin, as mentioned previously. The second candidate is interleukin-6 (IL-6) that is 
highly expressed in 5iLA day 8 and day 10 Reset cells, and day 10 N4+ t2iL+PKCi cells, but 
subsequently downregulated in established naïve hPSCs. IL-6 exerts its biological activities by 
binding to the IL-6R and inducing homodimerization of gp130 (IL6ST/CD130) (Heinrich et al., 
1998). Unsurprisingly IL6ST is highly expressed throughout reprogramming, as CD130 is one 
of the naïve-specific markers used for isolating reprogramming cells. Many other cytokines can 
also signal via gp130, including LIF (Gearing et al., 1992; Heinrich et al., 1998); however, the 
additional upregulation of both IL-6 and the IL-6 receptor indicates an important function for 
this cytokine and signal transduction pathway. However, experiments to examine IL6-R protein 
expression and IL-6 secretion would be necessary to both validate and distinguish their 
importance from LIF signalling in human PSCs. Finally, by performing DSigDB analysis I was 
able to identify candidate compounds to be added via media supplementation during 
reprogramming, with the overarching aim to enhance naïve cell formation. Amongst these were 
compounds with conceivable modes of action, such as promotion of DNA demethylation 
(Decitabine) and histone deacetylase inhibition (Trichostatin A). Additionally, several steroid 
hormones and hormone receptor agonists were identified, none of which have previously been 
examined for their ability to promote naïve pluripotency. This therefore provides an interesting 
and unexplored direction for future studies.  
The analysis of X-chromosome reactivation (XCR) under NK2 t2iL+PKCi reprogramming 
revealed that between day 10 and passage 5, the silent X-chromosome undergoes XCR. By 
performing the equivalent analysis using the 5iLA reprogramming transition with more 
frequent time-points, the window of XCR has been narrowed to passage 1 (day 14) – passage 
2 (day 18). In the scope of this work, is has not been possible to elaborate on this observation; 
however, deciphering the time point of interest to study will greatly facilitate the identification 
of candidates that regulate XCR. Future experiments can now be taken to mechanistically 
understand the function of key lncRNAs that purportedly govern X-chromosome activity in 
humans such as XIST and XACT (Sahakyan et al., 2017; Vallot et al., 2017), at a single-cell 
resolution throughout this period. More broadly, GRN analysis could be used to identify 
candidates that correlate with XCR; either in an unbiased or targeted manner by supplying 
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information of pre-existing regulators of X-chromosome activity. Identified candidates could 
subsequently formulate an enriched CRISPR library screen to be applied at the onset of 
reprogramming. Using a primed hPSC reporter line containing two different fluorescent 
proteins coupled to an X-linked gene on each X-chromosome would provide a readout of bi- or 
mono-allelic gene expression. The surface marker panel in combination with this type of 
reporter system would allow nascent naïve hPSCs with two active X-chromosomes, and 
populations that do not reprogram or do not display XaXa status, to be isolated using FACS. 
By comparing the different populations to see which CRISPR candidates are enriched or 
depleted, it would be possible to validate the predicted regulators of human X-chromosome 
activity.  
To summarise, I have shown that the antibody panel provides an opportunity to study naïve 
hPSC formation at a time point far earlier than previously possible, and the panel can be used 
reliably across different reprogramming methods. By studying the transcriptional dynamics 
across reprogramming, I have identified clusters of co-expressed genes that will provide a 
framework for the future assessment of cell identity along the spectrum of primed to naïve 
states. Similarly, a large number of candidates have been identified that will be experimentally 
tested in the future to establish the mechanisms by which they promote or inhibit 
reprogramming to a naïve state. These include chemical compounds and growth factors for cell 
culture media supplementation, and candidates for transcription factor mediated 
reprogramming. Moreover, the cross-comparison of early reprogramming populations has 
revealed that there are likely divergent routes from primed to naïve pluripotency. Further 
exploration of additional reprogramming methods, and reciprocal experiments to rule out PSC 
line differences, will help to elucidate these divergent routes and their significance.  Moreover, 
it will be interesting to assess the transcriptional similarity between the time points of 
reprogramming and the different embryonic lineages present within the human preimplantation 
blastocyst. This will help to provide clarity over their developmental staging and potential 












































The molecular and phenotypic studies of mouse, primate, and human embryos are providing 
clarity over the earliest stages of pluripotency, and are helping to define robust criteria by which 
to benchmark the different hPSC types against (Boroviak and Nichols, 2017; Huang et al., 
2014). There are now greater than ten reports that described the methodologies and growth 
conditions to derive human pluripotent stem cells with characteristic akin to those of the ICM 
of preimplantation‐stage embryos. These publications have generated a spectrum of different 
hPSC types that have collectively been termed ‘naïve’, even though some fulfil more of the 
hallmark characteristics of naïve pluripotency than others (Collier and Rugg‐Gunn, 2018). 
Nonetheless, the transcriptional and epigenetic profiling of these cells has provided a 
foundation of knowledge to distinguish primed and naïve human pluripotent states. This 
knowledge is providing new insights into the regulation of transcription, epigenetic states, and 
signalling requirements, which we can relate back to the human embryo for experimental 
validation. However, this information is restricted to the established states with no previous 
reports assessing how primed cells enter the naïve state of pluripotency, until now. The foremost 
reason for this being the absence of an isolation strategy capable of unambiguously identifying 
nascent naïve hPSCs early during reprogramming. 
The first outcome of my work addressed this problem through the comprehensive profiling of 
cell surface markers expressed by naïve and primed hPSCs. The results of the antibody library 
screen have identified eight naïve-specific surface markers, which are the first described 
candidates that can positively identify naïve from primed hPSCs; alongside a large number of 
primed-specific and shared markers. Collectively screening over 400 antibodies with diverse 
biological functions and inclusion of glycosylated epitopes was critical to identifying several 
naïve-specific markers, which would not have been identified by transcriptional analysis. Using 
the screen results, I subsequently validated a cohort of pluripotent state-specific markers across 
several different PSC lines and naïve culture conditions. Consistent state-specific results were 
obtained across PSC lines cultured under 5iLA and NK2 t2iL+PKCi conditions; however, I 
observed a mixed immunophenotype for RSeT conditions, which inferred RSeT cells fall 
somewhere in between primed and naïve states of pluripotency. Taken together, the screen 
results provide a large resource of markers present on the cell surface of primed and naive 
hPSCs, which should be valuable for future functional studies to interrogate the mechanisms 
that underlie the different states of human pluripotency. Nonetheless, there are bound to be 
many more state-specific surface markers that were not included across the two antibody library 
screens used during this work. This presents an opportunity in the future to examine more 
broadly the surface proteome and glycome of naïve and primed hPSCs to capture additional 
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markers, which in turn may provide new biological insights into additional signalling pathways 
regulating human pluripotent states.  
To fully demonstrate the pluripotent state-specific nature of the candidate surface markers, 
preimplantation-stage human embryos were examined for their expression. Three of the naïve-
specific markers, CD75, CD77, and CD130, were detected at the cell surface. CD130 showed 
an enrichment within the NANOG-positive cells of the ICM, whereas CD75 and CD77 were 
additionally expressed within the trophectoderm. This highlights that naïve hPSCs can be used 
to reveal new information relevant to human embryos. Moreover, this result indicates that CD75 
and CD77 are not restricted to pluripotent epiblast cells at this stage of human embryonic 
development, and suggests naïve hPSCs may possess some features of extraembryonic cell 
types. By contrast, all of the primed-specific surface markers were not expressed at this stage. 
It would be interesting in the future to examine their developmental expression using human 
post-implantation in-vitro models (Deglincerti et al., 2016; Shahbazi et al., 2016). Taken 
together, these results confirm the PSC state-specific markers generally correspond to their 
respective developmental staging.  
Whilst I have shown the state-specificity for a handful of identified markers, their biological 
roles in the context of pluripotency is unknown for many of these. Aforementioned, CD77 and 
CD75 are largely uncharacterised glycosylated epitopes. The enzymes purportedly responsible 
for the catalysis of CD75 and CD77, ST6GAL1 and A4GALT respectively, are 
transcriptionally upregulated in both 5iLA and NK2 t2iL+PKCi reprogramming cells and 
established naïve hPSCs. Additionally, both are highly expressed in human epiblast cells by 
scRNA-sequencing (Stirparo et al., 2017). Based upon the previous report of impaired hiPSC 
reprogramming and maintenance of primed pluripotency by ST6GAL1 perturbation, appropriate 
sialyation is required for pluripotency more generally (Schwarzkopf et al., 2002; Wang et al., 
2015). Similarly, reports show that numerous glycosyltransferase enzymes are required to 
maintain pluripotency and self-renewal of mESCs (comprehensively reviewed in: (Nishihara, 
2018)). Glycans participate in a variety of important cellular processes, including cell adhesion 
and ligand-receptor binding that helps to elicit signalling cascades. Several glycans that are 
more well characterised include heparan sulfate and chondroitin sulfate, which are known to 
bind to Wnt, FGF, TGF-β, and BMP ligands in Drosophila and mice (reviewed in (Bernfield et 
al., 1999)). Considering their significance in cell fate regulation by modulating cell signalling, 
surprisingly little is known about the specific downstream pathways beyond many glycosylated 
surface receptors in humans (Pshezhetsky and Ashmarina, 2013; Schauer, 2009). As mentioned 
previously, a handful of glycosylated epitopes (SSEA3, SSEA4, TRA-1-60 and TRA-1-8) are 
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routinely used to identify primed hPSCs (Kannagi et al., 1983; Wright and Andrews, 2009). 
However, the biological role for these four glycosylated epitopes are also not well understood. 
Collectively, these results prompt further exploration of sialyltransferase and 
galactosyltransferase enzymes in the context of human pluripotency. Future experiments that 
exploit CRISPR-deletion/inhibition, or an auxin-based degron system for targeted degradation 
of candidate enzymes, will help to confirm their involvement in the biosynthesis of specific 
surface receptors and subsequent requirement for human pluripotency. Future combinatorial 
approaches to perform antibody-mediated immunoprecipitation coupled to mass spectrometry 
of specific receptors, may also help to identify interacting protein partners to elucidate the target 
signalling pathways associated with each receptor.  
The second notable outcome from this work was the development of a multiplexed panel of 
state-specific antibodies capable of distinguishing naïve from primed cells by flow cytometry. 
I confirmed the sensitivity of the antibody panel by mixing together 10% naïve and 90% primed 
hPSCs. By gating for naïve surface marker expression and the absence of primed marker 
expression, all of the naïve hPSCs could be subsequently identified. This was the first critical 
step to ensuring the antibody panel could be used to isolate live naïve cells during 
reprogramming. The second critical step was to show that the antibody panel tracked the 
dynamics of heterogeneous pluripotent state conversions. The antibody panel collectively 
reflects the change from a primed to a naïve state, with the surface markers CD57, CD75, and 
CD130 being most reliable. By contrast, the predicted FGF target gene CD90 responded rapidly 
to the potent FGF/MEK/ERK inhibitor (PD0325901) added at the onset of reprogramming 
(Choi et al., 2001; Kaufman et al., 2001). Nonetheless, I have shown that the antibody panel is 
capable of robustly isolating nascent naïve hPSCs early during reprogramming for the very first 
time, alongside reprogramming intermediates that are refractory to reprogramming. Whilst 
there are a number of reported alternative isolation strategies (reviewed: (Collier and Rugg‐
Gunn, 2018; Trusler et al., 2018)), each one has been unable to demonstrate the ability to isolate 
early-naïve hPSCs. Consequently, our knowledge of the molecular events and their order during 
the reprogramming process has been limited. By using the antibody panel to isolate and 
characterise reprogramming populations and intermediate cell types, I have begun to map the 
molecular trajectory of cell fate changes during reprogramming. This has revealed new insights 
into the mechanisms which promote primed to naïve reprogramming, and highlighted possible 
methods to enhance this process.  
Using the complete antibody panel comprising of four naïve-specific and two primed-specific 
markers, several populations were isolated by FACS after only ten days of reprogramming. The 
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most “naïve-like” population designated N4+, and two reprogramming intermediates N3+ and 
N4- were sorted for downstream analysis. With an outlook on future usability, I also developed 
a minimised antibody panel combining two naïve- and two primed-specific markers. This was 
used to isolated N2+ cells to resemble the N4+ population. A variety of molecular assays were 
performed to evaluate how each reprogramming population compared to established naïve 
hPSCs. Encouragingly, N4+ and N2+ populations were indistinguishable from established 
hPSCs in terms of colony formation efficiency, KLF17 expression, and initial transcriptional 
analysis by RT-qPCR. Moreover, both N2+ and N4+ populations formed homogeneous naïve 
PSC lines that could be maintained for >20 passages, emphasising that the antibody panel is 
able to identify and isolate nascent naïve hPSCs. This analysis also underscored the importance 
of CD75 expression, as N3+ cells that lack CD75 generated significantly fewer naïve colonies, 
and expressed KLF17 to significantly lower levels.  
Upon inspection of the global transcriptome by RNA-sequencing, it became apparent that day 
10 nascent naïve hPSC populations (N2+ and N4+) had not yet acquired a mature naïve gene 
expression profile. However, by passage five and ten the N4+ population clustered with 
established naïve hPSCs, providing evidence that the nascent naïve population was isolated 
using the antibody panel. Consequently, assessment of the transcriptional profile of day 10 N4+ 
cells has provided the first insight into the order of gene expression changes that occur during 
reprogramming. Collectively, this revealed both early and late transcriptional responders under 
NK2 t2iL+PKCi reprogramming. This information will be useful to guide future experiments 
that will functionally examine the requirement of these factors to induce and sustain a naïve 
pluripotent state, and to understand their mode of action. Furthermore, I used the transcriptional 
data to examine the expression of transposable element classes, which Theunissen and 
colleagues propose as a means to distinguish naïve from primed hPSCs (Theunissen et al., 
2016). In agreement with their findings, transposable element classes were able to recapitulate 
the spatial separation of samples by PCA. This finding prompts further investigation into the 
intertwined relationship of the pluripotent state-specific roles and regulation of transposable 
element expression.  
Current reports that cross-compare established naïve and primed hPSCs generated using 
different reprogramming methods, have begun to highlight considerable variation in both the 
transcriptional and epigenetic profiles (Collier and Rugg‐Gunn, 2018; Guo et al., 2017; Pastor 
et al., 2016; Takahashi et al., 2018). To examine the epigenetic profiles across the time-series, 
I firstly determined the X-chromosome status of each population. This revealed that X-
chromosome reactivation occurred at a late time-point during reprogramming, somewhere 
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between day 10 and passage 5 (day 30), and is therefore a marker for mature naïve hPSCs. In 
collaboration with Ferdinand von Meyenn, assessment of the global CpG DNA methylation 
levels revealed a substantial decrease from 80% (NK2 primed) to 50% in day 10 N4+ cells. By 
passage 10, there was a further decrease to the equivalent level observed for established naïve 
hPSCs. This was accompanied by a widespread loss of imprint methylation, which was not the 
case at day 10.  
One of the theoretical benefits to naïve hPSCs was the hope that akin to naïve mESCs cultured 
in 2i/LIF, the epigenetic memory and lineage bias of primed hPSCs would be erased upon 
reprogramming (Bock et al., 2011; Guo et al., 2016a; Weinberger et al., 2016). The epigenetic 
memory in established naïve hPSCs is erased to some extent, exemplified by global DNA 
demethylation and reactivation of the silent X-chromosome (Guo et al., 2017; Pastor et al., 
2016; Sahakyan et al., 2017; Theunissen et al., 2016). However, there is a failure to faithfully 
reinstate these events after long-term culture in 5iLA(F) or t2iL+PKCi. Upon re-priming of 
naïve hPSCs, few imprinted loci regain DNA methylation, and X-chromosome silencing is 
biased towards the parental primed silenced X-chromosome (Pastor et al., 2016; Sahakyan et 
al., 2017; Theunissen et al., 2016). Moreover, the ability to erase any lineage bias present in the 
parental primed lines upon reprogramming and subsequent differentiation has yet to be 
examined. Nevertheless, the isolation of N4+ cells at early stages of reprogramming may 
harbour the desired characteristics to overcome lineage bias, whilst retaining genome stability. 
Future work will seek to address the differentiation potential of early naïve hPSCs.  
One of the major caveats to current human naïve PSCs is the loss of genome stability, such as 
the erasure of imprint methylation and frequent karyotype abnormalities that arise with long-
term culture. Efforts are required to solve these problems to fully harness the theoretical 
advantages that naïve hPSCs could offer. From the transcriptional comparison between day 10 
N4+ cells and established naïve hPSCs, gene ontology analysis revealed that >100 zinc finger 
proteins had yet to be upregulated by day 10. The failure to upregulate this class of 
transcriptional repressors before the onset of global DNA hypomethylation could be one cause 
for the loss of imprint methylation that cannot be faithfully reinstated. Alternatively, prolonged 
exposure to PD0325901 (FGF/MEK/ERK inhibitor) is reportedly responsible for the genome 
instability that arises with mESCs cultured in 2i/LIF (Choi et al., 2017). The authors infer the 
same is true for naïve hPSCs. However, this may not be the case as PD0325901 is a common 
component to all human naïve culture conditions, even those that do not exhibit global DNA 
hypomethylation (Gafni et al., 2013; Pastor et al., 2016). It is likely that a combination of factors 
are responsible and future efforts are necessary to establish these and to determine a solution.  
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To obtain a broader understanding of the cell fate transition from primed to naïve pluripotency, 
I used the antibody panel to examine 5iLA reprogramming in addition to NK2 t2iL+PKCi. The 
“Reset” population that closely mimics the N4+ gating strategy isolated ≈10% of day 10 
reprogramming cells under 5iLA culture, alongside a population that is refractory to 
reprogramming, “Not Reset” representing ≈55%. Assessing the colony formation efficiency 
revealed the day 10 Reset population captured virtually all reprogramming cells with the ability 
to generate naïve colonies, contrary to the Not Reset population that struggled to form colonies 
of any type. The isolation of nascent naïve hPSCs using different reprogramming methods 
highlights that the multiplexed antibody panel is a versatile and robust tool for the isolation of 
naïve hPSCs. Moreover, a cross-comparison of antibody panel populations and OCT4-ΔPE-
GFP reporter expression inadvertently revealed that this reporter is not specific to naïve hPSCs.  
 
Using the antibody panel to isolate nascent naïve cells as they emerge and progress throughout 
NK2 t2iL+PKCi reprogramming provided the first detailed insight into the transcriptional 
dynamics across the transitional period. From this it was apparent that substantial molecular 
changes occurred between day 10 and passage five. To address this, I used the antibody panel 
to track and subsequently isolate Reset cells at frequent intervals throughout 5iLA 
reprogramming. This provided an enhanced resolution to decipher the temporal order of 
molecular changes. Notably, X-chromosome reactivation occurred between P1 (day 14) and P2 
(day 18). This helps to narrow down the window to determine how this process is 
mechanistically regulated. Furthermore, frequent transcriptional profiling revealed extensive 
changes occur between primed hPSCs and day 8 and day 10 Reset cells; conversely, by P2 (day 
18) a naïve transcriptional profile had been established. Gene expression clustering analysis of 
the 5iLA reprogramming transition has revealed a large number of candidates that may be 
required at different stages of primed to naïve reprogramming. Future work will seek to 
experimentally establish the mechanisms by which they promote or inhibit reprogramming to 
a naïve state. As discussed previously, these include chemical compounds and growth factors 
for cell culture media supplementation, and transcriptional regulators that were common to both 
5iLA and NK2 t2iL+PKCi reprogramming.  
The similarity in gating strategies between the antibody panels used, and the matched time-
points examined, permitted a direct comparison between the two reprogramming methods. The 
global transcriptional overview by PCA, in combination with gene clustering analysis, revealed 
that there are likely divergent routes from primed to naïve pluripotency. Whilst some 
transcriptional changes can be attributed to inherited PSC line-specific differences, there was 
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still considerable variation in the utilisation of different transcription factors during the early 
stages of reprogramming; most notably the KLF and GATA family of transcription factors. To 
robustly exclude PSC line specific differences from those attributable to divergent pathways 
during reprogramming, the reciprocal experiments will be required. Moreover, it is important 
to consider the limitations to the bulk RNA-sequencing approach taken, even though an explicit 
and seemingly homogeneous population of cells was isolated. To reliably conclude that there 
are multiple routes from primed to naïve pluripotency, future experiments that utilise lineage 
tracing technologies coupled with single-cell RNA sequencing would be desirable. Numerous 
CRISPR “scarring” technologies such as LINNAEUS (Spanjaard et al., 2018), GESTALT 
(McKenna et al., 2016), or MEMOIR coupled with seqFISH (Frieda et al., 2017) could be 
employed to address this question moving forward. Similarly, this would provide an insight 
into the alternative cell types generated during the initial phases of reprogramming that might 
be masked by bulk sequencing. The expression of many trophoblast stem cell related 
transcription factors, hormones and growth factors during primed to naïve reprogramming led 
me to speculate that it may be possible to derive human TS-like cells during this process. Single 
cell analysis would reveal whether this is either driven by a subpopulation of TS-like cells, or 
if these genes are more generally involved in primed to naïve reprogramming, or whether cells 
with both an embryonic and extraembryonic transcriptional profile are generated.  
The idea of deriving a cell type with embryonic and extraembryonic capacity has been recently 
reported (Yang et al., 2017b). The human cells, termed extended pluripotent stem (EPS) cells, 
were shown to contribute to both the embryo and the placenta by performing an interspecies 
chimeric assay. However, the functionality and viability of the human cells was not assessed 
due to the limited integration. Moreover, the authors did not present data to suggest human EPS 
cells could differentiate into trophoblast cell types. Nonetheless, the ability to derive isogenic 
stem cells with both embryonic and extraembryonic capabilities would be highly desirable for 
the study of early human development, and pathogenesis of developmental disorders attributed 
to trophoblast defects. The recently reported culture conditions for the maintenance of human 
TS-cells will provide a basis to amend current naïve hPSC culture conditions  in the future 
(Okae et al., 2018), which will allow us to explore the possibility of deriving TS-like cells 
during primed to naïve reprogramming.  
Along a similar avenue, new and exciting in-vitro models have been developed that mimic in-
vivo self-organisation events that occur during mouse embryogenesis. By combining mouse 
ESC and TS cells, these reports have derived blastocyst like structures (termed blastoids) that 
resemble preimplantation (Rivron et al., 2018), and peri- to post- implantation-stage mouse 
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embryo structures (Harrison et al., 2017). In contrast to blastocysts, blastoids can be generated 
in large quantities that allows sufficient material to be collected for downstream assays that 
would be restricted using blastocysts, such as high-throughput biochemical and genetic 
engineering screens. Consequently, blastoids offer a scalable model to study the principals 
underlying mammalian embryogenesis. It will be exciting to see in the future whether human 
synthetic blastoids can be produced to mimic human embryogenesis, and what pluripotent cell 
types will be required. On a related note, human embryos have been cultured in-vitro for up to 
14 days to mimic elements of postimplantation development, a time point that is otherwise 
inaccessible (Deglincerti et al., 2016; Shahbazi et al., 2016). In the future, a combination of 
these models will help to validate transcriptionally where the different primed, naïve, and 
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